hasnat79/pubmed25_cardio · Datasets at Hugging Face

157

1

Mechanisms of glycolytic inhibition in ischemic rat hearts.

MEDLINE

Manual

NLM

The mechanisms of glycolytic inhibition in ischemic myocardium were investigated in the isolated, perfused rat heart. Glycolysis was inhibited at the level of glyceraldehyde-3-phosphate dehydrogenase. The major factors that accounted for the glycolytic inhibition in the ischemic heart compared with the anoxic heart appeared to be higher tissue levels of lactate and H+ in the ischemic tissue. Increased extracellular pH inhibited glycolysis in anoxic and hypoxic hearts much more readily than it did in aerobic hearts. However, maintenance of both extracellular and intracellular pH caused only a modest acceleration of glycolysis in ischemic hearts. Accumulation of tissue lactate and inhibition of glycolysis were directly proportional to the reduction in coronary bloow flow in both anoxic and ischemic hearts. At intracellular lactate concentrations between 15 and 20 mM, glycolysis was inhibited under both conditions. Addition of either 10, 20, or 40 mM lactate to the perfusate inhibited glycolysis in aerobic, anoxic, and ischemic hearts. The effect of lactate did not appear to be mediated through changes in intracellular pH. It is concluded that accumulation of lactate represents a major factor in the inhibition of glycolysis that develops in ischemic hearts.

Circulation research

0009-7330

Print

37

6

Print

1,975

Dec

null

742-51

M J Rovetto (MJ); W F Lamberton (WF); J R Neely (JR)

Journal Article (D016428); Research Support, U.S. Gov't, P.H.S. (D013487)

Insulin (Registry: 0, UI: D007328); Lactates (Registry: 0, UI: D007773); Glucose (Registry: IY9XDZ35W2, UI: D005947)

Animals (UI: D000818, Major: No); Blood Flow Velocity (UI: D001783, Major: No); Coronary Circulation (UI: D003326, Major: Yes); Coronary Disease (UI: D003327, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Extracellular Space (UI: D005110, Major: No); Glucose (UI: D005947, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: No); Glycolysis (UI: D006019, Major: Yes); Heart (UI: D006321, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); In Vitro Techniques (UI: D066298, Major: No); Insulin (UI: D007328, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: No); Intracellular Fluid (UI: D007424, Major: No); Lactates (UI: D007773, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Male (UI: D008297, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Perfusion (UI: D010477, Major: No); Rats (UI: D051381, Major: No)

|||metabolism (1)||administration & dosage (0)|||||administration & dosage (0)||pharmacology (0)||metabolism (1)||

0|0|1|0|0|0|1|0|0|0|0|0|0|0|0|0|0

null

1976-02-26

2019-07-06

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 157; doi: 10.1161/01.res.37.6.742

Myocardial Ischemia

['Coronary Disease']

404

1

Arterialization of the coronary veins in diffuse coronary arteriosclerosis.

MEDLINE

Manual

NLM

Since the coronary veins and capillaries are not involved with arteriosclerotic disease the authors performed experimental, and afterwards, clinical total and selective coronary vein arterialization. Acute myocardial ischaemia created for instance by ligation of the anterior descending branch, was treated by an internal mammary artery to regional coronary vein anastomosis. In 21 patients the selective arterialization of the ""Vena cordis magna"" or of ""Vena cordis media"", and total arterialization of the coronary sinus was performed. The clinical improvement and follow-up studies seem to be promising in the treatment of patients with advanced diffuse heavy coronary arteriosclerosis. In acute myocardial ischaemia with coronarographically localized coronary occlusion, the aim of regional vein arterialization is to minimize the area of infarction.

The Journal of cardiovascular surgery

0021-9509

Print

16

5

Print

null

520-5

J W Moll (JW); A J Dziatkowiak (AJ); M Edelman (M); W Iljin (W); E Ratajczyk-Pakalska (E); K Stengert (K)

Journal Article (D016428)

null

Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: surgery (UI: Q000601, Major: Yes); Coronary Vessels (UI: D003331, Major: No) - Qualifiers: surgery (UI: Q000601, Major: Yes); Female (UI: D005260, Major: No); Follow-Up Studies (UI: D005500, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Methods (UI: D008722, Major: No); Middle Aged (UI: D008875, Major: No); Myocardial Revascularization (UI: D009204, Major: No); Veins (UI: D014680, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No)

||surgery (1)|surgery (1)||||||||surgery (0)

0|0|0|0|0|0|0|0|0|0|0|0

null

1976-02-09

2023-08-15

pubmed: 1975-9-1; medline: 1975-9-1 0:1; entrez: 1975-9-1 0:0

pubmed: 404

Myocardial Ischemia

['Coronary Disease']

480

1

Recognition and significance of maternogenic fetal acidosis during intensive monitoring of labor.

MEDLINE

Manual

NLM

FHR monitoring and microanalysis of fetal blood are mutually complementary procedures, and optimal knowledge of the fetal state is achieved by making use of both, the former for the preliminary screening of all cases at risk and the latter for the purpose of deciding on obstetric management where pathological changes are evident in the FHR. The major difficulty in obtaining a precise value for the fetal acid-base balance lies in the occurence of ""falsely abnormal"" cases, i.e. cases in which the fetal pH falls during labor but the clinical condition at birth is good (APGAR greater than or equal to 7). In our own series the incidence of such cases among fetuses at risk was 11.2% (Tab. I). In the majority of these cases the fetal acidosis is thought to be a result of increased metabolic acidosis in the mother (maternogenic fetal metabolic acidosis). The importance of the maternogenic fetal acidosis during labor lies in the fact that unless it is recognised, rapid extraction of the fetus will appear necessary on clinical grounds, although it is in fact unnecessary, since this form of acidosis has no adverse effect on the fetus. Various parameters have been proposed for the differential diagnosis of the maternogenic fetal acidosis. These include the feto-maternal difference in base deficit (F/M deltaBD), the materno-fetal differences in pHqu 40 (M/F deltapHqu 40) the materno-fetal difference actual pH (M/F actual deltapH), and the materno-fetal difference in base deficit of the extra-cellular fluid (M/F deltaBDHb5). A critical analysis of these parameters has been carried out on the results of microtests performed during a 5 year period (1968-1972) at the First Clinic of Obstetrics and Gynecology of Milan University. The cases comprised 59 regarded as normal (normal course of pregnancy, spontaneous commencement of labor at term, clear amniotic fluid, regular FHR, spontaneous birth, APGAR at 90 sec between 8 and 10, weight at birth greater than 2500 g), and 335 considered to be at risk (maternal disease, presence of meconium stained amniotic fluid and/or abnormal changes in FHR). In all of these cases the FHR was recorded by cardiotokography, and the tracings were interpreted according to HON. Microsamples of blood were taken from both mother and fetus during labor and the following determinations were carried out: actual pH, pHqu 40, Hb concentration, hemoglobin oxygen saturation, base deficit Hb5 (BDHb5). The maternofetal differences were then calculated. The same determinations were carried out on samples of maternal blood and of arterial and venous cord blood taken immediately after delivery. The clinical condition of the infant was evaluated by the APGAR score at 90 seconds after birth.

Journal of perinatal medicine

0300-5577

Print

3

1

Print

1,975

null

53-67

G D Roversi (GD); V Canussio (V); M Spennacchio (M)

Journal Article (D016428)

Hemoglobins (Registry: 0, UI: D006454)

Acid-Base Equilibrium (UI: D000136, Major: No); Acidosis (UI: D000138, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: Yes); Apgar Score (UI: D001034, Major: No); Bradycardia (UI: D001919, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Electrocardiography (UI: D004562, Major: No) - Qualifiers: methods (UI: Q000379, Major: No); Female (UI: D005260, Major: No); Fetal Distress (UI: D005316, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: Yes); Fetal Heart (UI: D005318, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Heart Rate (UI: D006339, Major: No); Hemoglobins (UI: D006454, Major: No); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Infant, Newborn (UI: D007231, Major: No); Maternal-Fetal Exchange (UI: D008431, Major: Yes); Monitoring, Physiologic (UI: D008991, Major: No); Obstetric Labor Complications (UI: D007744, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: Yes); Pregnancy (UI: D011247, Major: No); Uterine Contraction (UI: D014590, Major: No)

|diagnosis (1)||diagnosis (0)|methods (0)||diagnosis (1)|physiopathology (0)||||||||diagnosis (1)||

0|0|0|0|0|0|0|0|0|0|0|0|0|1|0|0|0|0

null

1976-02-19

2019-09-18

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 480; doi: 10.1515/jpme.1975.3.1.53

Arrhythmias, Cardiac

['Bradycardia']

741

1

Role of cardiovascular and ionic changes in pathogenesis and prevention of isoprenaline-induced cardiac necrosis.

MEDLINE

Manual

NLM

Blood pressure, heart rate, oxygen uptake, and blood values of PO2, PCO2, and pH were studied in unanesthetized rats for 8 hours. After a cardiotoxic dose of 20 mg/kg isoprenaline, s.c., blood pressure fell from 117 to 72 mm Hg, heart rate accelerated from 326 to 497 beats/minute, and cardiac work diminished by about 15%. Metabolic rate increased by about 80%, blood values of PO2 rose, and those of PCO2 fell somewhat, whereas blood pH dropped from 7.48 to 7.38, indicating metabolic acidosis. Propranolol (40 mg/kg, i.p.) and verapamil (50 mg/kg, i.p.), both of which almost completely prevented isoprenaline-induced cardiac necroses, inhibited the chronotropic and calorigenic actions of isoprenaline by about 50%. While propranolol inhibited the depressor effect of isoprenaline completely, verapamil enhanced it: blood pressure fell to 46 mm Hg. Isoprenaline-induced fall of blood pH was not prevented by either propranolol or verapamil. Decrease of blood pH and cardionecrotisation were enhanced when isoprenaline was given together with 4.8 g/kg ethanol, p.o. In conclusion, hemodynamic actions of isoprenaline, especially hypotension, seem to be nonessential for the production of cardiac necroses. Strong acidification can aggravate the cardiotoxicity of isoprenaline.

Recent advances in studies on cardiac structure and metabolism

0363-5872

Print

6

null

Print

1,975

null

135-42

O Strubelt (O); C P Siegers (CP)

Journal Article (D016428)

Carbon Dioxide (Registry: 142M471B3J, UI: D002245); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433); Verapamil (Registry: CJ0O37KU29, UI: D014700); Isoproterenol (Registry: L628TT009W, UI: D007545); Oxygen (Registry: S88TT14065, UI: D010100)

Animals (UI: D000818, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Carbon Dioxide (UI: D002245, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Cardiomyopathies (UI: D009202, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: Yes); pathology (UI: Q000473, Major: No); physiopathology (UI: Q000503, Major: No); prevention & control (UI: Q000517, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Isoproterenol (UI: D007545, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: No); pharmacology (UI: Q000494, Major: Yes); Male (UI: D008297, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Necrosis (UI: D009336, Major: No); Oxygen (UI: D010100, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Oxygen Consumption (UI: D010101, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Propranolol (UI: D011433, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Rats (UI: D051381, Major: No); Verapamil (UI: D014700, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No)

|drug effects (0)|blood (0)|chemically induced (1); pathology (0); physiopathology (0); prevention & control (0)|drug effects (0)||antagonists & inhibitors (0); pharmacology (1)||metabolism (0)||blood (0)|drug effects (0)|therapeutic use (0)||therapeutic use (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-02-27

2013-11-21

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 741

Cardiomyopathies

[]

742

1

Alterations in norepinephrine pattern in the damaged myocardium in the rat.

MEDLINE

Manual

NLM

In the albino rat, the evolvement of myocardial necrosis induced by a single injection of ISO was accompanied by a fall in total NE. Pretreatment with propranolol and pargyline protected against ISO-induced necrosis and myocardial hypertrophy, but did not influence the ISO-induced depletion of NE stores. The depletion of NE stores is not due to impairment in synthesis or increased intraneuronal metabolism of NE since, in ISO-treated rats, neither cardiac tyrosine hydroxylase activity nor MAO activity was altered. The decrease in endogenous NE is not due to a defect in the storage of NE. The ability of myocardium to take up and store NE returned to normal within 48 hours, whereas endogenous levels returned to normal within 5 days, even in the presence of demonstrable necrosis. Thus, there is lack of correlation between chemical and morphological changes, since catecholamine depletion occurred in the absence of morphologically demonstrable tissue injury, and the function of the adrenergic neuron returns to normal in the presence of demonstrable necrosis.

Recent advances in studies on cardiac structure and metabolism

0363-5872

Print

6

null

Print

1,975

null

159-65

B Bhagat (B); J M Sullivan (JM); N S Dhalla (NS)

Journal Article (D016428)

Pargyline (Registry: 9MV14S8G3E, UI: D010293); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433); Tyrosine 3-Monooxygenase (Registry: EC 1.14.16.2, UI: D014446); Monoamine Oxidase (Registry: EC 1.4.3.4, UI: D008995); Isoproterenol (Registry: L628TT009W, UI: D007545); Norepinephrine (Registry: X4W3ENH1CV, UI: D009638)

Animals (UI: D000818, Major: No); Cardiomegaly (UI: D006332, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); Cardiomyopathies (UI: D009202, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); metabolism (UI: Q000378, Major: Yes); pathology (UI: Q000473, Major: No); Isoproterenol (UI: D007545, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Male (UI: D008297, Major: No); Monoamine Oxidase (UI: D008995, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: enzymology (UI: Q000201, Major: No); metabolism (UI: Q000378, Major: No); Necrosis (UI: D009336, Major: No); Norepinephrine (UI: D009638, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Pargyline (UI: D010293, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Propranolol (UI: D011433, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Rats (UI: D051381, Major: No); Tyrosine 3-Monooxygenase (UI: D014446, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No)

|chemically induced (0)|chemically induced (0); metabolism (1); pathology (0)|pharmacology (1)||metabolism (0)|enzymology (0); metabolism (0)||metabolism (1)|pharmacology (0)|pharmacology (0)||metabolism (0)

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-02-27

2013-11-21

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 742

Cardiomyopathies

[]

743

1

Prevention of myocardial Ca overload and necrotization by Mg and K salts or acidosis.

MEDLINE

Manual

NLM

The crucial point in the pathogenesis of isoproterenol-induced myocardial necrotization is an abundant intracellular Ca accumulation leading to high energy phosphate exhaustion. Accordingly, in the early stage of the isoproterenol-induced necrotization process, the onset of ATP and creatine phosphate breakdown strictly parallels the acute Ca gain. In this type of necrosis, the Mg losses from the myocardium appear as a concomitant phenomenon. The hearts can be protected against the deleterious Ca overload and necrotization by increasing the plasma concentration of Mg, K, or H ions in order to counterbalance Ca according to the ration (see article). On the other hand, if Mg, K, or H ion concentrations are too low, isoproterenol-induced Ca uptake and myocardial lesions are potentiated.

Recent advances in studies on cardiac structure and metabolism

0363-5872

Print

6

null

Print

1,975

null

33-42

J Janke (J); A Fleckenstein (A); B Hein (B); O Leder (O); H Sigel (H)

Journal Article (D016428)

Phosphocreatine (Registry: 020IUV4N33, UI: D010725); Adenosine Triphosphate (Registry: 8L70Q75FXE, UI: D000255); Magnesium (Registry: I38ZP9992A, UI: D008274); Isoproterenol (Registry: L628TT009W, UI: D007545); Potassium (Registry: RWP5GA015D, UI: D011188); Calcium (Registry: SY7Q814VUP, UI: D002118)

Adenosine Triphosphate (UI: D000255, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Animals (UI: D000818, Major: No); Calcium (UI: D002118, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: Yes); metabolism (UI: Q000378, Major: No); Cardiomyopathies (UI: D009202, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); metabolism (UI: Q000378, Major: No); prevention & control (UI: Q000517, Major: Yes); Dose-Response Relationship, Drug (UI: D004305, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Isoproterenol (UI: D007545, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: No); Magnesium (UI: D008274, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: Yes); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Necrosis (UI: D009336, Major: No); Phosphocreatine (UI: D010725, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Potassium (UI: D011188, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: Yes); Rats (UI: D051381, Major: No)

metabolism (0)||antagonists & inhibitors (1); metabolism (0)|chemically induced (0); metabolism (0); prevention & control (1)|||antagonists & inhibitors (0)|pharmacology (0); therapeutic use (1)|metabolism (0)||metabolism (0)|pharmacology (0); therapeutic use (1)|

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-02-27

2017-03-22

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 743

Cardiomyopathies

[]

1,351

1

Effect of the beta-receptor blocking agent Visken on the action of coumarin.

MEDLINE

Manual

NLM

In a double-blind study, the influence of Visken on the effect of anticoagulant therapy with Marcoumar was examined. In comparison to a placebo group, neither any influence on the Quick time, nor any increased tendency to haemorrhage bleeding could be detected.

International journal of clinical pharmacology and biopharmacy

0340-0026

Print

12

4

Print

1,975

Dec

null

458-60

H Vinazzer (H)

Clinical Trial (D016430); Controlled Clinical Trial (D018848); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Anticoagulants (Registry: 0, UI: D000925); Coumarins (Registry: 0, UI: D003374); Placebos (Registry: 0, UI: D010919)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Age Factors (UI: D000367, Major: No); Aged (UI: D000368, Major: No); Anticoagulants (UI: D000925, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Arterial Occlusive Diseases (UI: D001157, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Blood Coagulation (UI: D001777, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: Yes); Blood Coagulation Disorders (UI: D001778, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Body Height (UI: D001827, Major: No); Body Weight (UI: D001835, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Coumarins (UI: D003374, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Drug Interactions (UI: D004347, Major: No); Drug Therapy, Combination (UI: D004359, Major: No); Humans (UI: D006801, Major: No); Long-Term Care (UI: D008134, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Placebos (UI: D010919, Major: No); Time Factors (UI: D013997, Major: No)

pharmacology (1)|||therapeutic use (0)|drug therapy (0)|drug effects (1)|drug therapy (0)|||drug therapy (0)|pharmacology (1)|||||||drug therapy (0)||

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-03-24

2004-11-17

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 1351

Myocardial Ischemia

['Coronary Disease', 'Myocardial Infarction']

1,448

1

Defects in the biochemistry of collagen in diseases of connective tissue.

MEDLINE

Manual

NLM

The collagens are the major structural glycoproteins of connective tissues. A unique primary structure and a multiplicity of post-translational modification reactions are required for normal fibrillogenesis. The post-translational modifications include hydroxylation of prolyl and lysyl residues, glycosylation, folding of the molecule into triple-helical conformation, proteolytic conversion of precursor procollagen to collagen, and oxidative deamination of certain lysyl and hydroxylysyl residues. Any defect in the normal mechanisms responsible for the synthesis and secretion of collagen molecules or the deposition of these molecules into extracellular fibers could result in abnormal fibrillogenesis; such defects could result in a connective tissue disease. Recently, defects in the regulation of the types of collagen synthesized and in the enzymes involved in the post-translational modifications have been found in heritable diseases of connective tissue. Thus far, the primary heritable disorders of collagen metabolism in man include lysyl hydroxylase deficiency in Ehlers-Danlos syndrome type VI, p-collagen peptidase deficency in Ehlers-Danlos syndrome type VII, decreased synthesis of type III collagen in Ehlers-Danlos syndrome type IV, lysyl oxidase deficency in S-linked cutis laxa and Ehlers-Danlos syndrome type V, and decreased synthesis of type I collagen in osteogenesis imperfecta.

The Journal of investigative dermatology

0022-202X

Print

66

02

Print

1,976

Feb

null

59-79

J Uitto (J); J R Lichtenstein (JR)

Journal Article (D016428); Research Support, U.S. Gov't, Non-P.H.S. (D013486); Research Support, U.S. Gov't, P.H.S. (D013487); Review (D016454)

Hydroxylysine (Registry: 2GQB349IUB, UI: D006901); Collagen (Registry: 9007-34-5, UI: D003094); Protein-Lysine 6-Oxidase (Registry: EC 1.4.3.13, UI: D008249); Microbial Collagenase (Registry: EC 3.4.24.3, UI: D003012); Hydroxyproline (Registry: RMB44WO89X, UI: D006909)

Aortic Diseases (UI: D001018, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Bone and Bones (UI: D001842, Major: No) - Qualifiers: abnormalities (UI: Q000002, Major: No); Brain Diseases (UI: D001927, Major: No) - Qualifiers: genetics (UI: Q000235, Major: No); Collagen (UI: D003094, Major: No) - Qualifiers: biosynthesis (UI: Q000096, Major: Yes); metabolism (UI: Q000378, Major: No); Connective Tissue (UI: D003238, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Cutis Laxa (UI: D003483, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); pathology (UI: Q000473, Major: No); Ehlers-Danlos Syndrome (UI: D004535, Major: No) - Qualifiers: genetics (UI: Q000235, Major: No); metabolism (UI: Q000378, Major: No); pathology (UI: Q000473, Major: No); Fascia (UI: D005205, Major: No) - Qualifiers: abnormalities (UI: Q000002, Major: No); Genetic Linkage (UI: D008040, Major: No); Homocystinuria (UI: D006712, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Humans (UI: D006801, Major: No); Hydroxylysine (UI: D006901, Major: No) - Qualifiers: biosynthesis (UI: Q000096, Major: No); Hydroxyproline (UI: D006909, Major: No) - Qualifiers: biosynthesis (UI: Q000096, Major: No); urine (UI: Q000652, Major: No); Joints (UI: D007596, Major: No) - Qualifiers: abnormalities (UI: Q000002, Major: No); Marfan Syndrome (UI: D008382, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Microbial Collagenase (UI: D003012, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Osteogenesis Imperfecta (UI: D010013, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); pathology (UI: Q000473, Major: No); Protein Biosynthesis (UI: D014176, Major: No); Protein Conformation (UI: D011487, Major: No); Protein-Lysine 6-Oxidase (UI: D008249, Major: No) - Qualifiers: deficiency (UI: Q000172, Major: No); Sex Chromosomes (UI: D012730, Major: No); Skin Abnormalities (UI: D012868, Major: No)

etiology (0)|abnormalities (0)|genetics (0)|biosynthesis (1); metabolism (0)|metabolism (1)|metabolism (0); pathology (0)|genetics (0); metabolism (0); pathology (0)|abnormalities (0)||metabolism (0)||biosynthesis (0)|biosynthesis (0); urine (0)|abnormalities (0)|metabolism (0)|metabolism (0)|metabolism (0); pathology (0)|||deficiency (0)||

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-01

2019-07-23

pubmed: 1976-2-1; medline: 1976-2-1 0:1; entrez: 1976-2-1 0:0

pubmed: 1448; pii: S0022-202X(15)44682-2; doi: 10.1111/1523-1747.ep12481404

Heart Defects, Congenital

['Marfan Syndrome']

1,567

1

[Certain problems of treatment of ischemic heart disease].

MEDLINE

Manual

NLM

On the basis of extended personal experience and of the literature data, the authors give recommendations for differentiated rational drug therapy of different stages of ischaemic heart disease. The results of a study of comparative efficacy of 15 coronary-active drugs used in 709 patients with ischaemic heart disease are presented along with their clinical pharmacology, side effects, indications and counterindications. The conclusions were arrived at on the basis of an objective clinical and laboratory study of the effect of the drugs. The methods of evaluation of the drug's efficacy and of the selection of patients for the administration of adequate therapy are described, which permits to use these recommendations for practical purposes. Some problems of the pathogenesis of ischaemic heart disease are discussed in terms of the selection of pathogenetic therapy.

Kardiologiia

0022-9040

Print

15

7

Print

1,975

Jul

null

16-24

I P Zamotaev (IP); L G Lozinskiĭ (LG); M G Venediktova (MG); B L Sandomirskiĭ (BL)

English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Vasodilator Agents (Registry: 0, UI: D014665)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: Yes); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); physiopathology (UI: Q000503, Major: No); Drug Evaluation (UI: D004341, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Humans (UI: D006801, Major: No); Myocardial Contraction (UI: D009200, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Vasodilator Agents (UI: D014665, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: No)

pharmacology (0); therapeutic use (1)|drug therapy (0)|drug therapy (1); physiopathology (0)||physiopathology (0)||drug effects (0)|pharmacology (0); therapeutic use (0)

0|0|0|0|0|0|0|0

null

1976-04-02

2017-03-10

pubmed: 1975-7-1; medline: 1975-7-1 0:1; entrez: 1975-7-1 0:0

pubmed: 1567

Myocardial Ischemia

['Angina Pectoris', 'Coronary Disease']

1,568

1

[Stimulators of beta-adrenergic structures in treatment of ischemic heart disease].

MEDLINE

Manual

NLM

The beneficial effect of stimulators of beta-adrenergic structures (Myophedrin on the haemodynamics and the inotropic function of the myocardium was demonstrated experimentally (in 12 rabbits) and clinically (in 53 patients with ischaemic heart disease). A positive effect of the treatment was noted in 45.5% of those patients in whom ischaemic heart disease manifested itself in angina decubitus and angina of effort.

Kardiologiia

0022-9040

Print

15

7

Print

1,975

Jul

null

37-43

F I Komarov (FI); L I Ol'binskaia (LI); A A Abinder (AA); V V Iankin (VV); I T Kitaeva (IT)

English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Agonists (Registry: 0, UI: D000318)

Adrenergic beta-Agonists (UI: D000318, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: Yes); Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Animals (UI: D000818, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); physiopathology (UI: Q000503, Major: No); Electrocardiography (UI: D004562, Major: No); Female (UI: D005260, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Hemodynamics (UI: D006439, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Myocardial Contraction (UI: D009200, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: Yes); Rabbits (UI: D011817, Major: No); Stimulation, Chemical (UI: D013268, Major: No)

pharmacology (0); therapeutic use (1)||||drug therapy (1); physiopathology (0)|||physiopathology (0)|drug effects (0)||||drug effects (1)||

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-02

2017-03-10

pubmed: 1975-7-1; medline: 1975-7-1 0:1; entrez: 1975-7-1 0:0

pubmed: 1568

Myocardial Ischemia

['Coronary Disease']

1,569

1

[Nonachlasine--a new drug for treatment of ischemic heart disease].

MEDLINE

Manual

NLM

Data on the pharmacology of a new antianginal drug--Nonachlasine--are presented. Nonachlasine was found to increase the blood flow intensively and for long periods of time, increasing the oxygen reserve of the myocardium, thus increasing the cardiac output and the contractile function of the heart. The prevailing action of Nonachlasine on the blood supply and the function of the myocardium seems to be the result of several mechanisms: decreasing resistance of the coronaries due to the activation of the beta2-adrenergic structures; influence upon the extravascular factors of the regulation of the coronary circulation (changes in the metabolism and cardiac activity due to the excitation of the beta-adrenergic structures). The mechanism of the positive effect of Nonachlasine upon the blood supply and function of the heart is connected with its action on the adrenergic processes. The drug accumulates noradrenaline in the myocardium and increases the activity of phosphorilase-a. This coincides in time with the increased blood supply and contractile capacity of the heart. The beta-adrenoblocking agents prevent these effects. It was postulated that the effect of Nonachlasine in the blood supply and the activity of the heart is connected with its ability to utilize the energy reserve of the myocardium by way of switching over to the anaerobic way.

Kardiologiia

0022-9040

Print

15

7

Print

1,975

Jul

null

43-8

N V Kaverina (NV); G A Markova (GA); G G Chichkanov (GG); V B Chumburidze (VB); A I Basaeva (AI)

English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Agonists (Registry: 0, UI: D000318); Phenothiazines (Registry: 0, UI: D010640)

Adrenergic beta-Agonists (UI: D000318, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Animals (UI: D000818, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cardiac Output (UI: D002302, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cats (UI: D002415, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); physiopathology (UI: Q000503, Major: No); Drug Evaluation (UI: D004341, Major: No); Hemodynamics (UI: D006439, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Phenothiazines (UI: D010640, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Rabbits (UI: D011817, Major: No); Rats (UI: D051381, Major: No); Regional Blood Flow (UI: D012039, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Vascular Resistance (UI: D014655, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No)

therapeutic use (1)||drug effects (0)|drug effects (0)||drug therapy (1); physiopathology (0)||drug effects (0)|therapeutic use (1)|||drug effects (0)|drug effects (0)

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-02

2017-03-10

pubmed: 1975-7-1; medline: 1975-7-1 0:1; entrez: 1975-7-1 0:0

pubmed: 1569

Myocardial Ischemia

['Coronary Disease']

1,570

1

[Cordaron and nonachlasine in treatment of chronic coronary insufficiency].

MEDLINE

Manual

NLM

In a double blind study of the clinical effect of Cordaron conducted in 55 patients with chronic ischaemic heart disease a positive effect was obtained in 80.4% of the cases, an effect of placebo-in 24.3%. Cordaron was especially effective in patients with localized stenoses of the coronary arteries. Nonachlasine (an activator of the cardiac beta-adrenergic receptors) proved effective in 10 of 13 patients with chronic ischaemic heart disease.

Kardiologiia

0022-9040

Print

15

7

Print

1,975

Jul

null

48-51

V I Metelitsa (VI); L S Matveeva (LS); G A Borisova (GA); V P Lupanov (VP)

Clinical Trial (D016430); Controlled Clinical Trial (D018848); English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Agonists (Registry: 0, UI: D000318); Benzofurans (Registry: 0, UI: D001572); Phenothiazines (Registry: 0, UI: D010640); Amiodarone (Registry: N3RQ532IUT, UI: D000638)

Adrenergic beta-Agonists (UI: D000318, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: No); therapeutic use (UI: Q000627, Major: Yes); Amiodarone (UI: D000638, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Benzofurans (UI: D001572, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Chronic Disease (UI: D002908, Major: No); Clinical Trials as Topic (UI: D002986, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); Drug Evaluation (UI: D004341, Major: No); Follow-Up Studies (UI: D005500, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Phenothiazines (UI: D010640, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes)

administration & dosage (0); therapeutic use (1)|therapeutic use (1)|therapeutic use (1)|||drug therapy (1)||||||therapeutic use (1)

0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-02

2017-03-10

pubmed: 1975-7-1; medline: 1975-7-1 0:1; entrez: 1975-7-1 0:0

pubmed: 1570

Myocardial Ischemia

['Coronary Disease']

1,571

1

[Effect of certain drugs, used in treatment of chronic coronary insufficiency, on adenosine metabolism].

MEDLINE

Manual

NLM

It has been demonstrated that the study of the activity of 5'-nucleotidase and adenosine-desaminase permits to interpret the metabolism of adenosine. Curanthil, Sustac and Intensain influence the adenosine metabolism favouring an elevation of its content. The therapeutic effect of Obsidan is not conditioned by the ""adenosine"" metabolism.

Kardiologiia

0022-9040

Print

15

7

Print

1,975

Jul

null

51-6

E Sh Khalfen (ESh); S G Denisova (SG)

English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Vasodilator Agents (Registry: 0, UI: D014665); Nucleotidases (Registry: EC 3.1.3.-, UI: D009708); Adenosine Deaminase (Registry: EC 3.5.4.4, UI: D000243); Adenosine (Registry: K72T3FS567, UI: D000241)

Adenosine (UI: D000241, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Adenosine Deaminase (UI: D000243, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); enzymology (UI: Q000201, Major: No); metabolism (UI: Q000378, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: enzymology (UI: Q000201, Major: No); Nucleotidases (UI: D009708, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Vasodilator Agents (UI: D014665, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes)

metabolism (1)|metabolism (0)|therapeutic use (1)|||drug therapy (1); enzymology (0); metabolism (0)|||||enzymology (0)|metabolism (0)|therapeutic use (1)

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-02

2017-03-10

pubmed: 1975-7-1; medline: 1975-7-1 0:1; entrez: 1975-7-1 0:0

pubmed: 1571

Myocardial Ischemia

['Coronary Disease']

1,704

1

Cardiovascular effects of electrical stimulation of the forebrain in the fetal lamb.

MEDLINE

Manual

NLM

Modified stereotaxic techniques were applied to fetal lambs during the latter third of gestation. Electrical stimulation in the region of the hypothalamus in 10 acute experiments was associated with three patterns of arterial blood pressure and heart rate changes: a pressor-tachycardia response; a pure tachycardia response (abolished by propranolol); and a pure bradycardia response (abolished by atropine). The pressor-tachycardia response was examined in detail in 13 chronic preparations (115-135 days of gestation at operation). The systolic arterial blood pressure increase was never greater than 35 mm Hg and was probably blunted by the large noninnervated placental circulation. This pressure increase was abolished by phentolamine and was thus mediated by stimulation of alpha-adrenergic receptors. The initial tachycardia was prevented by propranolol and was due to beta-adrenergic stimulation. The tachycardia was followed in a few seconds by a bradycardia, abolished by atropine and possibly a vagal baroreflex. The pressor-tachycardia response was accentuated in two lambs who were delivered spontaneously and were studied after birth. These studies indicate that a suprabulbar neural framework exists in the fetal lamb for influencing the cardiovascular system from as early as 90 days of gestation.

Pediatric research

0031-3998

Print

10

1

Print

1,976

Jan

null

40-5

R L Williams (RL); R P Hof (RP); M A Heymann (MA); A M Rudolph (AM)

Journal Article (D016428); Research Support, U.S. Gov't, P.H.S. (D013487)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Animals (UI: D000818, Major: No); Blood Pressure (UI: D001794, Major: Yes) - Qualifiers: drug effects (UI: Q000187, Major: No); Bradycardia (UI: D001919, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Electric Stimulation (UI: D004558, Major: No); Heart Rate (UI: D006339, Major: Yes) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Hypothalamus (UI: D007031, Major: No) - Qualifiers: embryology (UI: Q000196, Major: No); physiology (UI: Q000502, Major: Yes); Sheep (UI: D012756, Major: No); Stereotaxic Techniques (UI: D013238, Major: No); Tachycardia (UI: D013610, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No)

pharmacology (0)||drug effects (0)|etiology (0)||drug effects (0)||embryology (0); physiology (1)|||etiology (0)

0|0|1|0|0|1|0|0|0|0|0

null

1976-03-30

2006-11-15

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 1704; doi: 10.1203/00006450-197601000-00008

Arrhythmias, Cardiac

['Bradycardia', 'Tachycardia']

1,832

1

Effects of pH and pCO2 on performance of ischemic myocardium.

MEDLINE

Manual

NLM

Contractile performance of ischemic feline myocardium was evaluated under conditions of selective changes in perfusate in pH and pCO2. A substantial increase in myocardial performance was noted when the pCO2 was lowered at constant pH, and depression of performance was noted when the pCO2 was increased at constant pH. Perfusate acidosis at constant pCO2 resulted in depression of performance and decreased performance only after 20 min of exposure. Alkalosis did not increase performance and decreased performance transiently during mild ischemia. These studies suggest that performance of myocardium during ischemia is closely related to tissue pCO2 and is minimally related to the level of extracellular pH.

Recent advances in studies on cardiac structure and metabolism

0363-5872

Print

10

null

Print

1,975

null

355-64

M L Weisfeldt (ML); R L Bishop (RL); H L Greene (HL)

Journal Article (D016428); Research Support, U.S. Gov't, P.H.S. (D013487)

Carbon Dioxide (Registry: 142M471B3J, UI: D002245)

Acidosis (UI: D000138, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); physiopathology (UI: Q000503, Major: No); Alkalosis (UI: D000471, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); physiopathology (UI: Q000503, Major: No); Animals (UI: D000818, Major: No); Carbon Dioxide (UI: D002245, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes); Cats (UI: D002415, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); physiopathology (UI: Q000503, Major: Yes); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Hydrogen-Ion Concentration (UI: D006863, Major: Yes); Pressure (UI: D011312, Major: No)

metabolism (0); physiopathology (0)|metabolism (0); physiopathology (0)||blood (1)||metabolism (0); physiopathology (1)|physiopathology (1)||

0|0|0|0|0|0|0|1|0

null

1976-04-01

2013-11-21

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 1832

Myocardial Ischemia

['Coronary Disease']

1,849

1

Roentgenological findings in cryptorchidism.

MEDLINE

Manual

NLM

Intravenous urography of 78 cryptorchid boys revealed no clinically significant upper urinary tract anomalies. Two boys had a rotated kidney and 2 others a double renal pelvis. One boy had previously been operated upon because of hydronephrosis. There thus appears to be no reason for routine intravenous urography of cryptorchid boys. Forty-two per cent of the boys had spina bifida occulta in the lumbar and sacral spine. One case of asymptomatic congenital cardiac disease was discovered at routine chest X-ray.

Scandinavian journal of urology and nephrology

0036-5599

Print

9

3

Print

1,975

null

171-3

K J Tveter (KJ); J Fjaerli (J)

Journal Article (D016428)

null

Abnormalities, Multiple (UI: D000015, Major: No); Cryptorchidism (UI: D003456, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnostic imaging (UI: Q000000981, Major: Yes); Heart Defects, Congenital (UI: D006330, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Humans (UI: D006801, Major: No); Kidney (UI: D007668, Major: No) - Qualifiers: abnormalities (UI: Q000002, Major: No); Male (UI: D008297, Major: No); Spinal Dysraphism (UI: D016135, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Urography (UI: D014567, Major: No)

|complications (0); diagnostic imaging (1)|complications (0)||abnormalities (0)||complications (0)|

0|0|0|0|0|0|0|0

null

1976-03-18

2019-09-02

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 1849; doi: 10.3109/00365597509134205

Heart Defects, Congenital

[]

1,865

1

Direct revascularization of acute myocardial infarction by implantation of left internal mammary artery into infarcted left ventricular myocardium.

MEDLINE

Manual

NLM

This is a preliminary report. Clearly, the internal mammary artery implanted into the infarcted anterolateral portion of the wall of the left ventricle has been of help in decreasing the size of the infarction and in maintaining the life of the dogs and normal function six hours after a large left ventricular wall myocardial infarction had been created. More animals need to be studied at the end of six hours, eight hours, and ten hours after implantation. More studies are needed to learn if ligation of the coronary veins at the same time as the arteries is beneficial or not. Two internal mammary arteries may act better than one when implanted side by side into a 5 by 5 centimeter infarction. In man, both internal mammary arteries and the right gastroepiploic artery could be used to revascularize acute myocardial infarctions in the posterior and anterolateral parts of the left ventricle.

Surgery, gynecology & obstetrics

0039-6087

Print

140

1

Print

1,975

Jan

null

44-52

A Vineberg (A); S Afridi (S); S Sahi (S)

Journal Article (D016428)

null

Acute Disease (UI: D000208, Major: No); Animals (UI: D000818, Major: No); Coronary Artery Bypass (UI: D001026, Major: No) - Qualifiers: methods (UI: Q000379, Major: No); Dogs (UI: D004285, Major: No); Humans (UI: D006801, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); pathology (UI: Q000473, Major: No); surgery (UI: Q000601, Major: Yes); Myocardial Revascularization (UI: D009204, Major: Yes) - Qualifiers: methods (UI: Q000379, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Radiography (UI: D011859, Major: No)

||methods (0)|||diagnostic imaging (0); pathology (0); surgery (1)|methods (0)|pathology (0)|

0|0|0|0|0|0|1|0|0

null

1976-04-01

2016-11-23

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 1865

Myocardial Ischemia

['Myocardial Infarction']

1,868

1

Effects of beta-adrenergic stimulating and blocking agents on the adrenaline response and adenyl cyclase activity of leukocyte in monkey and human being.

MEDLINE

Manual

NLM

Using the method in which leukocyte suspensions were incubated with NaF or metaproterenol at 30 degrees C for 15-30 min to allow them to convert 3H-ATP (10 muCi) to 3H-cyclic AMP, followed by separation of the formed 3H-cyclic AMP by common chromatography, the leukocyte adenyl cyclase activity of monkeys and human beings was measured with high reproducibility. The oral administration of metaproterenol increased the leukocyte adenyl cyclase activity which was stimulated by NaF and decreased the count of peripheral eosinophils in some of the monkeys. In the beta-adrenergic blockade of the monkey which was made by administration of propranolol, the leukocyte adenyl cyclase activity significantly decreased. The leukocyte adenyl cyclase from patients with coronary heart disease also decreased after oral medication with propranolol.

The Tohoku journal of experimental medicine

0040-8727

Print

117

2

Print

1,975

Oct

null

125-33

S Mue (S); T Ise (T); K Akasaka (K); T Takishima (T)

Journal Article (D016428)

Adrenergic beta-Agonists (Registry: 0, UI: D000318); Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Blood Glucose (Registry: 0, UI: D001786); Lactates (Registry: 0, UI: D007773); Metaproterenol (Registry: 53QOG569E0, UI: D009921); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433); Adenylyl Cyclases (Registry: EC 4.6.1.1, UI: D000262); Epinephrine (Registry: YKH834O4BH, UI: D004837)

Adenylyl Cyclases (UI: D000262, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes); Adrenergic beta-Agonists (UI: D000318, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Aged (UI: D000368, Major: No); Animals (UI: D000818, Major: No); Blood Glucose (UI: D001786, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: enzymology (UI: Q000201, Major: No); Eosinophils (UI: D004804, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Epinephrine (UI: D004837, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); pharmacology (UI: Q000494, Major: Yes); Female (UI: D005260, Major: No); Haplorhini (UI: D000882, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Lactates (UI: D007773, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Leukocytes (UI: D007962, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); enzymology (UI: Q000201, Major: Yes); Male (UI: D008297, Major: No); Metaproterenol (UI: D009921, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Middle Aged (UI: D008875, Major: No); Propranolol (UI: D011433, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Time Factors (UI: D013997, Major: No)

blood (1)|pharmacology (1)|pharmacology (1)|||metabolism (0)|enzymology (0)|drug effects (0)|blood (0); pharmacology (1)|||drug effects (0)||blood (0)|drug effects (0); enzymology (1)||pharmacology (0)||pharmacology (0)|

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-03-30

2019-07-27

pubmed: 1975-10-1; medline: 1975-10-1 0:1; entrez: 1975-10-1 0:0

pubmed: 1868; doi: 10.1620/tjem.117.125

Myocardial Ischemia

['Coronary Disease']

2,004

1

Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.

MEDLINE

Manual

NLM

Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants. Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease. Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs. A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.

The American journal of cardiology

0002-9149

Print

37

2

Print

1,976

Feb

null

223-30

N O Fowler (NO); D McCall (D); T C Chou (TC); J C Holmes (JC); I B Hanenson (IB)

Case Reports (D002363); Journal Article (D016428)

Adrenergic Agonists (Registry: 0, UI: D000322); Antidepressive Agents, Tricyclic (Registry: 0, UI: D000929); Digitalis Glycosides (Registry: 0, UI: D004071); Diuretics (Registry: 0, UI: D004232); Phenothiazines (Registry: 0, UI: D010640); Psychotropic Drugs (Registry: 0, UI: D011619); Mesoridazine (Registry: 5XE4NWM740, UI: D008653); Lidocaine (Registry: 98PI200987, UI: D008012); Thioridazine (Registry: N3D6TG58NI, UI: D013881); Chlorpromazine (Registry: U42B7VYA4P, UI: D002746)

Adrenergic Agonists (UI: D000322, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Antidepressive Agents, Tricyclic (UI: D000929, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: Yes); drug therapy (UI: Q000188, Major: No); Cardiovascular System (UI: D002319, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Chlorpromazine (UI: D002746, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: No); Digitalis Glycosides (UI: D004071, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Diuretics (UI: D004232, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Electrocardiography (UI: D004562, Major: Yes); Female (UI: D005260, Major: No); Heart Failure (UI: D006333, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); drug therapy (UI: Q000188, Major: No); Humans (UI: D006801, Major: No); Hypotension (UI: D007022, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); drug therapy (UI: Q000188, Major: No); Lidocaine (UI: D008012, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Male (UI: D008297, Major: No); Mesoridazine (UI: D008653, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: No); Middle Aged (UI: D008875, Major: No); Phenothiazines (UI: D010640, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Psychotropic Drugs (UI: D011619, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: Yes); Thioridazine (UI: D013881, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: No)

therapeutic use (0)|||pharmacology (0)|chemically induced (1); drug therapy (0)|drug effects (0)|adverse effects (0)|therapeutic use (0)|therapeutic use (0)|||chemically induced (0); drug therapy (0)||chemically induced (0); drug therapy (0)|therapeutic use (0)||adverse effects (0)||pharmacology (0)|adverse effects (1)|adverse effects (0)

0|0|0|0|0|0|0|0|0|1|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-02

2019-06-22

pubmed: 1976-2-1; medline: 1976-2-1 0:1; entrez: 1976-2-1 0:0

pubmed: 2004; pii: 0002-9149(76)90316-7; doi: 10.1016/0002-9149(76)90316-7

Heart Failure

[]

2,074

1

[Congenital cardiopathies appearing during the neonatal period. The view points of the cardiologist, the hemodynamics specialist, the surgeon, and the anesthetist].

MEDLINE

Manual

NLM

The best chances of survival for a new-born depend on the following factors: the possibility of clinical and haemodynamic diagnosis of the malformation, adequate reanimation and surgery. All this must be carried out as early as possible. Although catheterization is very risky it should be complete and as fast as possible, under monitoring of ventilation and haemodynamies. Reanimation is very important before, during and after surgery; it should be more preventive than curative. Very often, surgery is only palliative at this age. Taking into account progress in surgical techniques, the authors report their experience in anaesthesia and ressuscitation of 100 patients under 10 days old. They were all operated on in Laennec in Professor MATHEY's department but only some of them were catheterized there.

Annales de l'anesthesiologie francaise

0003-4061

Print

16 Spec No 1

null

Print

1,975

null

161-9

A Fiemeyer (A); F Leca-Chetochine (F); M Thibert (M); Y Louville (Y); J Mathey (J); M Cara (M)

English Abstract (D004740); Journal Article (D016428)

null

Anesthesia, General (UI: D000768, Major: Yes); Aortic Coarctation (UI: D001017, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No); Cardiac Catheterization (UI: D006328, Major: No); Heart Defects, Congenital (UI: D006330, Major: No) - Qualifiers: surgery (UI: Q000601, Major: Yes); Humans (UI: D006801, Major: No); Infant, Newborn (UI: D007231, Major: No); Preoperative Care (UI: D011300, Major: No); Tetralogy of Fallot (UI: D013771, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No); Transposition of Great Vessels (UI: D014188, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No)

|surgery (0)||surgery (1)||||surgery (0)|surgery (0)

1|0|0|0|0|0|0|0|0

null

1976-03-30

2017-03-22

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 2074

Heart Defects, Congenital

['Aortic Coarctation', 'Tetralogy of Fallot', 'Transposition of Great Vessels']

2,092

1

Effects of the cardioselective beta-blocker metoprolol in angina pectoris. A subacute study with exercise tests.

MEDLINE

Manual

NLM

The effects of the cardioselective beta-blocker, metoprolol, were evaluated under double-blind conditions in eighteen patients with angina pectoris. During an introductory run-in period of eight weeks, a placebo was given single-blindly. Thereafter two double-blind crossover periods each of four weeks followed, either 20 mg metroprolol or placebo being given t.i.d. Metoprolol gave a significant reduction in the number of anginal attacks and in nitroglycerin consumption. The patients' subjective assessments of their daily angina pectoris symptoms also showed a significant improvement compared with the placebo. At the end of each period, a standardized exercise test was performed. In comparison with placebo, metoprolol gave a significant increase of total work performed until the appearance of 1 mm ST-segment depression and until the end of exercise. The heart rate was significantly reduced at rest and during exercise. The blood pressure was significantly reduced only during exercise. None of the patients reported any severe unwanted effects. The complaints reported were mild to moderate, and the frequency during metoprolol treatment was even lower than during placebo treatment. No signs or symptoms of cardiac failure were seen in any of these patients on any occasion. It is concluded that 20 mg metoprolol t.i.d. is of benefit in the treatment of angina pectoris but further benefit might be obtained with higher doses.

Annals of clinical research

0003-4762

Print

7

6

Print

1,975

Dec

null

433-41

O Keyriläinen (O); A Uustialo (A)

Clinical Trial (D016430); Controlled Clinical Trial (D018848); Journal Article (D016428); Randomized Controlled Trial (D016449)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Propanolamines (Registry: 0, UI: D011412)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: No); therapeutic use (UI: Q000627, Major: Yes); Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cardiac Output (UI: D002302, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Clinical Trials as Topic (UI: D002986, Major: No); Drug Evaluation (UI: D004341, Major: No); Exercise Test (UI: D005080, Major: No); Female (UI: D005260, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); In Vitro Techniques (UI: D066298, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Propanolamines (UI: D011412, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: No); therapeutic use (UI: Q000627, Major: Yes); Time Factors (UI: D013997, Major: No)

adverse effects (0); therapeutic use (1)|||drug therapy (1)|drug effects (0)|drug effects (0)|||||drug effects (0)|||||adverse effects (0); therapeutic use (1)|

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-02

2014-11-20

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 2092

Myocardial Ischemia

['Angina Pectoris']

2,481

1

Cardiovascular and beta-adrenergic blocking effects of timolol.

MEDLINE

Manual

NLM

The haemodynamic effects of timolol and its inhibiting action on the cardiovascular and bronchial effects of isoproterenol have been studied. Splanchnic nerve activity was recorded. The antiarrhythmic action of timolol was studied on guinea pig isolated atria, using arrhythmias induced by epinephrine, ouabain or coronary ligation in the dog. Timolol is a very potent beta-adrenoceptor blocking agent, without specificity on beta1- or beta2-receptors. No intrinsic beta-stimulating or depressant effects were found. Timolol reduced splanchnic discharges. The antiarrhythmic effect of timolol was limited to epinephrine-induced arrhythmias.

European journal of pharmacology

0014-2999

Print

35

2

Print

1,976

Feb

null

235-43

P Mouillé (P); H Schmitt (H); G Cheymol (G); E Gauter (E)

Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Propanolamines (Registry: 0, UI: D011412); Thiadiazoles (Registry: 0, UI: D013830); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433); Isoproterenol (Registry: L628TT009W, UI: D007545)

Adrenergic beta-Antagonists (UI: D000319, Major: Yes); Airway Resistance (UI: D000403, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Animals (UI: D000818, Major: No); Aorta (UI: D001011, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); physiopathology (UI: Q000503, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Bronchi (UI: D001980, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Coronary Circulation (UI: D003326, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Dogs (UI: D004285, Major: No); Female (UI: D005260, Major: No); Guinea Pigs (UI: D006168, Major: No); Heart Atria (UI: D006325, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Hemodynamics (UI: D006439, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: Yes); In Vitro Techniques (UI: D066298, Major: No); Isoproterenol (UI: D007545, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: No); Male (UI: D008297, Major: No); Myocardial Contraction (UI: D009200, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Propanolamines (UI: D011412, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Propranolol (UI: D011433, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Splanchnic Nerves (UI: D013153, Major: No) - Qualifiers: physiology (UI: Q000502, Major: No); Thiadiazoles (UI: D013830, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Time Factors (UI: D013997, Major: No)

|drug effects (0)||drug effects (0)|chemically induced (0); physiopathology (0)|drug effects (0)|drug effects (0)|drug effects (0)||||drug effects (0)|drug effects (0)|drug effects (1)||antagonists & inhibitors (0)||drug effects (0)|pharmacology (1)|pharmacology (0)|physiology (0)|pharmacology (1)|

1|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-19

2019-06-23

pubmed: 1976-2-1; medline: 1976-2-1 0:1; entrez: 1976-2-1 0:0

pubmed: 2481; pii: 0014-2999(76)90225-9; doi: 10.1016/0014-2999(76)90225-9

Arrhythmias, Cardiac

[]

2,527

1

[Inflammatory cerebro-vascular disease: angiographic findings and distribution patterns (author's transl)].

MEDLINE

Manual

NLM

Although cerebral angiography should be approached with caution in the diagnosis of inflammatory cerebro-vascular disease there are some characteristic angiographic findings which may be helpful for classification and differential diagnosis. The proximal cerebral arteries are favourably affected by basal meningitis and thrombangiitis obliterans with resulting stenoses and occlusions. Whereas those inflammations originating from neighbouring skull structures mostly involve the intracavernous parts of the carotid artery, the tuberculous and mycotic arteritis prefer the supraclinoid carotid siphon. Peripheral vascular changes are found in luetic endangiitis, necrotizing and toxic angiitis and in collagenoses. Simultaneous involvement of the temporal arteries is of great diagnostic importance demonstrating the systemic character of the inflammatory process; in Horton's arteritis it can be a pathognomonic finding. Infectious endocarditis, some mycoses and malaria may lead to embolic occlusion of cerebral vessels. Mycotic aneurysms mostly have a broad base or a fusiform shape and do not prefer the localizations of congenital aneurysms. Angiographically, abscesses, tuberculomas and viral encephalitis may result in circumscribed hypervascularized areas. The characteristic angiographic findings are exemplified and discussed on the basis of 8 cases of inflammatory cerebro-vascular disease (tuberculosis, pneumococcal and unspecific bacterial meningitis, syphilis, mycosis, Takayasu-syndrome, panarteritis nodosa, temporal arteritis).

Fortschritte der Neurologie, Psychiatrie, und ihrer Grenzgebiete

0015-8194

Print

43

12

Print

1,975

Dec

null

631-47

P Stoeter (P); E Ortega-Suhrkamp (E); K Voigt (K)

Journal Article (D016428)

null

Adult (UI: D000328, Major: No); Arteritis (UI: D001167, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Cerebral Angiography (UI: D002533, Major: No); Cerebrovascular Disorders (UI: D002561, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnostic imaging (UI: Q000000981, Major: Yes); Diagnosis, Differential (UI: D003937, Major: No); Female (UI: D005260, Major: No); Giant Cell Arteritis (UI: D013700, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Humans (UI: D006801, Major: No); Malaria (UI: D008288, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Male (UI: D008297, Major: No); Meningitis (UI: D008581, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Middle Aged (UI: D008875, Major: No); Mycoses (UI: D009181, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Polyarteritis Nodosa (UI: D010488, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Syphilis, Cardiovascular (UI: D013589, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Thromboangiitis Obliterans (UI: D013919, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Tuberculosis, Cardiovascular (UI: D014381, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No)

|diagnostic imaging (0)||complications (0); diagnostic imaging (1)|||diagnostic imaging (0)||diagnostic imaging (0)||complications (0)||diagnostic imaging (0)|diagnostic imaging (0)|diagnostic imaging (0)|complications (0)|diagnostic imaging (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-19

2016-11-23

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 2527

Cerebrovascular Disorders

['Cerebrovascular Disorders']

2,820

1

Surgical management of severe aortic coarctation and interrupted aortic arch in neonates.

MEDLINE

Manual

NLM

Forty-four infants, 2 to 90 days of age, with severe obstructive lesions of the aortic arch, underwent emergency surgical correction between Jan. 1, 1966, and April 1, 1975. The typical clinical presentation was severe congestive heart failure and acidemia. Resection of an aortic coarctation with end-to-end anastomosis was performed in 31 patients. Eight (26 per cent) died after the operation. Since 1969, the mortality rate has been reduced to 14 per cent (3 of 22 patients) even though the incidence of major associated cardiac lesions has remained essentially constant (56 per cent from 1966 through 1969, 64 per cent from 1970 through March, 1975). This suggests that the higher survival rate has resulted from improved surgical techniques and postoperative care. The mortality rate in the infants operated upon during the second and third months of life was twice as high as that in those operated upon before the age of 1 month. Eight patients with Type A interrupted aortic arch were operated upon and 5 survived. Five patients with Type B aortic arch were operated upon and 3 survived.

The Journal of thoracic and cardiovascular surgery

0022-5223

Print

71

1

Print

1,976

Jan

null

35-48

N H Fishman (NH); M H Bronstein (MH); W Berman (W); B B Roe (BB); L H Edmunds (LH); S J Robinson (SJ); A M Rudolph (AM)

Journal Article (D016428)

null

Aorta (UI: D001011, Major: No) - Qualifiers: abnormalities (UI: Q000002, Major: Yes); Aortic Coarctation (UI: D001017, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); mortality (UI: Q000401, Major: No); surgery (UI: Q000601, Major: Yes); Heart Defects, Congenital (UI: D006330, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); mortality (UI: Q000401, Major: No); surgery (UI: Q000601, Major: Yes); Heart Failure (UI: D006333, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Infant (UI: D007223, Major: No); Infant, Newborn (UI: D007231, Major: No)

abnormalities (1)|complications (0); mortality (0); surgery (1)|complications (0); mortality (0); surgery (1)|etiology (0)||||

0|0|0|0|0|0|0|0

null

1976-04-15

2007-11-15

pubmed: 1976-1-1; medline: 2001-3-28 10:1; entrez: 1976-1-1 0:0

pubmed: 2820

Heart Failure

[]

2,821

1

Pharmacological analysis of the adrenergic control of the cerebral circulation.

MEDLINE

Manual

NLM

The adrenergic control of the cerebral circulation was subjected to pharmacological analysis. The status of the cerebral circulation was assessed using radioisotope, electromagnetic and resistographic methods. EEG, ECG and arterial pressure were recorded. The acid-base equilibrium and oxygen tension were measured in the arterial blood and cerebrospinal fluid. The experiments showed that the sympathetic innervation plays an important role in controlling cerebral circulation and in the development of cerebrovascular disorders. This was indicated by the constriction of intracranial arteries induced by noradrenaline, stimulation of sympathetic nerves, reflex sympathetic activations and the effect of potassium chloride on the centrol nervous system. The pharmacological study demonstrated that constriction of the intracranial vessels is brought about by an activation of the sympatho-adrenal system which is mediated via alpha-adrenoreceptors of cerebral blood vessels.

Medical biology

0302-2137

Print

53

6

Print

1,975

Dec

null

493-500

R S Mirzoyan (RS)

Journal Article (D016428)

Phenoxybenzamine (Registry: 0TTZ664R7Z, UI: D010643); Dihydroergotoxine (Registry: 11032-41-0, UI: D004088); Potassium Chloride (Registry: 660YQ98I10, UI: D011189); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433); Nialamide (Registry: T2Q0RYM725, UI: D009526); Norepinephrine (Registry: X4W3ENH1CV, UI: D009638); Guanethidine (Registry: ZTI6C33Q2Q, UI: D006145)

Acid-Base Equilibrium (UI: D000136, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Animals (UI: D000818, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cats (UI: D002415, Major: No); Cerebrovascular Circulation (UI: D002560, Major: Yes) - Qualifiers: drug effects (UI: Q000187, Major: No); Cerebrovascular Disorders (UI: D002561, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Dihydroergotoxine (UI: D004088, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Dogs (UI: D004285, Major: No); Electric Stimulation (UI: D004558, Major: No); Guanethidine (UI: D006145, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Nialamide (UI: D009526, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Norepinephrine (UI: D009638, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Partial Pressure (UI: D010313, Major: No); Phenoxybenzamine (UI: D010643, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Potassium Chloride (UI: D011189, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Propranolol (UI: D011433, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Vasomotor System (UI: D014666, Major: Yes) - Qualifiers: drug effects (UI: Q000187, Major: No)

drug effects (0)||drug effects (0)||drug effects (0)|physiopathology (0)|pharmacology (0)|||pharmacology (0)||pharmacology (0)|pharmacology (0)||pharmacology (0)|pharmacology (0)|pharmacology (0)|drug effects (0)

0|0|0|0|1|0|0|0|0|0|0|0|0|0|0|0|0|1

null

1976-04-09

2013-11-21

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 2821

Cerebrovascular Disorders

['Cerebrovascular Disorders']

2,928

1

Canine cardiac lymph potassium, pH and flow after experimental myocardial infarction.

MEDLINE

Manual

NLM

Canine cardiac lymph was studied after acute experimental myocardial infarction. The lymph potassium concentration remained the same, the lymph potassium content increased, the lymph pH decreased, and the lymph flow increased while the serum potassium and pH remained the same. It is suggested that localized hypoxia may result in cellular changes that release substances, e.g., potassium, to the interstitial space where they mobilize fluid and enhance lymph flow.

Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)

0037-9727

Print

151

1

Print

1,976

Jan

null

146-8

H N Uhley (HN); S E Leeds (SE); F R Elevitch (FR)

Journal Article (D016428); Research Support, U.S. Gov't, P.H.S. (D013487)

Potassium (Registry: RWP5GA015D, UI: D011188)

Animals (UI: D000818, Major: No); Dogs (UI: D004285, Major: No); Endocardium (UI: D004699, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: Yes); Lymph Nodes (UI: D008198, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); physiology (UI: Q000502, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Potassium (UI: D011188, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); metabolism (UI: Q000378, Major: Yes)

||||metabolism (1); physiology (0)|metabolism (1)|blood (0); metabolism (1)

0|0|0|1|0|0|0

null

1976-04-09

2020-09-30

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 2928; doi: 10.3181/00379727-151-39162

Myocardial Ischemia

['Myocardial Infarction']

2,973

1

[Prinzmetal angina: clinical aspects and coronarographic findings].

MEDLINE

Manual

NLM

The clinical course and coronary arteriographic findings in 5 patients with Prinzmetal's variant angina pectoris are reviewed. In 4 patients who had ST-elevations inferiorly, 1 had minimal, 1 only slight, and 1 medium coronary artery disease; 1 had coronary spasm. 1 patient with ST-elevation anteriorly had severe stenosis of the anterior descending coronary artery. All 5 patients had normal left ventriculograms, 3 also had normal left enddiastolic pressure, and 2 slight elevation. Medical treatment was carried out in 2 patients and surgical revascularization in 2. Both treatments were accompanied by marked symptomatic improvement. Spontaneous loss of angina occurred in 1 patient. Prinzmetal's variant angina pectoris may be accompanied by a variety of coronary arteriographic findings and the prognosis appears to be more favorable than previously reported.

Schweizerische medizinische Wochenschrift

0036-7672

Print

106

5

Print

1,976

Jan

31

141-6

I Renggli (I); F Burkart (F)

English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Nitroglycerin (Registry: G59M7S0WS3, UI: D005996)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Adult (UI: D000328, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: Yes); drug therapy (UI: Q000188, Major: No); surgery (UI: Q000601, Major: No); Arterial Occlusive Diseases (UI: D001157, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Coronary Angiography (UI: D017023, Major: Yes); Coronary Artery Bypass (UI: D001026, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Nitroglycerin (UI: D005996, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No)

therapeutic use (0)||diagnosis (1); drug therapy (0); surgery (0)|diagnosis (0)|||||||therapeutic use (0)

0|0|0|0|1|0|0|0|0|0|0

null

1976-04-27

2013-11-21

pubmed: 1976-1-31; medline: 1976-1-31 0:1; entrez: 1976-1-31 0:0

pubmed: 2973

Myocardial Ischemia

['Angina Pectoris']

3,026

1

[The correlation between activity of enzymes participating in the formation and utilization of acetyl CoA in rabbit heart mitochondria in myocarditis and normal state].

MEDLINE

Manual

NLM

Activities in rabbit heart mitochondria of acetoacetyl-CoA-thyolase, pyruvate dehydrogenase, acetyl CoA-synthetase, citrate synthase and acetyl carnitine transferase were compared. These enzymes participate in formation and utilization of acetyl-CoA. The acetoacetyl-CoA-thyolase and acetyl CoA-synthetase were shown to possess the more distinct capacity in vitro to form acetyl CoA. The co-enzyme was most efficiently utilized under these experimental conditions by the citrate synthase. The enzymes studied were localized within the mitochondria fraction in both the subfractions of soluble and membrane-bound proteins. In myocarditis a distinct decrease in activities of the acetoacetyl-CoA-thyolase and citrate synthase was observed.

Voprosy meditsinskoi khimii

0042-8809

Print

21

6

Print

null

625-9

E V Sharkova (EV)

English Abstract (D004740); Journal Article (D016428)

Pyruvate Dehydrogenase Complex (Registry: 0, UI: D011768); Acetyl Coenzyme A (Registry: 72-89-9, UI: D000105); Acetyltransferases (Registry: EC 2.3.1.-, UI: D000123); Acetyl-CoA C-Acetyltransferase (Registry: EC 2.3.1.9, UI: D000101); Citrate (si)-Synthase (Registry: EC 2.3.3.1, UI: D002950); Coenzyme A (Registry: SAA04E81UX, UI: D003065)

Acetyl Coenzyme A (UI: D000105, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Acetyl-CoA C-Acetyltransferase (UI: D000101, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Acetyltransferases (UI: D000123, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Animals (UI: D000818, Major: No); Citrate (si)-Synthase (UI: D002950, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Coenzyme A (UI: D003065, Major: No) - Qualifiers: analogs & derivatives (UI: Q000031, Major: Yes); Mitochondria, Muscle (UI: D008931, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Myocarditis (UI: D009205, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Pyruvate Dehydrogenase Complex (UI: D011768, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Rabbits (UI: D011817, Major: No)

metabolism (1)|metabolism (0)|metabolism (0)||metabolism (0)|analogs & derivatives (1)|metabolism (1)|metabolism (1)|metabolism (1)|metabolism (0)|

0|0|0|0|0|0|0|0|0|0|0

null

1976-04-23

2013-11-21

pubmed: 1975-11-1; medline: 1975-11-1 0:1; entrez: 1975-11-1 0:0

pubmed: 3026

Cardiomyopathies

['Myocarditis']

3,073

1

[Findings of subpartal monitoring, status of the newborn infant and evaluation of cardiotocographic findings].

MEDLINE

Manual

NLM

The parameters of the intrapartal fetal CTG and the actual pH are related to each other and to the Apgar score of the newborn. The interpretation was carried out by means of groups of 300 to 600 cases. The actual fetal pH has the most compact relation to the Apgar score of the newborn (C equals 0,31). But also this contingence is unsatisfactory. At fetal acidosis most of the Apgar scores are pathological, in that manner the pH is the most important test for indication of operative delivery. The rare CTG pattern as dip II and variable decelerations combined with tachycardia of bradycardia, the bradycardia with 80 bpm or less, are likewise indications of urgent delivery.

Zentralblatt fur Gynakologie

0044-4197

Print

98

1

Print

1,976

null

3-9

V Bollmann (V); E P Issel (EP); H Halle (H); D Ballauf (D); C Füssel (C)

English Abstract (D004740); Journal Article (D016428)

null

Acidosis (UI: D000138, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Apgar Score (UI: D001034, Major: No); Bradycardia (UI: D001919, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Female (UI: D005260, Major: No); Fetal Blood (UI: D005312, Major: No); Fetal Diseases (UI: D005315, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: Yes); Fetal Heart (UI: D005318, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Heart Rate (UI: D006339, Major: No); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Infant, Newborn (UI: D007231, Major: Yes); Obstetric Labor Complications (UI: D007744, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Pregnancy (UI: D011247, Major: No); Prenatal Diagnosis (UI: D011296, Major: No); Tachycardia (UI: D013610, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Uterine Contraction (UI: D014590, Major: No)

diagnosis (0)||diagnosis (0)|||diagnosis (1)|physiopathology (0)|||||diagnosis (0)|||diagnosis (0)|

0|0|0|0|0|0|0|0|0|0|1|0|0|0|0|0

null

1976-04-27

2008-02-11

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 3073

Arrhythmias, Cardiac

['Bradycardia', 'Tachycardia']

3,096

1

Factors of importance for the degree of ischemic injury in the isolated rat heart.

MEDLINE

Manual

NLM

Isolated working rat hearts were made ischemic by introducing a one-way aortic ball valve. After the ischemic period the hearts were perfused in a retrograde non-working way for 30 min. Flow rates, glycogen, ATP, and creatine-phosphate went down during the time of ischemia, whereas tissue lactate accumulated. For shorter periods of ischemia these values were normalized but after 30 min of ischemia the hearts seemed to be irreversibly damaged. There was a leakage of GOT, GPT, LDH, and CPK from all hearts when ischemic from 5 to 30 min. Different factors that might be of importance for the degree of ischemic injury were tested. The injury tended to be more severe at higher heart rates. Addition of adrenaline 10(-6)M resulted in excessive myocardial damage. A variation of pH from 7.1 to 7.7 did not alter the effects of the ischemic injury. One group of rats were injected with adrenaline for 8 weeks to simulate chronic stress. When hearts from these rats were made ischemic they were more prone to fail compared to controls. The failing hearts, on the other hand, had a lower leakage of enzymes, possibly due to a less severe myocardial damage. A high mechanical performance and a normal noradrenaline content of the hearts are key factors for the development of myocardial infarction, as indicated by this study.

Acta medica Scandinavica. Supplementum

0365-463X

Print

587

null

Print

1,976

null

141-9

A P Waldenstrõm (AP); A C Hjalmarson (AC)

Journal Article (D016428)

Lactates (Registry: 0, UI: D007773); Phosphocreatine (Registry: 020IUV4N33, UI: D010725); Adenosine Triphosphate (Registry: 8L70Q75FXE, UI: D000255); Glycogen (Registry: 9005-79-2, UI: D006003)

Adenosine Triphosphate (UI: D000255, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Animals (UI: D000818, Major: No); Coronary Circulation (UI: D003326, Major: No); Coronary Disease (UI: D003327, Major: Yes) - Qualifiers: metabolism (UI: Q000378, Major: No); physiopathology (UI: Q000503, Major: No); Glycogen (UI: D006003, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Heart Rate (UI: D006339, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Lactates (UI: D007773, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Male (UI: D008297, Major: No); Perfusion (UI: D010477, Major: No); Phosphocreatine (UI: D010725, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Rats (UI: D051381, Major: No)

metabolism (0)|||metabolism (0); physiopathology (0)|metabolism (0)|physiopathology (0)|||metabolism (0)|||metabolism (0)|

0|0|0|1|0|0|0|0|0|0|0|0|0

null

1976-04-30

2019-09-11

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 3096; doi: 10.1111/j.0954-6820.1976.tb05876.x

Myocardial Ischemia

['Coronary Disease']

3,095

1

Effects of metabolic and pharmacologic interventions on myocardial infarct size following coronary occlusion.

MEDLINE

Manual

NLM

A number of hemodynamic, pharmacologic and metabolic interventions were found to change the extent of acute ischemic injury of the myocardium and subsequent necrosis following experimental coronary artery occlusion. Reduction in myocardial damage occurred by decreasing myocardial oxygen demands (beta-adrenergic blocking agents, intra-aortic balloon counterpulsation, external counterpulsation, nitroglycerin, decreasing afterload in hypertensive patients, inhibition of lipolysis, and digitalis in the failing heart); by increasing myocardial oxygen supply either directly (coronary artery reperfusion or elevating arterial pO2), or through collateral vessels (elevation of coronary perfusion pressure by alpha-adrenergic agonists, intra-aortic balloon counterpulsation); or by increasing plasma osmolality (mannitol, hypertonic glucose); presumably by augmenting anaerobic metabolism (glucose-insulin-potassium, hypertonic glucose); by enhancing transport to the ischemic zone of substrates utilized in energy production (hyaluronidase); by protecting against autolytic and heterolytic damage (hydrocortisone, cobra venom factor, aprotinin). Augmentation of myocardial ischemic damage occurred as a consequence of increasing myocardial oxygen requirements (isoproterenol, glucagon, ouabain, bretylium tosylate, tachycardia); by decreasing myocardial oxygen supply either directly (hypoxia, anemia) or through reduction of collateral flow (hemorrhagic hypotension, minoxidil) or by decreasing substrate availability glycemia). Pilot studies have been carried out in patients with hyaluronidase, nitroglycerin, intra-aortic balloon counterpulsation, beta-blocking agents and Arfonad and have shown that these interventions may also reduce myocardial damage, suggesting that the concept of reduction in infarct size following coronary occlusion is applicable clinically.

Acta medica Scandinavica. Supplementum

0365-463X

Print

587

null

Print

1,976

null

125-36

P R Maroko (PR); E Braunwald (E)

Journal Article (D016428); Research Support, U.S. Gov't, P.H.S. (D013487)

Adrenergic alpha-Agonists (Registry: 0, UI: D000316); Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Isoproterenol (Registry: L628TT009W, UI: D007545)

Acute Disease (UI: D000208, Major: No); Adrenergic alpha-Agonists (UI: D000316, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: No); Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: No); Animals (UI: D000818, Major: No); Assisted Circulation (UI: D001243, Major: No); Dogs (UI: D004285, Major: No); Hemodynamics (UI: D006439, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Isoproterenol (UI: D007545, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: No); Myocardial Infarction (UI: D009203, Major: Yes) - Qualifiers: drug therapy (UI: Q000188, Major: No); metabolism (UI: Q000378, Major: No); physiopathology (UI: Q000503, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); pathology (UI: Q000473, Major: No); Necrosis (UI: D009336, Major: No); Oxygen Consumption (UI: D010101, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No)

|pharmacology (0); therapeutic use (0)|pharmacology (0); therapeutic use (0)||||drug effects (0)||pharmacology (0); therapeutic use (0)|drug therapy (0); metabolism (0); physiopathology (0)|metabolism (1); pathology (0)||drug effects (0)

0|0|0|0|0|0|0|0|0|1|0|0|0

null

1976-04-30

2019-09-11

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 3095; doi: 10.1111/j.0954-6820.1976.tb05874.x

Myocardial Ischemia

['Myocardial Infarction']

3,098

1

Double-blind study of the effect of cardioselective beta-blockade on chest pain in acute myocardial infarction.

MEDLINE

Manual

NLM

A double-blind study including three different cardioselective beta-blockers, practolol, H 87/07 and metoprolol, was performed in 54 patients with acute myocardial infarction and chest pain shortly after onset of symptoms. Transmural infarctions were found in 42 patients while 12 patients had nontransmural infarctions. Chest pain and the product of heart rate and systolic blood pressure were significantly reduced in the beta-blocker groups whereas no changes were seen after saline. All patients with nontransmural infarctions and 14 out of 29 with transmural infarctions got pain relief lasting for at least 30 min. None of the patients developed signs of left ventricular backward failure, shock, or bradycardia. A decrease in ST segment elevation was observed in all the transmural infarctions after beta-blockade. No changes in ST segment elevation were found after analgesics when given after saline, but in some cases an increase was seen in this parameter when analgesics were given due to insufficient pain relief after beta-blockers or due to return of chest pain. It is suggested that pain relief by beta-blockers indicates decrease of myocardial ischemia.

Acta medica Scandinavica. Supplementum

0365-463X

Print

587

null

Print

1,976

null

201-8

F Waagstein (F); A C Hjalmarson (AC)

Clinical Trial (D016430); Journal Article (D016428); Randomized Controlled Trial (D016449)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Propanolamines (Registry: 0, UI: D011412); Practolol (Registry: SUG9176GRW, UI: D011217)

Acute Disease (UI: D000208, Major: No); Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: Yes); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Clinical Trials as Topic (UI: D002986, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Middle Aged (UI: D008875, Major: No); Myocardial Contraction (UI: D009200, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); Pain (UI: D010146, Major: No); Practolol (UI: D011217, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: No); Propanolamines (UI: D011412, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: Yes)

|pharmacology (0); therapeutic use (1)|drug effects (0)||drug effects (0)|||drug effects (0)|drug therapy (1)||pharmacology (0); therapeutic use (0)|pharmacology (0); therapeutic use (1)

0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-30

2019-09-11

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 3098; doi: 10.1111/j.0954-6820.1976.tb05882.x

Myocardial Ischemia

['Myocardial Infarction']

3,150

1

Kawasaki disease. Relationship with infantile periarteritis nodosa.

MEDLINE

Manual

NLM

Until 1972, Kawasaki disease, or acute febrile infantile mucocutaneous lymph node syndrome (MCLS), was considered in Japan to be a nonfatal disease with a favorable prognosis. Based on the findings from two autopsy cases of MCLS, we believe that sudden and unexpected death during convalescence may be due to arterial lesions, especially those involving the coronary artery, that resemble those of periarteritis nodosa. Of 29 autopsy cases of MCLS, gathered from all over Japan, all exhibited arteritis lesions (eg, aneurysm due to coronary arteritis). Such vascular pathological findings may in fact represent the same entity as infantile periarteritis nodosa. Whether infantile periarteritis nodosa can be identified with the adult type is still debatable. The particular manifestations of infantile periarteritis nodosa might be related to severe vasculitis. Autopsy cases of infantile periarteritis nodosa without MCLS manifestations are being collected and studied.

Archives of pathology & laboratory medicine

0003-9985

Print

100

2

Print

1,976

Feb

null

81-6

N Tanaka (N); K Sekimoto (K); S Naoe (S)

Journal Article (D016428)

null

Age Factors (UI: D000367, Major: No); Child (UI: D002648, Major: No); Child, Preschool (UI: D002675, Major: No); Coronary Vessels (UI: D003331, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Edema, Cardiac (UI: D004489, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Erythema (UI: D004890, Major: No) - Qualifiers: mortality (UI: Q000401, Major: No); pathology (UI: Q000473, Major: No); Female (UI: D005260, Major: No); Heart Aneurysm (UI: D006322, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Humans (UI: D006801, Major: No); Infant (UI: D007223, Major: No); Japan (UI: D007564, Major: No); Lymphatic Diseases (UI: D008206, Major: No) - Qualifiers: mortality (UI: Q000401, Major: No); pathology (UI: Q000473, Major: Yes); Male (UI: D008297, Major: No); Polyarteritis Nodosa (UI: D010488, Major: No) - Qualifiers: mortality (UI: Q000401, Major: No); pathology (UI: Q000473, Major: Yes); Renal Artery (UI: D012077, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Syndrome (UI: D013577, Major: No); Thymus Gland (UI: D013950, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No)

|||pathology (0)|pathology (0)|mortality (0); pathology (0)||pathology (0)||||mortality (0); pathology (1)||mortality (0); pathology (1)|pathology (0)||pathology (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-04-30

2004-11-17

pubmed: 1976-2-1; medline: 1976-2-1 0:1; entrez: 1976-2-1 0:0

pubmed: 3150

Cardiomyopathies

['Edema, Cardiac']

3,241

1

[Role of P50 in resuscitation (author's transl)].

MEDLINE

Manual

NLM

The amount of oxygen made available to the tissues of the body depends essentially upon pulmonary gas exchanges, cardiac output and its regional distribution, haemoglobin concentration and also upon the oxygen affinity of the haemoglobin molecule. That a standard oxyhaemoglobin dissociation curve faithfully describes oxygen loading and unloading both in healthy subjects and in those suffering from pathological process has come under attack. Beside the effect of pH, PCO2 and temperature, the oxyhaemoglobin dissociation curve can be modified by alterations of other factors (concentration of 2,3-diphosphoglycerate, hormones, drugs). Although the shifts of the oxyhaemoglobin dissociation curve, expressed by variations of P50 may seem minute, the effect of these shifts, expressed in terms of the ""functional value of haemoglobin"" are very large. Assessment of the intensive care patient must take into account the effect of alterations of the oxyhaemoglobin dissociation curve which can either increase or diminish tissue oxygenation.

Bulletin de physio-pathologie respiratoire

0007-439X

Print

11

5

Print

null

637-58

P Foëx (P)

Journal Article (D016428); Review (D016454)

Carbon Dioxide (Registry: 142M471B3J, UI: D002245)

Blood (UI: D001769, Major: No); Carbon Dioxide (UI: D002245, Major: No) - Qualifiers: physiology (UI: Q000502, Major: No); Cardiac Output (UI: D002302, Major: No); Cardiovascular Diseases (UI: D002318, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Diabetes Mellitus (UI: D003920, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Extracorporeal Circulation (UI: D005112, Major: No); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Hypoxia (UI: D000860, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Kidney Failure, Chronic (UI: D007676, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Respiratory Tract Diseases (UI: D012140, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Resuscitation (UI: D012151, Major: Yes); Shock (UI: D012769, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No)

|physiology (0)||physiopathology (0)|physiopathology (0)|physiopathology (0)||||physiopathology (0)|physiopathology (0)|physiopathology (0)||physiopathology (0)

0|0|0|0|0|0|0|0|0|0|0|0|1|0

null

1976-05-18

2016-11-23

pubmed: 1975-9-1; medline: 1975-9-1 0:1; entrez: 1975-9-1 0:0

pubmed: 3241

Myocardial Ischemia

['Coronary Disease']

3,242

1

[Isotopic study of fluid and electrolyte disturbances in decompensated chronic respiratory insufficiency (author's transl)].

MEDLINE

Manual

NLM

The study of fluid and electrolyte disturbances by isotope radiodilution method is carried out in 22 patients with chronic respiratory insufficiency and cardiac failure. The simultaneous measurements of hydro-ionic compartments have been carried out with tritiated water (HTO), labelled sodium (22Na), labelled potassium (42K) and labelled bromine (82Br). From these measurements, the various water spaces are calculated: total water (ET) and extracellular fluids (LEC), also exchangeable electrolytes: sodium (NaE), potassium (KE), chlorine (ClE) and derived values. Results are compared to corresponding values in controls with the same obesity index. Patients with respiratory insufficiency show a fluid and sodium rise, similar to that found in cardiac failure and denutrition. The (NaE + KE)/ET ratio is not significantly decreased and the natremia is only slightly lower. There is no real potassium depletion in most patients.

Bulletin de physio-pathologie respiratoire

0007-439X

Print

11

5

Print

null

683-707

F Wattel (F); J Lefèvre (J); C Chopin (C); D Lottin (D); B Raviart (B)

English Abstract (D004740); Journal Article (D016428)

Carbon Dioxide (Registry: 142M471B3J, UI: D002245); Chlorine (Registry: 4R7X1O2820, UI: D002713); Sodium (Registry: 9NEZ333N27, UI: D012964); Potassium (Registry: RWP5GA015D, UI: D011188); Oxygen (Registry: S88TT14065, UI: D010100)

Aged (UI: D000368, Major: No); Blood (UI: D001769, Major: No); Body Water (UI: D001834, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Carbon Dioxide (UI: D002245, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Chlorine (UI: D002713, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Extracellular Space (UI: D005110, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Middle Aged (UI: D008875, Major: No); Obesity (UI: D009765, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Oxygen (UI: D010100, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Potassium (UI: D011188, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Respiratory Insufficiency (UI: D012131, Major: No) - Qualifiers: complications (UI: Q000150, Major: Yes); Sodium (UI: D012964, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Water-Electrolyte Imbalance (UI: D014883, Major: No) - Qualifiers: etiology (UI: Q000209, Major: Yes)

||metabolism (0)|blood (0)|metabolism (0)|metabolism (0)|metabolism (0)||||complications (0)|blood (0)|metabolism (0)|complications (1)|metabolism (0)|etiology (1)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-05-18

2013-11-21

pubmed: 1975-9-1; medline: 1975-9-1 0:1; entrez: 1975-9-1 0:0

pubmed: 3242

Myocardial Ischemia

['Coronary Disease']

3,293

1

Contribution of tissue acidosis to ischemic injury in the perfused rat heart.

MEDLINE

Manual

NLM

The isolated perfused working rat heart preparation has been used to study the effects of respiratory acidosis on myocardial metabolism and contractilly. Hearts were perfused with 5 mM glucose and 10(-2) U/ml of insulin in order to enhance metabolsim of glucose relative to that of fatty acids. After perfusion with Krebs bicarbonate medium at pH 6.6, hearts rapidly ceased performing external work and peak left ventricular pressure fell by 75% after 5 minutes. Oxygen consumption, rate of ATP generation and overall glycolytic flux also declined rapidly. After about 2 minutes of perfusion, the fall of glycolytic flux showed a partial reversal, which was largely accounted for by increased lactate production, so that glucose oxidation decreased further. The reversal of glycoltic flux could be accounted for by partial release of H+ inhibition of phospho-fructokinase by increased tissue levels of adenosine 5'-diphosphate (ADP), adenosine monophosphate (AMP) and P1 and decreased levels of adenosine triphosphate (ATP) and creatine phosphate. The increased proportion of glucose uptake converted to lactate together with an increase of the tissue lactate/pyruvate ratio could be accounted for by inhibition of the malate-aspartate cycle combined with tissue hypoxia. Lactate accumulated in the tissue as a result of a decreased permeability of the plasma membrane to lactate. Decreased oxygen delivery to the myocardium was caused by secondary constriction of the coronary vessels. In further experiments, the coronary flow was regulated by an external pump which delivered fluid at a controlled rate into the aortic cannula above the coronary arteries, and the degree of tissue hypoxia was monitored by measuring changes of pyridine nucleotide reduction state by surface fluorescence techniques. The effects of acidosis uncomplicated by possible hypoxia were compared directly with those produced by ischemic hypoxia. The effects of acidosis under these conditions were similar to those described above, and to those produced by ischemia. From these and other data it is concluded that the effects of ischemia are caused by a lowering of the intracellular pH, which decreases the rate of energy production relative to the rate of energy demand. However, it is suggested that the primary cause of the decreased peak systolic pressure with either acidosis or ischemia is not a result of a defect of energy metabolism, but is due to alteration of the calcium cycle of the heart. Possible causes of irreversible heart failure after prolonged ischemia are discussed.

Circulation

0009-7322

Print

53

3 Suppl

Print

1,976

Mar

null

I3-14

J R Williamson (JR); S W Schaffer (SW); C Ford (C); B Safer (B)

Journal Article (D016428); Research Support, U.S. Gov't, P.H.S. (D013487)

Adenine Nucleotides (Registry: 0, UI: D000227); Fatty Acids (Registry: 0, UI: D005227); Fructosephosphates (Registry: 0, UI: D005636); Glucosephosphates (Registry: 0, UI: D005958); Lactates (Registry: 0, UI: D007773); Pyruvates (Registry: 0, UI: D011773); Phosphocreatine (Registry: 020IUV4N33, UI: D010725); NAD (Registry: 0U46U6E8UK, UI: D009243); Adenosine Monophosphate (Registry: 415SHH325A, UI: D000249); NADP (Registry: 53-59-8, UI: D009249); Glucose (Registry: IY9XDZ35W2, UI: D005947)

Acidosis, Respiratory (UI: D000142, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); physiopathology (UI: Q000503, Major: No); Adenine Nucleotides (UI: D000227, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Adenosine Monophosphate (UI: D000249, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Animals (UI: D000818, Major: No); Coronary Circulation (UI: D003326, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); physiopathology (UI: Q000503, Major: No); Cytosol (UI: D003600, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Fatty Acids (UI: D005227, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Fructosephosphates (UI: D005636, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Glucose (UI: D005947, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Glucosephosphates (UI: D005958, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Heart Ventricles (UI: D006352, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); In Vitro Techniques (UI: D066298, Major: No); Lactates (UI: D007773, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Male (UI: D008297, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); NAD (UI: D009243, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); NADP (UI: D009249, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Oxygen Consumption (UI: D010101, Major: No); Phosphocreatine (UI: D010725, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Pressure (UI: D011312, Major: No); Pyruvates (UI: D011773, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Rats (UI: D051381, Major: No)

metabolism (1); physiopathology (0)|metabolism (0)|metabolism (0)|||metabolism (1); physiopathology (0)|metabolism (0)|metabolism (0)|metabolism (0)|metabolism (0)|metabolism (0)|physiopathology (0)|||metabolism (0)||metabolism (1)|metabolism (0)|metabolism (0)||metabolism (0)||metabolism (0)|

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-05-25

2014-11-20

pubmed: 1976-3-1; medline: 1976-3-1 0:1; entrez: 1976-3-1 0:0

pubmed: 3293

Myocardial Ischemia

['Coronary Disease']

3,420

1

Anti-arrhythmic action of nadolol, a beta-adrenergic receptor blocking agent.

MEDLINE

Manual

NLM

The anti-arrhythmic action of 2,3-cis-1,2,3,4-tetrahydro-5-[(2-hydroxy-3-tert-butylamino)propoxy]2,3-naphthalenediol (nadolol) was evaluated and compared with that of propranolol in several experimental models of cardiac arrhythmias. Both nadolol and propranolol antagonized isoproterenol-induced tachycardia and ouabain-induced arrhythmias in cats, antagonized coronary artery ligation-induced ventricular fibrillation and suppressed ventricular ectopic activity during vagal stimulation in dogs. In contrast to propranolol, nadolol was considerably weaker in suppressing existing digoxin-induced arrhythmias, lacked local anesthetic activity and did not depress the heart in dogs. Because of these findings, it is concluded that the anti-arrhythmic activity of nadolol is apparently related to blockade of beta-adrenergic receptors.

European journal of pharmacology

0014-2999

Print

35

1

Print

1,976

Jan

null

17-27

D B Evans (DB); M T Peschka (MT); R J Lee (RJ); R J Laffan (RJ)

Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Anti-Arrhythmia Agents (Registry: 0, UI: D000889); Naphthols (Registry: 0, UI: D009284); Propanolamines (Registry: 0, UI: D011412); Ouabain (Registry: 5ACL011P69, UI: D010042); Isoproterenol (Registry: L628TT009W, UI: D007545)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Animals (UI: D000818, Major: No); Anti-Arrhythmia Agents (UI: D000889, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); Dogs (UI: D004285, Major: No); Electric Stimulation (UI: D004558, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Heart Conduction System (UI: D006329, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Isoproterenol (UI: D007545, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: No); Male (UI: D008297, Major: No); Naphthols (UI: D009284, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Neural Conduction (UI: D009431, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Ouabain (UI: D010042, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: No); Propanolamines (UI: D011412, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Vagus Nerve (UI: D014630, Major: No) - Qualifiers: physiology (UI: Q000502, Major: No); Ventricular Fibrillation (UI: D014693, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No)

pharmacology (1)||pharmacology (1)|chemically induced (0)|||physiopathology (0)|drug effects (0)|antagonists & inhibitors (0)||pharmacology (0)|drug effects (0)|antagonists & inhibitors (0)|pharmacology (1)|physiology (0)|physiopathology (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-06-02

2019-06-23

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 3420; pii: 0014-2999(76)90296-X; doi: 10.1016/0014-2999(76)90296-x

Arrhythmias, Cardiac

['Ventricular Fibrillation']

3,643

1

The antiarrhythmic and cardiovascular properties of 1-dimethyl isopropylamino-3-(2-phenylphenoxy)-propan-2-ol chloride, UM-424.

MEDLINE

Manual

NLM

The quarternary ammonium compound, UM-424 [1-dimethyl isopropylamino-3-(2-phenylphenoxy)-propan-2-ol chloride], was evaluated for its antiarrhythmic and hemodynamic effects. UM-424 converted ouabain-induced ventricular tachycardia in the anesthetized dog when administered in an average dose of 4.6 mg/kg i.v. Pretreatment of anesthetized dogs with UM-424, 10 mg/kg, provided complete protection against the development of premature beats and ventricular fibrillation when the left anterior descending coronary artery was occluded for 20 minutes and then released. UM-424 was effective in reversing ventricular arrhythmias in conscious animals which had been subjected to a two-stage ligation of the anterior descending coronary artery. The mean ectopic rate in a group of five dogs was 143 +/- 4.0 (S.E.M.) beats/min 24 hours after coronary ligation. Normal sinus rhythm was restored with a mean dose of 9.5 mg/kg of UM-424 and was maintained for a period in excess of 60 minutes. The ventricular fibrillation threshold was increased from a control value of 4.0 +/- 0.4 to 26.2 +/- 8.6 mA (P less than .05) 30 minutes after pretreatment with UM-424, 10 mg/kg. Inotropic and chronotropic dose-response studies to isoproterenol in the anesthetized dog demonstrated that the quarternary compound lacked beta adrenergic receptor blocking properties. UM-424, 10 mg/kg, did not produce any persistent changes in spontaneous heart rate, cardiac contractile force, left ventricular dP/ct, mean arterial blood pressure, cardiac output and mean pulmonary arterial pressure.

The Journal of pharmacology and experimental therapeutics

0022-3565

Print

196

2

Print

1,976

Feb

null

420-32

F J Kniffen (FJ); S Winokur (S); R E Counsell (RE); B R Lucchesi (BR)

Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Anti-Arrhythmia Agents (Registry: 0, UI: D000889); Propanolamines (Registry: 0, UI: D011412); Quaternary Ammonium Compounds (Registry: 0, UI: D000644); UM-424 (Registry: 58520-98-2, UI: C011588); Ouabain (Registry: 5ACL011P69, UI: D010042); Isoproterenol (Registry: L628TT009W, UI: D007545)

Adrenergic beta-Antagonists (UI: D000319, Major: No); Animals (UI: D000818, Major: No); Anti-Arrhythmia Agents (UI: D000889, Major: Yes); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); physiopathology (UI: Q000503, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cardiac Output (UI: D002302, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cats (UI: D002415, Major: No); Coronary Vessels (UI: D003331, Major: No) - Qualifiers: physiology (UI: Q000502, Major: No); Dogs (UI: D004285, Major: No); Drug Interactions (UI: D004347, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Hemodynamics (UI: D006439, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: Yes); Isoproterenol (UI: D007545, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Ligation (UI: D008026, Major: No); Male (UI: D008297, Major: No); Myocardial Contraction (UI: D009200, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Ouabain (UI: D010042, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Papillary Muscles (UI: D010210, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Propanolamines (UI: D011412, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Quaternary Ammonium Compounds (UI: D000644, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Ventricular Fibrillation (UI: D014693, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No)

|||chemically induced (0); physiopathology (0)|drug effects (0)|drug effects (0)||physiology (0)|||drug effects (0)|drug effects (1)|pharmacology (0)|||drug effects (0)|pharmacology (0)|drug effects (0)|pharmacology (1)|pharmacology (1)|physiopathology (0)

0|0|1|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-05-10

2019-12-10

pubmed: 1976-2-1; medline: 1976-2-1 0:1; entrez: 1976-2-1 0:0

pubmed: 3643

Arrhythmias, Cardiac

['Ventricular Fibrillation']

3,647

1

A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.

MEDLINE

Manual

NLM

A series of 1-(2-acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols has been synthesized and examined for beta-receptor blocking and antiarrhythmic activity. Several of these compounds are more than 20 times as active in blocking cardiac beta-receptors than vascular beta-receptors when given intravenously to anesthetized cats. The activities have been correlated quantitatively with partition and steric substitution constants. The observed relationships are consistent with a tentative proposal that the vascular receptor is situated in a more lipophilic environment than the cardiac receptor so that there is a differential transport effect between the two types of receptor.

Journal of medicinal chemistry

0022-2623

Print

19

3

Print

1,976

Mar

null

399-402

B Basil (B); J R Clark (JR); E C Coffee (EC); R Jordon (R); A H Loveless (AH); D L Pain (DL); K R Wooldridge (KR)

Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Anilides (Registry: 0, UI: D000813); Propanolamines (Registry: 0, UI: D011412); Receptors, Adrenergic (Registry: 0, UI: D011941); Ouabain (Registry: 5ACL011P69, UI: D010042); Isoproterenol (Registry: L628TT009W, UI: D007545)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: chemical synthesis (UI: Q000138, Major: Yes); pharmacology (UI: Q000494, Major: No); Anilides (UI: D000813, Major: No) - Qualifiers: chemical synthesis (UI: Q000138, Major: No); pharmacology (UI: Q000494, Major: No); Animals (UI: D000818, Major: No); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); Cats (UI: D002415, Major: No); Dogs (UI: D004285, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Isoproterenol (UI: D007545, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: No); Molecular Conformation (UI: D008968, Major: No); Organ Specificity (UI: D009928, Major: No); Ouabain (UI: D010042, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: No); Propanolamines (UI: D011412, Major: No) - Qualifiers: chemical synthesis (UI: Q000138, Major: Yes); pharmacology (UI: Q000494, Major: No); Receptors, Adrenergic (UI: D011941, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Structure-Activity Relationship (UI: D013329, Major: No)

chemical synthesis (1); pharmacology (0)|chemical synthesis (0); pharmacology (0)||chemically induced (0)|||drug effects (0)|antagonists & inhibitors (0)|||antagonists & inhibitors (0)|chemical synthesis (1); pharmacology (0)|drug effects (0)|

0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-05-25

2019-07-09

pubmed: 1976-3-1; medline: 1976-3-1 0:1; entrez: 1976-3-1 0:0

pubmed: 3647; doi: 10.1021/jm00225a012

Arrhythmias, Cardiac

[]

3,889

1

[Extracardiac factors in the development of arrhythmias (author's transl)].

MEDLINE

Manual

NLM

A brief survey is given of some of the most frequent extracardiac causes which may provoke disturbances of rhythm. The importance of psychogenic and metabolic factors is emphasized. Additional organic lesions cannot be excluded in every case.

Wiener klinische Wochenschrift

0043-5325

Print

87

22

Print

null

737-40

H Mösslacher (H); J Slany (J)

English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Hypnotics and Sedatives (Registry: 0, UI: D006993); Sympathomimetics (Registry: 0, UI: D013566); Atropine (Registry: 7C0697DR9I, UI: D001285)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); drug therapy (UI: Q000188, Major: No); etiology (UI: Q000209, Major: Yes); Atropine (UI: D001285, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Central Nervous System Diseases (UI: D002493, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Humans (UI: D006801, Major: No); Hyperthyroidism (UI: D006980, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Hypnotics and Sedatives (UI: D006993, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Neurotic Disorders (UI: D009497, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Psychotherapy (UI: D011613, Major: No); Reflex (UI: D012018, Major: No); Sympathomimetics (UI: D013566, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Water-Electrolyte Imbalance (UI: D014883, Major: No) - Qualifiers: complications (UI: Q000150, Major: No)

therapeutic use (0)|chemically induced (0); drug therapy (0); etiology (1)|therapeutic use (0)|complications (0)||complications (0)|therapeutic use (0)|complications (0)|||therapeutic use (0)|complications (0)

0|0|0|0|0|0|0|0|0|0|0|0

null

1976-06-02

2013-11-21

pubmed: 1975-11-1; medline: 1975-11-1 0:1; entrez: 1975-11-1 0:0

pubmed: 3889

Arrhythmias, Cardiac

[]

3,949

1

Pattern of enzyme activity following acute myocardial infarction with special reference to gamma-glutamyl transpeptidase.

MEDLINE

Manual

NLM

The present study on 55 consecutive patients with acute myocardial infarction (AMI) draws attention to the relationship between different enzyme maxima in AMI, with special reference to serum gamma-glutamyl transpeptidase (S-GT). In more than 60% of the patients the S-GT was increased during the hospital stay. The S-GT rise nearly always began during the first days, reached a maximum within 5--8 days and normalized with 2--3 weeks. We failed to find the late increase in S-GT reported by others. The rise of S-GT is particularly common in patients with inferior infarction, with or without right ventricular involvement. We conclude that S-GT activity is not a useful early or late indicator of AMI but a very sensitive test for hepatic dysfunction in patients with AMI.

Acta medica Scandinavica

0001-6101

Print

199

3

Print

1,976

null

217-21

U Säwe (U); L R Erhardt (LR); A Sjögren (A)

Journal Article (D016428)

L-Lactate Dehydrogenase (Registry: EC 1.1.1.27, UI: D007770); gamma-Glutamyltransferase (Registry: EC 2.3.2.2, UI: D005723); Alanine Transaminase (Registry: EC 2.6.1.2, UI: D000410); Creatine Kinase (Registry: EC 2.7.3.2, UI: D003402); Alkaline Phosphatase (Registry: EC 3.1.3.1, UI: D000469)

Acute Disease (UI: D000208, Major: No); Alanine Transaminase (UI: D000410, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Alkaline Phosphatase (UI: D000469, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Creatine Kinase (UI: D003402, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); L-Lactate Dehydrogenase (UI: D007770, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Liver (UI: D008099, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Male (UI: D008297, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: enzymology (UI: Q000201, Major: Yes); physiopathology (UI: Q000503, Major: No); Time Factors (UI: D013997, Major: No); gamma-Glutamyltransferase (UI: D005723, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes)

|blood (0)|blood (0)|blood (0)|||blood (0)|physiopathology (0)||enzymology (1); physiopathology (0)||blood (1)

0|0|0|0|0|0|0|0|0|0|0|0

null

1976-05-25

2019-08-12

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 3949; doi: 10.1111/j.0954-6820.1976.tb06719.x

Myocardial Ischemia

['Myocardial Infarction']

3,959

1

Myocardial ischemia and cell acidosis: Modification by alkali and the effects on ventricular function and cation composition.

MEDLINE

Manual

NLM

Myocardial cell pH was measured with 5, 5 dimethyl-2, 4-oxazolidinedione (DMO) in intact anesthetized dogs by a transient indicator dilution technique. Bolus injections of labeled DMO, vascular, extracellular and water indicators were made into the left anterior descending coronary artery, and blood samples were collected from the great cardiac vein. The steady state distribution of DMO between cells and plasma was calculated from the mean transit times of the indicator. Normal myocardial cell pH averaged 6.94 and changed by 58% of the concomitant alterations in plasma pH after infusions of acid or alkali. Myocardial ischemia induced by inflation of a balloon tip catheter in the left anterior descending coronary artery resulted in progressive decreases in cell pH to 6.59 by 1 hour. Infusions of sodium carbonate diminished intracellular acidosis. Hemodynamic studies during 4 hours of ischemia with blood pH at 7.55 to 7.60 indicated a significantly reduced left ventricular end-diastolic pressure and increased stroke volume by comparison with findings in animals given infusions of saline solution. Ventriculograms revealed improved wall motion in the ischemic segment after infusion of alkali. Precordial mapping showed a significant reduction in the number of leads with S-T segment elevation as well as in the sum of S-T segment elevations, but R wave amplitudes did not differ from those in control studies. Calculations of extracellular space, tissue water and cation content revealed a reduced gain of cell sodium ion and loss of cell potassium ion during ischemia after alkali treatment. The latter may account for the S-T segment responses, whereas enhanced ventricular performance may be related to reduced competition of hydrogen ion with calcium ion for binding sites on contractile protein.

The American journal of cardiology

0002-9149

Print

37

4

Print

1,976

Mar

31

501-7

T J Regan (TJ); R M Effros (RM); B Haider (B); H A Oldewurtel (HA); P O Ettinger (PO); S S Ahmed (SS)

Journal Article (D016428); Research Support, U.S. Gov't, P.H.S. (D013487)

Alkalies (Registry: 0, UI: D000468); Carbonates (Registry: 0, UI: D002254); Cations, Monovalent (Registry: 0, UI: D002414); Edetic Acid (Registry: 9G34HU7RV0, UI: D004492); Dimethadione (Registry: ALU9NPM703, UI: D004114)

Acidosis (UI: D000138, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Alkalies (UI: D000468, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); therapeutic use (UI: Q000627, Major: No); Animals (UI: D000818, Major: No); Body Water (UI: D001834, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Carbonates (UI: D002254, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Cations, Monovalent (UI: D002414, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); metabolism (UI: Q000378, Major: No); physiopathology (UI: Q000503, Major: No); Coronary Vessels (UI: D003331, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Dimethadione (UI: D004114, Major: No); Dogs (UI: D004285, Major: No); Edetic Acid (UI: D004492, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Extracellular Space (UI: D005110, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Hydrogen-Ion Concentration (UI: D006863, Major: No); Indicator Dilution Techniques (UI: D007201, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); pathology (UI: Q000473, Major: No)

metabolism (1)|pharmacology (1); therapeutic use (0)||metabolism (0)|pharmacology (0)||drug therapy (0); metabolism (0); physiopathology (0)|drug effects (0)|||pharmacology (0)|metabolism (0)|physiopathology (1)|||metabolism (0); pathology (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-06-02

2019-06-22

pubmed: 1976-3-31; medline: 1976-3-31 0:1; entrez: 1976-3-31 0:0

pubmed: 3959; pii: 0002-9149(76)90388-X; doi: 10.1016/0002-9149(76)90388-x

Myocardial Ischemia

['Coronary Disease']

3,960

1

Effects of allopurinol, propranolol and methylprednisolone on infarct size in experimental myocardial infarction.

MEDLINE

Manual

NLM

With use of a canine model of occlusion of the left anterior descending coronary artery and an intracellular lactic dehydrogenase stain to measure infarct size directly, the effects of allopurinol, methylprednisolone sodium succinate and propranolol were studied. Allopurinol did not influence the extent of myocardial necrosis, whereas both methylprednisolone and propranolol significantly reduced myocardial infarct size. Possible mechanisms of action and clinical applicability of these agents are discussed.

The American journal of cardiology

0002-9149

Print

37

4

Print

1,976

Mar

31

572-80

C H Shatney (CH); D J MacCarter (DJ); R C Lillehei (RC)

Journal Article (D016428)

Allopurinol (Registry: 63CZ7GJN5I, UI: D000493); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433); Oxygen (Registry: S88TT14065, UI: D010100); Methylprednisolone (Registry: X4W7ZR7023, UI: D008775)

Allopurinol (UI: D000493, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); therapeutic use (UI: Q000627, Major: No); Animals (UI: D000818, Major: No); Blood (UI: D001769, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Disease Models, Animal (UI: D004195, Major: Yes); Dogs (UI: D004285, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Hemodynamics (UI: D006439, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Methylprednisolone (UI: D008775, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); therapeutic use (UI: Q000627, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: pathology (UI: Q000473, Major: Yes); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Oxygen (UI: D010100, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Propranolol (UI: D011433, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); therapeutic use (UI: Q000627, Major: No)

pharmacology (1); therapeutic use (0)|||drug therapy (0)|||drug effects (0)|drug effects (0)||pharmacology (1); therapeutic use (0)|pathology (1)|metabolism (0)|blood (0)|pharmacology (1); therapeutic use (0)

0|0|0|0|1|0|0|0|0|0|0|0|0|0

null

1976-06-02

2019-06-22

pubmed: 1976-3-31; medline: 1976-3-31 0:1; entrez: 1976-3-31 0:0

pubmed: 3960; pii: 0002-9149(76)90398-2; doi: 10.1016/0002-9149(76)90398-2

Myocardial Ischemia

['Coronary Disease', 'Myocardial Infarction']

4,080

1

Effects of the cardioselective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests.

MEDLINE

Manual

NLM

The effect of a cardioselective beta-adrenergic blocking agent, metoprolol, on symptoms and exercise tolerance was studied in 16 patients with angina pectoris. Metroprolol was compared with placebo at two dose levels (20 mg t.d.s. and 50 mg t.d.s.) in a double-blind trial in 14 patients. Compared with placebo, metroprolol caused a significant reduction of heart rate and systolic blood pressure during exercise, and consequently a reduction of the rate-pressure product. The reduction was greater with 50 mg t.d.s. than with 20 mg t.d.s. The exercise tolerance measured as total work increased significantly by 21 per cent during treatment with metroprolol 20 mg t.d.s., and by 17 per cent during treatment with 50 mg t.d.s. There was a reduction in the number of anginal attacks and in nitroglycerin consumption, and subjective improvement of angina pectoris at both dose levels of metroprolol. No signs of cardiac failure appeared during any of the four treatment periods. Heart volume showed no significant change. Unwanted effects were of the same frequency and severity during treatment with metroprolol at both dose levels as with placebo.

British heart journal

0007-0769

Print

38

2

Print

1,976

Feb

null

155-61

L G Ekelund (LG); A G Olsson (AG); L Orö (L); S Rössner (S)

Clinical Trial (D016430); Comparative Study (D003160); Controlled Clinical Trial (D018848); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Propanolamines (Registry: 0, UI: D011412); Nitroglycerin (Registry: G59M7S0WS3, UI: D005996)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: Yes); Aged (UI: D000368, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); physiopathology (UI: Q000503, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Clinical Trials as Topic (UI: D002986, Major: No); Drug Administration Schedule (UI: D004334, Major: No); Exercise Test (UI: D005080, Major: No); Female (UI: D005260, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Nitroglycerin (UI: D005996, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: No); Propanolamines (UI: D011412, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes)

pharmacology (0); therapeutic use (1)||drug therapy (1); physiopathology (0)|drug effects (0)|||||physiopathology (0)|drug effects (0)||||administration & dosage (0)|therapeutic use (1)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2019-05-03

pubmed: 1976-2-1; medline: 1976-2-1 0:1; entrez: 1976-2-1 0:0

pubmed: 4080; pmc: PMC482986; doi: 10.1136/hrt.38.2.155

Myocardial Ischemia

['Angina Pectoris']

4,084

1

The use of a single venous blood sample to assess oxygen binding in haemoglobin.

MEDLINE

Manual

NLM

The measurement of pH, PO2, PCO2 and SO2 in a single venous blood sample can be used to determine the P50 at standard or at in vivo conditions. This technique makes it feasible for a physician, firstly, to make an assessment of the net adaptation of the red cell to reductions in blood oxygen content or flow and, secondly, to make an initial assessment of whether a haemoglobin with altered affinity for oxygen is present in subjects with polycythaemia or anaemia.

British journal of haematology

0007-1048

Print

32

1

Print

1,976

Jan

null

89-98

M A Lichtman (MA); M Murphy (M); M Pogal (M)

Journal Article (D016428); Research Support, U.S. Gov't, Non-P.H.S. (D013486); Research Support, U.S. Gov't, P.H.S. (D013487)

Hemoglobins (Registry: 0, UI: D006454); Oxygen (Registry: S88TT14065, UI: D010100)

Acidosis (UI: D000138, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Alkalosis (UI: D000471, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Anemia (UI: D000740, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Anemia, Sickle Cell (UI: D000755, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Blood Specimen Collection (UI: D001800, Major: Yes); Body Temperature (UI: D001831, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Female (UI: D005260, Major: No); Fetal Blood (UI: D005312, Major: No); Heart Failure (UI: D006333, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Hemoglobins (UI: D006454, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Male (UI: D008297, Major: No); Methods (UI: D008722, Major: No); Oxygen (UI: D010100, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes); Veins (UI: D014680, Major: No)

blood (0)|blood (0)|blood (0)|blood (0)|||blood (0)|||blood (0)|metabolism (1)|||||blood (1)|

0|0|0|0|1|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2019-07-04

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 4084; doi: 10.1111/j.1365-2141.1976.tb01878.x

Myocardial Ischemia

['Coronary Disease']

4,177

1

[Case of congenital megaurethra associated with bilateral renal hyperplasia].

MEDLINE

Manual

NLM

Authors report a very rare malformation of the external genital organs in a male new-born who died 48 hours after birth. This malformation consisted in a total aplasia of the corpus cavernosum and bulbus penis with a fusiforme dilatation of the anterior urethra. The malformation was associated with an anal imperforation, bilateral cryptorchidism and renal hypoplasia.

Bulletin de l'Association des anatomistes

0376-6160

Print

59

166

Print

1,975

Sep

null

591-600

M Colas (M); B Lauras (B); A Morin (A); J Cuilleret (J)

Case Reports (D002363); English Abstract (D004740); Journal Article (D016428)

null

Abnormalities, Multiple (UI: D000015, Major: Yes); Anus, Imperforate (UI: D001006, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Cryptorchidism (UI: D003456, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Heart Defects, Congenital (UI: D006330, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Humans (UI: D006801, Major: No); Infant, Newborn (UI: D007231, Major: No); Infant, Premature (UI: D007234, Major: No); Infant, Premature, Diseases (UI: D007235, Major: Yes); Kidney (UI: D007668, Major: No) - Qualifiers: abnormalities (UI: Q000002, Major: Yes); Male (UI: D008297, Major: No); Penis (UI: D010413, Major: No) - Qualifiers: abnormalities (UI: Q000002, Major: No); Urethra (UI: D014521, Major: No) - Qualifiers: abnormalities (UI: Q000002, Major: Yes)

|complications (0)|complications (0)|complications (0)|||||abnormalities (1)||abnormalities (0)|abnormalities (1)

1|0|0|0|0|0|0|1|0|0|0|0

null

1976-07-06

2006-11-15

pubmed: 1975-9-1; medline: 1975-9-1 0:1; entrez: 1975-9-1 0:0

pubmed: 4177

Heart Defects, Congenital

[]

4,256

1

Acebultolol: basis for the prediction of effect on exercise tolerance.

MEDLINE

Manual

NLM

Twelve unselected males suffering from documented coronary insufficiency and moderately severe angina submitted to graded multistage treadmill exercise testing on 3 separate days, 3.5 hr after a single dose of 0,200, or 400 mg of acebulolol, a cardioselective beta blocker. Control measures included random allocation of 2 patients to each of 6 balanced sequences of administration, standardized double-blind conditions, and variance analysis for Latin-square design with repeated measures on each subject. Performance was evaluated by measuring time elapsed until anginal pain, peak heart rate, peak product of heart rate and blood pressure, and peak oxygen consumption. Mean values for all criteria were significantly atered by 400 mg of acebutolol. Seven out of twelve patients were classified as responders (i.e., exercise duration increased 100% or more). The response after acebutolol was correlated with the performance on placebo in the base of exercise duration, peak heart rate, and peak product of heart rate and blood pressure. It is concluded that: (1) performance criteria are useful predictors of response to beta blockade and (2) acebutolol is a potent antianginal agent when judged by an objective treadmill exercise test.

Clinical pharmacology and therapeutics

0009-9236

Print

19

3

Print

1,976

Mar

null

333-8

P Biron (P); G Tremblay (G)

Clinical Trial (D016430); Journal Article (D016428); Randomized Controlled Trial (D016449)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Acebutolol (Registry: 67P356D8GH, UI: D000070)

Acebutolol (UI: D000070, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Adult (UI: D000328, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Exercise Test (UI: D005080, Major: Yes); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Middle Aged (UI: D008875, Major: No); Oxygen Consumption (UI: D010101, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Physical Exertion (UI: D005082, Major: No); Time Factors (UI: D013997, Major: No)

pharmacology (1)|pharmacology (0)||physiopathology (0)|drug effects (0)|physiopathology (1)||drug effects (0)|||drug effects (0)||

0|0|0|0|0|0|1|0|0|0|0|0|0

null

1976-07-06

2019-05-09

pubmed: 1976-3-1; medline: 1976-3-1 0:1; entrez: 1976-3-1 0:0

pubmed: 4256; doi: 10.1002/cpt1976193333

Myocardial Ischemia

['Angina Pectoris', 'Coronary Disease']

4,288

1

The difficult hypertensive.

MEDLINE

Manual

NLM

With the wide range of medications available today it should be possible to obtain satisfactory control in the majority of hypertensive patients. However, there are various categories of patients who may present particular problems in management, as for example patients with cerebro-vascular and coronary disease, or with renal failure. A particularly important group is those presenting with severe resistant hypertension, and these patients may constitute about 5 to 10% of the hypertensive population. Considerations relevant to the management of patients presenting with such problems are discussed. Combined drug regimens employing clonidine or beta-blockers with peripheral vasodilators appear to be particularly useful.

Drugs

0012-6667

Print

11

1

Print

1,976

null

55-60

J Raftos (J)

Journal Article (D016428); Review (D016454)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Antihypertensive Agents (Registry: 0, UI: D000959); Diuretics (Registry: 0, UI: D004232); Vasodilator Agents (Registry: 0, UI: D014665)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Alcoholism (UI: D000437, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Antihypertensive Agents (UI: D000959, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Cerebrovascular Disorders (UI: D002561, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Depression (UI: D003863, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Diuretics (UI: D004232, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Drug Resistance (UI: D004351, Major: No); Drug Therapy, Combination (UI: D004359, Major: No); Emotions (UI: D004644, Major: No); Humans (UI: D006801, Major: No); Hypertension (UI: D006973, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnosis (UI: Q000175, Major: No); drug therapy (UI: Q000188, Major: No); therapy (UI: Q000628, Major: Yes); Stress, Physiological (UI: D013312, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Substance-Related Disorders (UI: D019966, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Vasodilator Agents (UI: D014665, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No)

therapeutic use (0)|complications (0)|therapeutic use (0)|complications (0)|complications (0)|complications (0)|therapeutic use (0)|||||complications (0); diagnosis (0); drug therapy (0); therapy (1)|complications (0)|complications (0)|therapeutic use (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2018-10-25

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 4288; doi: 10.2165/00003495-197611010-00005

Cerebrovascular Disorders

['Cerebrovascular Disorders']

4,649

1

Morphologic and biochemical changes in autolysing dog heart muscle.

MEDLINE

Manual

NLM

The progressive changes in pH, lactate content, and light and electron microscopic appearances were studied in dog myocardium undergoing a 6-hour period of autolysis in vitro at 37 degrees C. and at room temperature. At 37 degrees C. there was a rapid cumulative fall in pH during the 1st hour after excision of the heart and a corresponding increase in lactate content, but little additional change in either subsequently. The nature and sequence of the morphologic alterations at this temperature were generally similar to those which occur in ischemic myocardium in vivo. At room temperature, a much slower cumulative decrease in pH and increase in lactate content took place throughout the whole period of investigation and was paralleled by a slower rate of development of morphologic change.

Laboratory investigation; a journal of technical methods and pathology

0023-6837

Print

34

4

Print

1,976

Apr

null

357-62

L C Armiger (LC); R N Seelye (RN); V M Carnell (VM); C U Smith (CU); J B Gavin (JB); P B Herdson (PB)

Journal Article (D016428)

Lactates (Registry: 0, UI: D007773); Glycogen (Registry: 9005-79-2, UI: D006003)

Animals (UI: D000818, Major: No); Autolysis (UI: D001329, Major: Yes); Dogs (UI: D004285, Major: No); Glycogen (UI: D006003, Major: No) - Qualifiers: analysis (UI: Q000032, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Lactates (UI: D007773, Major: No) - Qualifiers: analysis (UI: Q000032, Major: No); Mitochondria (UI: D008928, Major: No) - Qualifiers: ultrastructure (UI: Q000648, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: analysis (UI: Q000032, Major: No); pathology (UI: Q000473, Major: Yes); ultrastructure (UI: Q000648, Major: No); Myofibrils (UI: D009210, Major: No) - Qualifiers: ultrastructure (UI: Q000648, Major: No)

|||analysis (0)||analysis (0)|ultrastructure (0)|pathology (0)|analysis (0); pathology (1); ultrastructure (0)|ultrastructure (0)

0|1|0|0|0|0|0|0|0|0

null

1976-07-06

2003-11-14

pubmed: 1976-4-1; medline: 1976-4-1 0:1; entrez: 1976-4-1 0:0

pubmed: 4649

Myocardial Ischemia

['Myocardial Infarction']

4,779

1

Atherosclerotic cerebral infarction: pathophysiologic aspects.

MEDLINE

Manual

NLM

When the supply of substrate to the brain is threatened, homeostatic mechanisms induce cerebral vasodilatation to compensate for the insufficiency. When a region of the brain is rendered completely ischemic, local infarction occurs. The size of the infarct depends partly on the availability of collateral circulation and the adequacy of the homeostatic mechanisms controlling blood flow in stillpatent vessels. Several approaches to acute-phase treatment of stroke derive from clinical and experimental studies of cerebral blood flow and metabolism. We must conclude that both surgical and nonsurgical therapeutic measures have been of limited value in the treatment of cerebral infarction and that the basic therapy for completed stroke remains good medical management of complications and attentive nursing care.

Postgraduate medicine

0032-5481

Print

59

3

Print

1,976

Mar

null

115-8

J J Caronna (JJ); F H McDowell (FH)

Journal Article (D016428)

null

Blood Flow Velocity (UI: D001783, Major: No); Brain (UI: D001921, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Brain Edema (UI: D001929, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); therapy (UI: Q000628, Major: No); Cerebrovascular Circulation (UI: D002560, Major: Yes); Cerebrovascular Disorders (UI: D002561, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); prevention & control (UI: Q000517, Major: No); therapy (UI: Q000628, Major: No); Energy Metabolism (UI: D004734, Major: No); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Hypertension (UI: D006973, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Oxygen Consumption (UI: D010101, Major: No); Regional Blood Flow (UI: D012039, Major: No); Time Factors (UI: D013997, Major: No)

|metabolism (1)|etiology (0); therapy (0)||physiopathology (1); prevention & control (0); therapy (0)||||complications (0)|||

0|0|0|1|0|0|0|0|0|0|0|0

null

1976-07-06

2019-07-13

pubmed: 1976-3-1; medline: 1976-3-1 0:1; entrez: 1976-3-1 0:0

pubmed: 4779; doi: 10.1080/00325481.1976.11714300

Cerebrovascular Disorders

['Cerebrovascular Disorders']

4,782

1

Myocardial ischemia from coronary arterial spasm.

MEDLINE

Manual

NLM

Spasm of coronary arteries can cause chest pain indistinguishable from classic angina pectoris in patients without atherosclerosis of these vessels or recognizable heart disease. Associated electrocardiographic changes usually correspond to the coronary artery affected and disappear when the attack of pain ends. Sublingual nitrates are excellent agents for the control of the episodic anginal symptoms. There have been scattered reports of myocardial infarction occurring in patients with normal coronary arteries; a role of arterial spasm in these cases in speculative.

Postgraduate medicine

0032-5481

Print

59

4

Print

1,976

Apr

null

207-11

S J Gulotta (SJ); K Geller (K)

Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); drug therapy (UI: Q000188, Major: No); etiology (UI: Q000209, Major: Yes); Coronary Vessels (UI: D003331, Major: Yes); Electrocardiography (UI: D004562, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Spasm (UI: D013035, Major: No) - Qualifiers: complications (UI: Q000150, Major: Yes); diagnosis (UI: Q000175, Major: No); drug therapy (UI: Q000188, Major: No)

therapeutic use (0)|diagnosis (0); drug therapy (0); etiology (1)|||||||etiology (0)|complications (1); diagnosis (0); drug therapy (0)

0|0|1|0|0|0|0|0|0|0

null

1976-07-06

2019-07-13

pubmed: 1976-4-1; medline: 1976-4-1 0:1; entrez: 1976-4-1 0:0

pubmed: 4782; doi: 10.1080/00325481.1976.11714341

Myocardial Ischemia

['Angina Pectoris', 'Myocardial Infarction']

4,783

1

Angina pectoris. Diagnosis and treatment.

MEDLINE

Manual

NLM

The physician who understands the pathophysiology of angina pectoris can apply rational therapeutic measures based on an appreciation of the determinants of myocardial oxygen supply and demand. Most patients with angina secondary to coronary atherosclerosis can be treated conservatively using a systematic approach that includes correction or removal of underlying causes or precipitating factors and the judicious use of sublingual nitroglycerin. In patients with more resistant angina, use of oral or topical nitroglycerin or sublingual isosorbide dinitrite as well as propranolol can be advised. Aortocoronary bypass surgery can offer significant improvement in carefully selected patients with frequent angina poorly controlled by medical therapy. The most important consideration in the treatment of angina is protection of coronary blood flow reserve by primary prevention of the atherosclerotic process itself. All individuals from families prone to coronary artery disease should be evaluated for alterable risk factors, the most important being cigarette smoking, hypertension, and hypercholesterolemia. Considering the high risk of unheralded sudden death in previously asymptomatic patients with coronary atherosclerosis, angina can, in a sense, be considered a fortunate harbinger of coronary stenosis, identifying candidates for secondary preventive measures aimed at retarding the progression of vascular disease. More importantly, angina serves as an index for detecting families at high risk of coronary artery disease, in whom early application of primary prevention may afford a more promising outlook.

Postgraduate medicine

0032-5481

Print

59

5

Print

1,976

May

null

179-88

R Zelis (R); J A Liedtke (JA); D M Leaman (DM); J D Babb (JD); B H Roberts (BH)

Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Digitalis Glycosides (Registry: 0, UI: D004071); Ethanol (Registry: 3K9958V90M, UI: D000431); Nitroglycerin (Registry: G59M7S0WS3, UI: D005996)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); etiology (UI: Q000209, Major: No); therapy (UI: Q000628, Major: Yes); Coronary Disease (UI: D003327, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Diagnosis, Differential (UI: D003937, Major: No); Digitalis Glycosides (UI: D004071, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Ethanol (UI: D000431, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Exercise Therapy (UI: D005081, Major: No); Humans (UI: D006801, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Nitroglycerin (UI: D005996, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Oxygen Consumption (UI: D010101, Major: No); Pain (UI: D010146, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No)

therapeutic use (0)|diagnosis (0); etiology (0); therapy (1)|complications (0)||therapeutic use (0)|therapeutic use (0)|||metabolism (0)|therapeutic use (0)||diagnosis (0)

0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2019-07-13

pubmed: 1976-5-1; medline: 1976-5-1 0:1; entrez: 1976-5-1 0:0

pubmed: 4783; doi: 10.1080/00325481.1976.11714365

Myocardial Ischemia

['Angina Pectoris', 'Coronary Disease']

4,787

1

[Congenital heart malformations in neonates, infants and young children (author's transl)].

MEDLINE

Manual

NLM

Congenital heart malformations in neonates, infants and young children represent the main problem of paediatric cardiology in Poland. Congenital cardiovascular diseases (incidence also approximately 8 per 1000 in liveborn infants) cause very high mortality, particularly in the neonatal and infantile period. Approximately 5000 live-born children are affected every year by serious heart malformations. For at least two thirds of these previously hopelessly ill infants there are real possibilities of effective medical and surgical treatment. Not only a considerable drop in mortality in the earliest infancy would be achieved, but: a further normal physical and psychical growth and development of these children would be possible. At present, however, the available possibilities are by far not sufficient, as in all hitherto functioning centres we were able to manage 200-300 children yearly, whereas the real needs are at leasttenfold greater. Therefore it is necessary to: Increase the number and capacity of hospital wards capable enough to provide the intensive cardiopulmonary care; to execute appropriate reorganization aimed to concentrating the appropriate specialists (pediatric cardiologists, radiologists, surgeons, anesthesiologists, nurses) and equipment (cardiological and cardiosurgical appliances, X-ray equipment, intensive care units etc.) in centres designated for the above tasks. At least 7 paediatric intensive care and cardiosurgical centres should be instituted in Poland for a satisfactory management of congenital heart diseases.

Problemy medycyny wieku rozwojowego

0303-2264

Print

5

null

Print

1,975

null

191-2

J Swiderski (J)

Congress (D016423)

null

Age Factors (UI: D000367, Major: No); Child, Preschool (UI: D002675, Major: No); Congresses as Topic (UI: D003226, Major: No); Heart Defects, Congenital (UI: D006330, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); surgery (UI: Q000601, Major: No); therapy (UI: Q000628, Major: Yes); Humans (UI: D006801, Major: No); Infant (UI: D007223, Major: No); Infant, Newborn (UI: D007231, Major: No); Poland (UI: D011044, Major: No)

|||diagnosis (0); surgery (0); therapy (1)||||

0|0|0|0|0|0|0|0

null

1976-07-06

2018-12-03

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 4787

Heart Defects, Congenital

[]

4,896

1

Reduction in myocardial infarct size: prevention of heart cell death.

MEDLINE

Manual

NLM

The course of myocardial necrosis, the clinical syndrome, and methods of treatment are presented. Heart cell death may be prevented by maintaining the balance between myocardial oxygen and energy supply and consumption. New technics of improving this balance by reducing myocardial energy demand, altering metabolism, increasing myocardial substrate supply, and protecting cellular integrity are discussed.

Southern medical journal

0038-4348

Print

69

4

Print

1,976

Apr

null

442-8

R J Kones (RJ); J H Phillips (JH)

Journal Article (D016428)

Adrenal Cortex Hormones (Registry: 0, UI: D000305); Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Insulin (Registry: 0, UI: D007328); Vasodilator Agents (Registry: 0, UI: D014665); Hyaluronoglucosaminidase (Registry: EC 3.2.1.35, UI: D006821); Glucose (Registry: IY9XDZ35W2, UI: D005947); Potassium (Registry: RWP5GA015D, UI: D011188)

Adrenal Cortex Hormones (UI: D000305, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Assisted Circulation (UI: D001243, Major: No); Autolysis (UI: D001329, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Cardiac Output (UI: D002302, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Coronary Circulation (UI: D003326, Major: No); Energy Metabolism (UI: D004734, Major: Yes); Energy Transfer (UI: D004735, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Glucose (UI: D005947, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Humans (UI: D006801, Major: No); Hyaluronoglucosaminidase (UI: D006821, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Insulin (UI: D007328, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); metabolism (UI: Q000378, Major: No); pathology (UI: Q000473, Major: Yes); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); pathology (UI: Q000473, Major: Yes); Necrosis (UI: D009336, Major: No); Oxygen Consumption (UI: D010101, Major: No); Perfusion (UI: D010477, Major: No); Potassium (UI: D011188, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Vasodilator Agents (UI: D014665, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No)

therapeutic use (0)|therapeutic use (0)||drug therapy (0)|drug effects (0)|||drug effects (0)|metabolism (0)||therapeutic use (0)|metabolism (0)|drug therapy (0); metabolism (0); pathology (1)|metabolism (0); pathology (1)||||metabolism (0)|therapeutic use (0)

0|0|0|0|0|0|1|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2019-07-02

pubmed: 1976-4-1; medline: 1976-4-1 0:1; entrez: 1976-4-1 0:0

pubmed: 4896; doi: 10.1097/00007611-197604000-00020

Myocardial Ischemia

['Myocardial Infarction']

4,907

1

Influence of adrenergic receptor blockade on circulatory and metabolic effects of disordered neurotransmitter function in stroke patients.

MEDLINE

Manual

NLM

Cerebral hemispheric blood flow and metabolism were measured before and after therapy with intracarotid infusion of combined PBZ and PPL in 15 patients with recent cerebral infarction. HBF was unaltered despite decrease in cerebral perfusion pressure. Cerebral hemispheric oxygen comsumption and carbon dioxide production decreased while cerebral hemispheric lactate production increased. Biphasic cerebral uptake of tyrosine was observed during and immediately after PBZ and PPL infusion. CSF HVA increased, indicating altered DA turnover. CSF 5HIAA levels also increased, suggesting altered 5HT turnover after PBZ and PPL. Release of cyclic AMP from ischemic brain into cerebral venous blood seen in the steady state was abolished after therapy. Cerebral hemodynamic studies suggest a functional balance between monaminergic neurogenic influences in the control of cerebral circulation. Imbalance of such controlling factors in ischemic brain may lead to paradoxical vascular responses to induced hypertension and hypotension. PBZ and PPL enhance such responses perhaps by increasing central neurotransmitter turnover and release. Further shift toward cerebral anaerobic metabolism may occur in ischemic brain following the use of phenoxybenzamine and propranolol. Worsening of neurological deficit occurred in four cases. Combined therapy with PBZ and PPL does not appear beneficial in the therapy of patients with recent stroke.

Stroke

0039-2499

Print

7

2

Print

null

158-67

J S Meyer (JS); Y Miyakawa (Y); K M Welch (KM); Y Itoh (Y); N Ishihara (N); E Chabi (E); J Nell (J); K Bartosh (K); A D Ericsson (AD)

Journal Article (D016428); Research Support, U.S. Gov't, P.H.S. (D013487)

Drug Combinations (Registry: 0, UI: D004338); Lactates (Registry: 0, UI: D007773); Neurotransmitter Agents (Registry: 0, UI: D018377); Pyruvates (Registry: 0, UI: D011773); Receptors, Adrenergic (Registry: 0, UI: D011941); Phenoxybenzamine (Registry: 0TTZ664R7Z, UI: D010643); Serotonin (Registry: 333DO1RDJY, UI: D012701); Tyrosine (Registry: 42HK56048U, UI: D014443); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433); Cyclic AMP (Registry: E0399OZS9N, UI: D000242); Dopamine (Registry: VTD58H1Z2X, UI: D004298); Norepinephrine (Registry: X4W3ENH1CV, UI: D009638)

Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Brain (UI: D001921, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Cerebrovascular Circulation (UI: D002560, Major: No); Cerebrovascular Disorders (UI: D002561, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); metabolism (UI: Q000378, Major: No); Cyclic AMP (UI: D000242, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Dopamine (UI: D004298, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Drug Combinations (UI: D004338, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Lactates (UI: D007773, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Neurotransmitter Agents (UI: D018377, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Norepinephrine (UI: D009638, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Oxygen Consumption (UI: D010101, Major: No); Phenoxybenzamine (UI: D010643, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: Yes); therapeutic use (UI: Q000627, Major: No); Propranolol (UI: D011433, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: Yes); therapeutic use (UI: Q000627, Major: No); Pyruvates (UI: D011773, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Receptors, Adrenergic (UI: D011941, Major: No); Serotonin (UI: D012701, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Tyrosine (UI: D014443, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No)

||metabolism (0)||drug therapy (1); metabolism (0)|metabolism (0)|metabolism (0)||||metabolism (0)|||metabolism (1)|metabolism (0)||administration & dosage (1); therapeutic use (0)|administration & dosage (1); therapeutic use (0)|metabolism (0)||metabolism (0)|metabolism (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2019-07-27

pubmed: 1976-3-1; medline: 1976-3-1 0:1; entrez: 1976-3-1 0:0

pubmed: 4907; doi: 10.1161/01.str.7.2.158

Cerebrovascular Disorders

['Cerebrovascular Disorders']

4,970

1

Internal mammary artery bypass graft in reoperative myocardioal revascularization.

MEDLINE

Manual

NLM

Thirty-two consecutive patients who earlier received indirect or direct myocardial revascularization underwent reoperation with one or more internal mammary artery grafts either alone or in combination with saphenous vein grafts. The main indication for reoperation was graft closure or progression of coronary atherosclerosis in nongrafted vessels, or both. Graft construction was performed under normothermic perfusion and anoxic arrest with interrupted suture technique. No intraoperative infarctions or hospital deaths occurred. All patients are alive after an average follow-up period of 20 months, and two thirds are asymptomatic. Arteriography after reoperation in nine patients revealed patency of eight of nine internal mammary artery and five of five secondary vein grafts. When angiographic and symptomatic indications for reoperation exist, the internal mammary artery bypass graft has become a valuable alternative, particularly for patients with small coronary vessels or previous vein graft failure.

The American journal of cardiology

0002-9149

Print

37

6

Print

1,976

May

null

890-5

F D Loop (FD); N R Carabajal (NR); P C Taylor (PC); M J Irarrazaval (MJ)

Journal Article (D016428)

null

Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Blood Vessel Prosthesis (UI: D001807, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnostic imaging (UI: Q000000981, Major: No); surgery (UI: Q000601, Major: Yes); Female (UI: D005260, Major: No); Follow-Up Studies (UI: D005500, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Myocardial Revascularization (UI: D009204, Major: Yes) - Qualifiers: mortality (UI: Q000401, Major: No); Postoperative Complications (UI: D011183, Major: No); Radiography (UI: D011859, Major: No); Recurrence (UI: D012008, Major: No); Saphenous Vein (UI: D012501, Major: No) - Qualifiers: transplantation (UI: Q000637, Major: No); Transplantation, Autologous (UI: D014182, Major: No)

||adverse effects (0)|complications (0); diagnostic imaging (0); surgery (1)||||||mortality (0)||||transplantation (0)|

0|0|0|0|0|0|0|0|0|1|0|0|0|0|0

null

1976-07-06

2019-06-22

pubmed: 1976-5-1; medline: 1976-5-1 0:1; entrez: 1976-5-1 0:0

pubmed: 4970; pii: 0002-9149(76)90115-6; doi: 10.1016/0002-9149(76)90115-6

Myocardial Ischemia

['Coronary Disease']

5,015

1

[Clinical evaluation of the new anesthetic "Ethrane"].

MEDLINE

Manual

NLM

Seventy-four patients aged 14 months to 71 years, classified as ASA I and II were anesthetised with Ethrane for surgical interventions of mean duration 117 minutes. With the exception of 5 patients who were directly anesthetised with Ethrane, the others received Ethrane after induction with Penthiobarbitone. Maintenance of anesthesia was ensured with 1 to 4p. 100 concentrations of Ethrane and 33p. 100 oxygen and 66p. 100 nitrous oxide. Tracheal intubation was facilitated by injection of 1 mg/kg of succinylcholine. Induction with enflurane is rapid with no phenomena of excitation or irritation of the ear passages. The cardiovascular apparatus is stable with no arrythmia but an increase in heart rate of 11 to 50p. 100 is noted and in 41p. 100 of the cases hypotension of 35p. 100 of the intitial value. During spontaneous ventilation, a type of rapid and superficial respiration is observed with a flow volume of 5.3 ml/kg for an average frequency of 25/min. The arterial blood gases show slight hypercapnia. Myorelaxation is significant and better than that obtained with halothane. Coming round poses few problems apart from agitation in adolescents. Response to simple orders appears at 13 minutes. Trembling and rigidity occur in 41p. 100 of the cases for 5 to 30 minutes. From the hepatic point of view, no lastin enzyme changes were noted and no renal toxicity was demonstrated. Ethrane appears to be a good anesthetic agent but the few advantages mentioned means that it does not fulfil ideal conditions.

Annales de l'anesthesiologie francaise

0003-4061

Print

16

8

Print

1,975

Dec

null

587-92

M T Daurelle (MT); M G Soliman (MG); G F Brindle (GF)

English Abstract (D004740); Journal Article (D016428)

Methyl Ethers (Registry: 0, UI: D008738); Thiobarbiturates (Registry: 0, UI: D013858); Enflurane (Registry: 91I69L5AY5, UI: D004737); L-Lactate Dehydrogenase (Registry: EC 1.1.1.27, UI: D007770); Aspartate Aminotransferases (Registry: EC 2.6.1.1, UI: D001219); Alanine Transaminase (Registry: EC 2.6.1.2, UI: D000410)

Adolescent (UI: D000293, Major: No); Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Alanine Transaminase (UI: D000410, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Anesthesia, Inhalation (UI: D000769, Major: No); Aspartate Aminotransferases (UI: D001219, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Child (UI: D002648, Major: No); Child, Preschool (UI: D002675, Major: No); Drug Evaluation (UI: D004341, Major: No); Enflurane (UI: D004737, Major: No) - Qualifiers: standards (UI: Q000592, Major: Yes); Humans (UI: D006801, Major: No); Hypotension (UI: D007022, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); Infant (UI: D007223, Major: No); L-Lactate Dehydrogenase (UI: D007770, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Liver (UI: D008099, Major: No) - Qualifiers: enzymology (UI: Q000201, Major: No); Methyl Ethers (UI: D008738, Major: No) - Qualifiers: standards (UI: Q000592, Major: Yes); Middle Aged (UI: D008875, Major: No); Postoperative Complications (UI: D011183, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Premedication (UI: D011292, Major: No); Respiration (UI: D012119, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Tachycardia (UI: D013610, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); Thiobarbiturates (UI: D013858, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No)

|||metabolism (0)||metabolism (0)||||standards (1)||chemically induced (0)||metabolism (0)|enzymology (0)|standards (1)||drug therapy (0)||drug effects (0)|chemically induced (0)|therapeutic use (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2013-11-21

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 5015

Arrhythmias, Cardiac

['Tachycardia']

5,026

1

[Effect of increasing doses of dopamine on the left ventricular function in the dog].

MEDLINE

Manual

NLM

A study on eleven dogs of the effects of increasing doses of dopamine on the left ventricular function. A description of the method which consists of a venous shunt connected to an extra-corporeal circuit and which allows modification simply and rapidly of the state of vascular refilling of the animal. The results differ according to the pressure-level of the refilling of the left ventricule. At low pressure, the dopamine increases the arterial pressure, the cardiac output and the systolic activity of the left ventricle for a reduced tachycardic effect. At higher pressure, the average aortic pressure is only slightly increased and the systolic activity is elevated without increase in cardiac output. These facts indicate dopamine in states of shock with a low pressure of refilling.

Annales de l'anesthesiologie francaise

0003-4061

Print

16

9

Print

1,975

Dec

null

657-60

G Guiraudon (G); J Luciani (J); A Lienhart (A); J J Guillosson (JJ); J Nafziger (J); C Conseiller (C)

English Abstract (D004740); Journal Article (D016428)

Dopamine (Registry: VTD58H1Z2X, UI: D004298)

Animals (UI: D000818, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cardiac Output (UI: D002302, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Dogs (UI: D004285, Major: No); Dopamine (UI: D004298, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: No); pharmacology (UI: Q000494, Major: Yes); therapeutic use (UI: Q000627, Major: No); Drug Administration Schedule (UI: D004334, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Heart Ventricles (UI: D006352, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: Yes); Shock (UI: D012769, Major: No); Shock, Septic (UI: D012772, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Tachycardia (UI: D013610, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No)

|drug effects (0)|drug effects (0)||administration & dosage (0); pharmacology (1); therapeutic use (0)||drug effects (0)|drug effects (1)||drug therapy (0)|chemically induced (0)

0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2013-11-21

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 5026

Arrhythmias, Cardiac

['Tachycardia']

5,027

1

[The effect of intravenous dopamine on the hemodynamics of the heart].

MEDLINE

Manual

NLM

The pharmacological study of dopamine was conducted on 14 patients: eleven normal patients and three with incipient myocardiopathies. The dosages used were 3, 6 and 12 mug/kg/min. The ""pump"" function, the peripheral resistances, the contractility and the ventricular compliance were studied. Dopamine is a positive inotropic agent without chronotropic action at doses of 6 and 12 mug/kg/min. It acts by increasing the contractility and the venous return and by decreasing the peripheral resistances; this effect disappears with strong dosages.

Annales de l'anesthesiologie francaise

0003-4061

Print

16

9

Print

1,975

Dec

null

661-8

M Sicart (M); P Besse (P); H Bricaud (H)

English Abstract (D004740); Journal Article (D016428)

Dopamine (Registry: VTD58H1Z2X, UI: D004298)

Aorta (UI: D001011, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cardiac Catheterization (UI: D006328, Major: No); Cardiac Output (UI: D002302, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cardiomyopathies (UI: D009202, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Dopamine (UI: D004298, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Femoral Artery (UI: D005263, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Heart Ventricles (UI: D006352, Major: No); Humans (UI: D006801, Major: No); Myocardial Contraction (UI: D009200, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: Yes); Pulmonary Artery (UI: D011651, Major: No)

|drug effects (0)||drug effects (0)|diagnosis (0)|pharmacology (1)||drug effects (0)|||drug effects (1)|

0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2021-01-09

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 5027; pii: 33145960

Cardiomyopathies

[]

5,028

1

[Hemodynamic study of dopamine used in chronic heart failures and in cardiogenic shock as a complication of acute myocardial infarct].

MEDLINE

Manual

NLM

The object of this study is to examine the properties of dopamine at the hemodynamic and renal level in 16 patients with decompensated chronic cardiopathies or very serious cardiogenic shock due to myocardial infarction. The results show an increase in the cardiac index in 75 p. 100 of the cases with a favourable diminution of the arterio-venous difference in O2 and of the pulmonary arterial resistances. The most noticeable and the most constant effect is the recovery and increase of the diuresis. Positive chronotropic and bathmotropic effects were observed which necessitated the limitation of prescription of dopamine in those subjects showing signs of disturbances in ventricular excitability.

Annales de l'anesthesiologie francaise

0003-4061

Print

16

9

Print

1,975

Dec

null

669-72

D Flammang (D); P Sebastien (P); Y Bouvrain (Y)

English Abstract (D004740); Journal Article (D016428)

Potassium (Registry: RWP5GA015D, UI: D011188); Dopamine (Registry: VTD58H1Z2X, UI: D004298)

Angina Pectoris (UI: D000787, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Brachial Artery (UI: D001916, Major: No); Diuresis (UI: D004231, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Dopamine (UI: D004298, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: No); therapeutic use (UI: Q000627, Major: Yes); Heart Failure (UI: D006333, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Hemodynamics (UI: D006439, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Oxygen Consumption (UI: D010101, Major: No); Potassium (UI: D011188, Major: No) - Qualifiers: urine (UI: Q000652, Major: No); Shock, Cardiogenic (UI: D012770, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); etiology (UI: Q000209, Major: No); Tachycardia (UI: D013610, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No); Ventricular Fibrillation (UI: D014693, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No)

chemically induced (0)|drug effects (0)||drug effects (0)|adverse effects (0); therapeutic use (1)|drug therapy (1)|drug effects (0)|drug effects (0)||complications (0)||urine (0)|drug therapy (1); etiology (0)|chemically induced (0)|chemically induced (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2013-11-21

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 5028

Myocardial Ischemia

['Angina Pectoris', 'Myocardial Infarction']

5,030

1

[The use of dopamine during postoperative cardiogenic shock in children. Preliminary results].

MEDLINE

Manual

NLM

Dopamine was used in a dose of 5 mug/kg/min in ten infants with congenital cardiopathy and presenting in the immediate postoperative period a syndrome of low cardiac output. The output was not measured but, based on the evolution of the clinical signs, six favourable results, with correction of the syndrome, can be reported.

Annales de l'anesthesiologie francaise

0003-4061

Print

16

9

Print

1,975

Dec

null

679-82

J A Lejeune (JA)

English Abstract (D004740); Journal Article (D016428)

Dopamine (Registry: VTD58H1Z2X, UI: D004298)

Dopamine (UI: D004298, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Heart Defects, Congenital (UI: D006330, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No); Humans (UI: D006801, Major: No); Infant (UI: D007223, Major: No); Postoperative Complications (UI: D011183, Major: No); Shock, Cardiogenic (UI: D012770, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes)

therapeutic use (1)|surgery (0)||||drug therapy (1)

0|0|0|0|0|0

null

1976-07-06

2013-11-21

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 5030

Heart Defects, Congenital

[]

5,031

1

[Use of dopamine in postoperative reanimation after heart surgery. Preliminary results].

MEDLINE

Manual

NLM

The dopamine was used on ten patients having undergone one or several valvular replacements under extra-corporeal circulation. The essential indication was the appearance postoperatively of more or less serious circulatory failure. The dopamine was administered by drip in doses of 2.5, 5 or 10 mug/kg/min. The effects on the frequency of the cardiac rhythm were moderate. On two cases, ventricular hyperexcitability induced by isoprenaline disappeared under dopamine. The chief effects were an increase in cardiac output, in the form of an increase in the volume of systolic ejection and lowering of the peripheral resistances. A steady increase in urinary volume preceded the amelioration of clinical signs of circulatory failure.

Annales de l'anesthesiologie francaise

0003-4061

Print

16

9

Print

1,975

Dec

null

683-9

B Du Gres (B)

English Abstract (D004740); Journal Article (D016428)

Dopamine (Registry: VTD58H1Z2X, UI: D004298)

Adolescent (UI: D000293, Major: No); Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cardiac Output (UI: D002302, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Diuresis (UI: D004231, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Dopamine (UI: D004298, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: No); therapeutic use (UI: Q000627, Major: Yes); Extracorporeal Circulation (UI: D005112, Major: No); Female (UI: D005260, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Heart Valve Diseases (UI: D006349, Major: No) - Qualifiers: surgery (UI: Q000601, Major: Yes); Heart Valve Prosthesis (UI: D006350, Major: No); Humans (UI: D006801, Major: No); Infusions, Parenteral (UI: D007263, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Postoperative Care (UI: D011182, Major: Yes); Venous Pressure (UI: D014690, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No)

|||drug effects (0)|drug effects (0)|drug effects (0)|administration & dosage (0); therapeutic use (1)|||drug effects (0)|surgery (1)|||||||drug effects (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|1|0

null

1976-07-06

2021-01-09

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 5031; pii: 33145961

Heart Valve Diseases

[]

5,034

1

[Use of dopamine in the treatment of cardiogenic shock. Preliminary results].

MEDLINE

Manual

NLM

A study of seven patients, each of whom was treated with dopamine within three hours after suffering a myocardial infarction. For four of these, a comparative study was made with isoproterenol, glucagon and ouabaine. The average age of the subjects was 72 years, and all presented considerable myocardial lesions before the treatment was begun. Despite improvement, particularly in diuresis and cardiac output, none of the patients survived. The authors explain these results by the fact that, like all powerful inotropic agents, dopamine produces an increase in oxygen consumption of the myocardium for the ischemic cells situated in the zone contiguous to the infarct.

Annales de l'anesthesiologie francaise

0003-4061

Print

16

9

Print

1,975

Dec

null

705-10

P Chiche (P); S Baligadoo (S)

English Abstract (D004740); Journal Article (D016428)

Ouabain (Registry: 5ACL011P69, UI: D010042); Furosemide (Registry: 7LXU5N7ZO5, UI: D005665); Glucagon (Registry: 9007-92-5, UI: D005934); Isoproterenol (Registry: L628TT009W, UI: D007545); Dopamine (Registry: VTD58H1Z2X, UI: D004298)

Aged (UI: D000368, Major: No); Diuresis (UI: D004231, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Dopamine (UI: D004298, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Female (UI: D005260, Major: No); Furosemide (UI: D005665, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Glucagon (UI: D005934, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Humans (UI: D006801, Major: No); Isoproterenol (UI: D007545, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Ouabain (UI: D010042, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Shock, Cardiogenic (UI: D012770, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); etiology (UI: Q000209, Major: No); Venous Pressure (UI: D014690, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No)

|drug effects (0)|therapeutic use (1)||therapeutic use (0)|therapeutic use (0)||therapeutic use (0)|||complications (0)|therapeutic use (0)|drug therapy (1); etiology (0)|drug effects (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-07-06

2013-11-21

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 5034

Myocardial Ischemia

['Myocardial Infarction']

5,062

1

Revascularization of the heart through the coronary veins.

MEDLINE

Manual

NLM

Fifty-six dogs were used in a study to evaluate perfusion of the left anterior descending vein by the internal mammary artery in hearts with normal coronary arteries and those with ligated desending coronary arteries. Perfusion of the myocardium with arterial blood through the cardiac veins offers minimal immediate protection from infarction, as evidenced by light and electron microscopy studies. This protection is of short duration due to intimal fibrosis and luminal stenosis or obstruction of the perfused veins. Nineteen animals in which the coronary vein was perfused and the corresponding coronary artery was not ligated died within sixty hours from the time of operation. Pathological examination revealed patent grafts in all the animals. There was marked congestion of the myocardium with petechial hemorrhages over the surface of the heart. No evidence of myocardial infarction was found.

The Annals of thoracic surgery

0003-4975

Print

21

4

Print

1,976

Apr

null

318-21

R Zajtchuk (R); W H Heydorn (WH); J G Miller (JG); T E Strevey (TE); R L Treasure (RL)

Journal Article (D016428)

null

Animals (UI: D000818, Major: No); Coronary Circulation (UI: D003326, Major: Yes); Coronary Disease (UI: D003327, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); surgery (UI: Q000601, Major: No); Coronary Vessels (UI: D003331, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); surgery (UI: Q000601, Major: Yes); Disease Models, Animal (UI: D004195, Major: No); Dogs (UI: D004285, Major: No); Ligation (UI: D008026, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: prevention & control (UI: Q000517, Major: No); Myocardial Revascularization (UI: D009204, Major: No) - Qualifiers: methods (UI: Q000379, Major: Yes); Veins (UI: D014680, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No)

||pathology (0); surgery (0)|pathology (0); surgery (1)||||prevention & control (0)|methods (1)|surgery (0)

0|1|0|0|0|0|0|0|0|0

null

1976-07-06

2019-06-28

pubmed: 1976-4-1; medline: 1976-4-1 0:1; entrez: 1976-4-1 0:0

pubmed: 5062; pii: S0003-4975(10)64319-6; doi: 10.1016/s0003-4975(10)64319-6

Myocardial Ischemia

['Coronary Disease', 'Myocardial Infarction']

5,202

1

Effects of regional ischemia on metabolism of glucose and fatty acids. Relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia.

MEDLINE

Manual

NLM

The rate of coronary flow reaching the oxygen-linited heart appears to be crucial in determining the myocardial tissue metabolic response. The tissue metabolic response to anoxia, well studied in hearts perfused with anoxic media, differs in many important ways from the response to ischemia. In regional ischemia (developing infarction) there is still a residual oxygen uptake which is reduced approximately to the same extent as the delivery of O2; there is also decreased delivery of substrates and decreased removal of CO2, H+, and lactate, with increased concentrations of these metabolites. Contents of hexose monophosphates rise rather than fall in anoxia. Measurements of glycolytic intermediates show an initial burst of accelerated glycolytic flux lasting less than 1 minute after coronary artery ligation; thereafter rates of flux decrease to control values or even less at 120 minutes. Relative inhibition of phosphofructokinase (PFK) activity may be explained by a slow rate of fall of ATP and a developing intracellular acidosis. In this model, glucose accounts for a greater part of the residual oxidative metabolism than does free fatty acid (FFA).

Circulation research

0009-7330

Print

38

5 Suppl 1

Print

1,976

May

null

I52-74

L H Opie (LH)

Comparative Study (D003160); Journal Article (D016428)

Fatty Acids (Registry: 0, UI: D005227); Adenosine Triphosphate (Registry: 8L70Q75FXE, UI: D000255); Glucose (Registry: IY9XDZ35W2, UI: D005947)

Adenosine Triphosphate (UI: D000255, Major: No) - Qualifiers: biosynthesis (UI: Q000096, Major: No); Aerobiosis (UI: D000332, Major: No); Anaerobiosis (UI: D000693, Major: No); Animals (UI: D000818, Major: No); Collateral Circulation (UI: D003097, Major: No); Coronary Circulation (UI: D003326, Major: No); Dogs (UI: D004285, Major: No); Energy Metabolism (UI: D004734, Major: No); Fatty Acids (UI: D005227, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Glucose (UI: D005947, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Glycolysis (UI: D006019, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Hypoxia (UI: D000860, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Lipid Metabolism (UI: D050356, Major: No); Models, Biological (UI: D008954, Major: No); Myocardial Contraction (UI: D009200, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes)

biosynthesis (0)||||||||metabolism (1)|metabolism (1)|||metabolism (1)||||metabolism (1)|metabolism (1)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-08-02

2016-11-23

pubmed: 1976-5-1; medline: 1976-5-1 0:1; entrez: 1976-5-1 0:0

pubmed: 5202

Myocardial Ischemia

['Myocardial Infarction']

5,203

1

Control of ionic permeabilities in normal and ischemic heart.

MEDLINE

Manual

NLM

The major ionic conductances underlying electrical activity in cardiac tissues are described. The participation of electrogenic active transport in electrical phenomenon and the influence of metabolic inhibition on cardiac action potentials are briefly summarized. Some electrophysiological effects of lactate and acidosis, such as might be induced by ischemia, are described. In dog Purkinje fibers, lactate (20 mM pH 7.0) may induce transient periods of arrhythmias. Acidosis decreases rapid sodium conductance, slow calcium-sodium conductance, and anomalous and delayed rectifications in frog atrial fibers. CO2-induced acidosis (20% CO2, pH 6.6) may alter the repolarization phase of the action potential in dog Purkinje fibers, presumably because it decreases potassium conductance. Alterations consist of partial depolarizations (humps) that result in reexcitation of the fibers and lead to a maintained depolarization. It is proposed that acidosis induces a decrease in potassium conductance that can be responsible for ectopic foci causing arrhythmias during ischemia.

Circulation research

0009-7330

Print

38

5 Suppl 1

Print

1,976

May

null

I92-8

E Coraboeuf (E); E Deroubaix (E); J Hoerter (J)

Comparative Study (D003160); Journal Article (D016428)

Chlorides (Registry: 0, UI: D002712); Lactates (Registry: 0, UI: D007773); Sodium (Registry: 9NEZ333N27, UI: D012964); Potassium (Registry: RWP5GA015D, UI: D011188); Calcium (Registry: SY7Q814VUP, UI: D002118)

Action Potentials (UI: D000200, Major: Yes); Animals (UI: D000818, Major: No); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Calcium (UI: D002118, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Cell Membrane Permeability (UI: D002463, Major: Yes); Chlorides (UI: D002712, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Heart Conduction System (UI: D006329, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Lactates (UI: D007773, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Models, Biological (UI: D008954, Major: No); Myocardial Contraction (UI: D009200, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Potassium (UI: D011188, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Purkinje Fibers (UI: D011690, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Sodium (UI: D012964, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No)

||physiopathology (0)|metabolism (0)||metabolism (0)|metabolism (1)|physiopathology (0)||pharmacology (0)|||metabolism (1)|metabolism (0)|drug effects (0)|metabolism (0)

1|0|0|0|1|0|0|0|0|0|0|0|0|0|0|0

null

1976-08-02

2013-11-21

pubmed: 1976-5-1; medline: 1976-5-1 0:1; entrez: 1976-5-1 0:0

pubmed: 5203

Myocardial Ischemia

['Coronary Disease']

5,383

1

Biofeedback and self-control of physiological functions: clinical applications.

MEDLINE

Manual

NLM

The parameters amenable to biofeedback learning are mentioned, including brainwaves, muscle tension, temperature, the cardiovascular system, and others. A discussion follows of the clinical application of biofeedback in the treatment of such disorders as tension headaches, neuromuscular re-education, epilepsy, ""dysponesis,"" cardiac arrhythmias, blood pressure and migraines. The usefulness of biofeedback has been demonstrated also in the field of psychotherapy for purposes of desensitization, treating anxious patients, encouraging specific personality changes, and indicating stress to patients.

International journal of psychiatry in medicine

0091-2174

Print

6

1-2

Print

1,975

null

255-65

P P Hauri (PP)

Journal Article (D016428); Research Support, U.S. Gov't, Non-P.H.S. (D013486); Review (D016454)

null

Anxiety (UI: D001007, Major: No) - Qualifiers: therapy (UI: Q000628, Major: No); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: therapy (UI: Q000628, Major: No); Autonomic Nervous System (UI: D001341, Major: No) - Qualifiers: physiology (UI: Q000502, Major: Yes); Blood Pressure (UI: D001794, Major: No); Brain (UI: D001921, Major: No) - Qualifiers: physiology (UI: Q000502, Major: No); Desensitization, Psychologic (UI: D003887, Major: No); Epilepsy (UI: D004827, Major: No) - Qualifiers: therapy (UI: Q000628, Major: No); Feedback (UI: D005246, Major: Yes); Galvanic Skin Response (UI: D005712, Major: No); Gastric Juice (UI: D005750, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Headache (UI: D006261, Major: No) - Qualifiers: therapy (UI: Q000628, Major: No); Heart Rate (UI: D006339, Major: No); Humans (UI: D006801, Major: No); Hypertension (UI: D006973, Major: No) - Qualifiers: therapy (UI: Q000628, Major: No); Migraine Disorders (UI: D008881, Major: No) - Qualifiers: therapy (UI: Q000628, Major: No); Muscle Contraction (UI: D009119, Major: No); Personality (UI: D010551, Major: No); Skin Temperature (UI: D012881, Major: No); Stress, Psychological (UI: D013315, Major: No)

therapy (0)|therapy (0)|physiology (1)||physiology (0)||therapy (0)|||metabolism (0)|therapy (0)|||therapy (0)|therapy (0)||||

0|0|0|0|0|0|0|1|0|0|0|0|0|0|0|0|0|0|0

null

1976-08-02

2018-12-03

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 5383; doi: 10.2190/L766-9GFR-HXFD-WFFX

Arrhythmias, Cardiac

[]

5,583

1

Ruptured coronary aneurysm and valvulitis in an infant with polyarteritis nodosa.

MEDLINE

Manual

NLM

This report describes a 4-mth-old infant with polyarteritis nodosa who had a rapidly fatal course with the diagnosis ultimately being made at necropsy. The pathological lesions consisted of diffuse arterial disease with severe coronary involvement, and additional unusual features included a ruptured coronary artery aneurysm and a valvulitis of the mitral and aortic valves similar to that seen in rheumatic fever. The aetiology of polyarteritis is briefly summarised and the possibility of an immune reaction to foreign antigens, such as drugs or viruses, is considered.

The Journal of pathology

0022-3417

Print

117

2

Print

1,975

Oct

null

83-7

S Holt (S); P Jackson (P)

Case Reports (D002363); Journal Article (D016428)

null

Aneurysm (UI: D000783, Major: No) - Qualifiers: etiology (UI: Q000209, Major: Yes); Arteries (UI: D001158, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Cardiac Tamponade (UI: D002305, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: etiology (UI: Q000209, Major: Yes); Coronary Vessels (UI: D003331, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Heart Valve Diseases (UI: D006349, Major: No) - Qualifiers: complications (UI: Q000150, Major: Yes); Heart Valves (UI: D006351, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Humans (UI: D006801, Major: No); Infant (UI: D007223, Major: No); Male (UI: D008297, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Polyarteritis Nodosa (UI: D010488, Major: No) - Qualifiers: complications (UI: Q000150, Major: Yes); pathology (UI: Q000473, Major: No); Rupture, Spontaneous (UI: D012422, Major: No)

etiology (1)|pathology (0)|etiology (0)|etiology (1)|pathology (0)|complications (1)|pathology (0)||||pathology (0)|complications (1); pathology (0)|

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-08-02

2004-11-17

pubmed: 1975-10-1; medline: 1975-10-1 0:1; entrez: 1975-10-1 0:0

pubmed: 5583; doi: 10.1002/path.1711170204

Myocardial Ischemia

['Coronary Disease']

5,699

1

Oxygen transport in congenital heart disease: influence of fetal hemoglobin, red cell pH, and 2,3-diphosphoglycerate.

MEDLINE

Manual

NLM

In 48 individuals (age 1 day to 13 years) with congenital heart disease, blood oxygen transport function was studied in order to evaluate adaptive changes in shunt hypoxemia and to investigate the in vivo regulation of erythrocyte 2, 3-diphosphoglycerate concentration (RBC 2, 3-DPG) in the presence of fetal hemoglobin (HbF). Arterial pO2 and oxygen content, oxygen capacity, acid base status, oxygen affinity, HbF fraction, plasma pH, red cell pH, and RBC 2, 3-DPG were determined. During the first 50 days of life values of standard P50 (stdP50) (37, pH 7.4), actual in vivo P50 (actP50), RBC 2, 3-DPG, O2 capacity, arterial plasma pH, and red cell pH were scattered around the normal range, although tending to low values for stdP50 and arterial plasma pH and to high values for O2 capacity. After the third month, stdP50 actP50, RBC 2, 3-DPG, O2 capacity, and red cell pH were found to be elevated. Plasma pH and actP50 were scattered around the normal range (Figs. 1 and 2). Intraerythrocytic pH in hypoxemic infants was increased compared with normal children when related to plasma pH (Fig. 3). A close to normal intraerythrocytic pH was therefore found in the hypoxemic infants with low plasma pH, and an increased intraerythrocytic pH in the hypoxemic children with normal plasma pH (Fig. 1). A significant negative correlation exists between erythrocyte H+ ion and 2, 3-DPG concentration (Fig. 5); regression constants derived from data at high (mean 47%) and low (mean 9%) fractions of HbF are not significantly different (Regression Equations 8 and 11 in Table 1). Thus, the known difference in 2, 3-DPG binding to fetal or adult deoxyhemoglobin does not measurably influence the erythrocyte 2, 3-DPG concentration, indicating that in vivo the 2, 3-DPG synthesis in hypoxia is virtually regulated by the erythrocyte pH, which in turn is determined by plasma pH and the oxygenation state of hemoglobin.

Pediatric research

0031-3998

Print

10

6

Print

1,976

Jun

null

566-70

H T Versmold (HT); C Linderkamp (C); C Döhlemann (C); K P Riegel (KP)

Journal Article (D016428)

Diphosphoglyceric Acids (Registry: 0, UI: D004163); Carbon Dioxide (Registry: 142M471B3J, UI: D002245); Fetal Hemoglobin (Registry: 9034-63-3, UI: D005319); Oxygen (Registry: S88TT14065, UI: D010100)

Adaptation, Biological (UI: D000220, Major: No); Adolescent (UI: D000293, Major: No); Carbon Dioxide (UI: D002245, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Child (UI: D002648, Major: No); Child, Preschool (UI: D002675, Major: No); Cyanosis (UI: D003490, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Diphosphoglyceric Acids (UI: D004163, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes); physiology (UI: Q000502, Major: No); Erythrocytes (UI: D004912, Major: No) - Qualifiers: analysis (UI: Q000032, Major: Yes); Fetal Hemoglobin (UI: D005319, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Heart Defects, Congenital (UI: D006330, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Hypoxia (UI: D000860, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Infant (UI: D007223, Major: No); Infant, Newborn (UI: D007231, Major: No); Oxygen (UI: D010100, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes)

||blood (0)|||blood (0)|blood (1); physiology (0)|analysis (1)|metabolism (1)|blood (1)|||blood (0)|||blood (1)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-08-02

2016-11-23

pubmed: 1976-6-1; medline: 1976-6-1 0:1; entrez: 1976-6-1 0:0

pubmed: 5699; doi: 10.1203/00006450-197606000-00002

Heart Defects, Congenital

[]

5,756

1

Inhibition of glycolysis in hearts during ischemic perfusion.

MEDLINE

Manual

NLM

Rates of glycolysis were determined in the isolated perfused rat heart under aerobic, anoxic, and ischemic conditions. The rate was accelerated in anoxic and was inhibited in ischemic tissue. Glycolytic inhibition developed at the level of glyceraldehyde-3-P dehydrogenase and was associated with accumulation of high levels of tissue lactate and H+.

Recent advances in studies on cardiac structure and metabolism

0363-5872

Print

7

null

Print

1,975

null

243-8

J R Neely (JR); J T Whitmer (JT); M J Rovetto (MJ)

Journal Article (D016428)

Lactates (Registry: 0, UI: D007773)

Anaerobiosis (UI: D000693, Major: No); Animals (UI: D000818, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); physiopathology (UI: Q000503, Major: No); Disease Models, Animal (UI: D004195, Major: No); Glycolysis (UI: D006019, Major: Yes); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Heart Rate (UI: D006339, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Hypoxia (UI: D000860, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); physiopathology (UI: Q000503, Major: No); Lactates (UI: D007773, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Perfusion (UI: D010477, Major: No); Rats (UI: D051381, Major: No)

||metabolism (1); physiopathology (0)|||physiopathology (0)|||metabolism (0); physiopathology (0)|metabolism (0)|metabolism (1)||

0|0|0|0|1|0|0|0|0|0|0|0|0

null

1976-08-02

2016-11-23

pubmed: 1975-1-1; medline: 1975-1-1 0:1; entrez: 1975-1-1 0:0

pubmed: 5756

Myocardial Ischemia

['Coronary Disease']

5,902

1

Accidental hypothermia: core rewarming with partial bypass.

MEDLINE

Manual

NLM

Three patients with profound hypothermia were treated by rewarming on partial bypass. Two surivived and have normal mental and metabolic functions. The resuscitation of the hypothermic patient should be approached with enthusiasm since the outcome is often much better than expected from initial vital signs and neurologic examination. To avoid ventricular fibrillation the patient should be handled gently and an effort should be made to keep the patient well oxygenated and the pH normal. Blood gases should be measured often and corrected for temperature. The potassium concentration and hydration status of the patient should also be monitored closely. The rewarming of profoundly hypothermic patients can readily be accomplished with a pump oxygenator and heat exchanger. The indications for this method are not established from our small experience and the few cases reported in the literature. Certainly ventricular fibrillation is a compelling indication. Patients with frozen extremities might also benefit from this method since theoretically tissue salvage would be increased. Finally, those patients who do not respond rapidly to external rewarming may be at less risk of ventricular fibrillation if rewarmed on bypass.

American journal of surgery

0002-9610

Print

131

5

Print

1,976

May

null

622-5

P Wickstrom (P); E Ruiz (E); G P Lija (GP); J P Hinterkopf (JP); J J Haglin (JJ)

Case Reports (D002363); Journal Article (D016428)

null

Accidents (UI: D000059, Major: No); Aged (UI: D000368, Major: No); Blood Gas Analysis (UI: D001784, Major: No); Cold Temperature (UI: D003080, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: No); Female (UI: D005260, Major: No); Heart-Lung Machine (UI: D006355, Major: Yes); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Hypothermia (UI: D007035, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); therapy (UI: Q000628, Major: Yes); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Oxygenators (UI: D010106, Major: No); Ventricular Fibrillation (UI: D014693, Major: No) - Qualifiers: therapy (UI: Q000628, Major: No)

|||adverse effects (0)|||||blood (0); therapy (1)||||therapy (0)

0|0|0|0|0|1|0|0|0|0|0|0|0

null

1976-08-02

2022-04-01

pubmed: 1976-5-1; medline: 1976-5-1 0:1; entrez: 1976-5-1 0:0

pubmed: 5902; pii: 35354260; doi: 10.1016/0002-9610(76)90029-5

Arrhythmias, Cardiac

['Ventricular Fibrillation']

5,922

1

The effect of enflurane, isoflurane, fluroxene, methoxyflurane and diethyl ether anesthesia on ouabain tolerance in the dog.

MEDLINE

Manual

NLM

Digitalis tolerance in dogs anesthetized with enflurane, isoflurane, fluroxene, methoxyflurane, and diethyl ether was compared with that in dogs anesthetized with pentobarbital. Ouabain dosage needed to cause ventricular tachycardia was significantly higher than that of pentobarbital with all agents except fluroxene, as was the LD50. The relative potency of these anesthetics in converting ouabain-induced ventricular tachycardia to sinus rhythm, in order of descending effectiveness, was: diethyl ether, methoxyflurane, enflurane, fluroxene, isoflurane, pentobarbital.

Anesthesia and analgesia

0003-2999

Print

55

3

Print

null

360-5

A D Ivankovich (AD); D J Miletich (DJ); R K Grossman (RK); R F Albrecht (RF); A A El-Etr (AA); V J Cairoli (VJ)

Comparative Study (D003160); Journal Article (D016428)

Ethers (Registry: 0, UI: D004987); Ethyl Ethers (Registry: 0, UI: D005019); Methyl Ethers (Registry: 0, UI: D008738); Ether (Registry: 0F5N573A2Y, UI: D004986); Methoxyflurane (Registry: 30905R8O7B, UI: D008733); Ouabain (Registry: 5ACL011P69, UI: D010042); Enflurane (Registry: 91I69L5AY5, UI: D004737); Isoflurane (Registry: CYS9AKD70P, UI: D007530); Pentobarbital (Registry: I4744080IR, UI: D010424); Potassium (Registry: RWP5GA015D, UI: D011188); Halothane (Registry: UQT9G45D1P, UI: D006221)

Anesthesia, Inhalation (UI: D000769, Major: Yes); Anesthesia, Intravenous (UI: D000771, Major: No); Animals (UI: D000818, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Dogs (UI: D004285, Major: No); Drug Tolerance (UI: D004361, Major: No); Enflurane (UI: D004737, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Ether (UI: D004986, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Ethers (UI: D004987, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Ethyl Ethers (UI: D005019, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Halothane (UI: D006221, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Isoflurane (UI: D007530, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Methoxyflurane (UI: D008733, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Methyl Ethers (UI: D008738, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Ouabain (UI: D010042, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: No); adverse effects (UI: Q000009, Major: No); pharmacology (UI: Q000494, Major: Yes); Pentobarbital (UI: D010424, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Potassium (UI: D011188, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Tachycardia (UI: D013610, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: No)

|||drug effects (0)|||pharmacology (1)|pharmacology (1)|pharmacology (1)|pharmacology (1)|pharmacology (0)|drug effects (0)|pharmacology (1)|pharmacology (1)|pharmacology (1)|administration & dosage (0); adverse effects (0); pharmacology (1)|pharmacology (0)|metabolism (0)|chemically induced (0)

1|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-08-02

2019-07-03

pubmed: 1976-5-1; medline: 1976-5-1 0:1; entrez: 1976-5-1 0:0

pubmed: 5922; doi: 10.1213/00000539-197605000-00017

Arrhythmias, Cardiac

['Tachycardia']

6,504

1

Urologic sepsis/shock.

MEDLINE

Manual

NLM

At Columbia-Presbyterian Medical Center during the six-year period 1968-1973, there were 1236 cases of sepsis from Gram-negative pathogens; 124 of these originated in the urinary tract. Of these 124 patients, 19 died-a mortality rate of 15.3 percent. There were 205 deaths among the 1236 patients with sepsis from Gramnegative organisms-a mortality rate of 16.6 percent. Previously, in the 1959-1964 and 1965-19067 periods, the mortality rates had been 56.3 percent and 19.6 percent respectively. The lowered mortality rate during 1968-1973 for urologic sepsis/shock was associated with improved management procedures: a) preventive measures such as postponement of urologic instrumentation and surgical intervention in patients infected with drug-resistant urea splitters, until the infection is under control, with emergency surgical patients being treated by susceptibility-tested drugs to control possible postoperative complications; b) early diagnosis and treatment of sepsis and immediate administration of bactericidal antibiotics parenterally; c) immediate restoration of fluid/electrolyte balance, with monitoring of renal and pulmonary functions and metabolic acidosis; and d) early administration of large pharmacologic doses of glucocorticoids, with monitoring of the microcirculation and use of beta-adrenergic isoproterenol.

Journal of the American Geriatrics Society

0002-8614

Print

24

7

Print

1,976

Jul

null

292-300

H Seneca (H); J P Grant (JP)

Journal Article (D016428)

Adrenal Cortex Hormones (Registry: 0, UI: D000305); Anabolic Agents (Registry: 0, UI: D045930); Anti-Bacterial Agents (Registry: 0, UI: D000900); Vasoconstrictor Agents (Registry: 0, UI: D014662)

Acute Kidney Injury (UI: D058186, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Adrenal Cortex Hormones (UI: D000305, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Anabolic Agents (UI: D045930, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Anti-Bacterial Agents (UI: D000900, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Heart Failure (UI: D006333, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Kidney (UI: D007668, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Sepsis (UI: D018805, Major: No) - Qualifiers: etiology (UI: Q000209, Major: Yes); physiopathology (UI: Q000503, Major: No); prevention & control (UI: Q000517, Major: No); Shock, Septic (UI: D012772, Major: No) - Qualifiers: etiology (UI: Q000209, Major: Yes); physiopathology (UI: Q000503, Major: No); prevention & control (UI: Q000517, Major: No); Urinary Tract Infections (UI: D014552, Major: No) - Qualifiers: complications (UI: Q000150, Major: Yes); physiopathology (UI: Q000503, Major: No); Vasoconstrictor Agents (UI: D014662, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Water-Electrolyte Imbalance (UI: D014883, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No)

etiology (0)|therapeutic use (0)|therapeutic use (0)|therapeutic use (0)|etiology (0)|||physiopathology (0)|etiology (1); physiopathology (0); prevention & control (0)|etiology (1); physiopathology (0); prevention & control (0)|complications (1); physiopathology (0)|therapeutic use (0)|etiology (0)

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-08-23

2024-12-02

pubmed: 1976-7-1; medline: 1976-7-1 0:1; entrez: 1976-7-1 0:0

pubmed: 6504; doi: 10.1111/j.1532-5415.1976.tb06799.x; pii: 39431387

Heart Failure

[]

6,806

1

Elevated plasma renin activity in aortitis syndrome.

MEDLINE

Manual

NLM

Plasma renin activity (PRA) was measured in 38 cases of aortitis syndrome. The values of resting peripheral vein blood PRA were 32.2 +/- 4.2 (SE) mmug/ml. These values were 3 times higher than those of normal subjects. Hypertension due to renal arterial stenosis was observed in 18 cases. Their resting PRA values were 41.2 +/- 6.0 mmug/ml, while in the remaining 20 patients without renovascular hypertension those values were 24.2 +/- 5.4 mmug/ml. The patients belonging to aortic arch type or extensive type had 2 times higher PRA values than those of abdominal type. The patients with stenosis or obstruction of common carotid arteries had significantly higher PRA values than the patients without these lesions. Hyperresponse of renin secretion to upright posture was also observed in the same patients with carotid artery stenosis. Abnormal renin release in Takayasu's arteritis disappeared after denervation of the carotid sinus nerve. The present study suggests that the unstable state of carotid sinus reflex is the main cause for the hypersecretion of renin.

Japanese heart journal

0021-4868

Print

17

1

Print

1,976

Jan

null

1-11

K Abe (K); S Miyazaki (S); T Kusaka (T); N Irokawa (N); H Aoyagi (H)

Journal Article (D016428)

Renin (Registry: EC 3.4.23.15, UI: D012083)

Adolescent (UI: D000293, Major: No); Adult (UI: D000328, Major: No); Aortic Arch Syndromes (UI: D001015, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes); Arterial Occlusive Diseases (UI: D001157, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Asian People (UI: D044466, Major: No); Carotid Artery Diseases (UI: D002340, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Carotid Sinus (UI: D002346, Major: No) - Qualifiers: innervation (UI: Q000294, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Hypertension, Renal (UI: D006977, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); complications (UI: Q000150, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Posture (UI: D011187, Major: No); Renin (UI: D012083, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes); Takayasu Arteritis (UI: D013625, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes); complications (UI: Q000150, Major: No)

||blood (1)|blood (0)||blood (0)|innervation (0)|||blood (0); complications (0)||||blood (1)|blood (1); complications (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-09-01

2022-12-07

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 6806; doi: 10.1536/ihj.17.1

Cerebrovascular Disorders

['Carotid Artery Diseases']

6,826

1

Monitoring of midmyocardial and subendocardial pH in normal and ischemic ventricles.

MEDLINE

Manual

NLM

Midmyocardial and subendocardial pH monitoring was used as an indirect method for continuous evaluation of regional canine myocardial ischemia. Left ventricular midmyocardial pH (pHm) at 4 mm. depth was monitored in 10 dogs, under resting conditions, by means of a 5 mm. Beckman pH probe. pHm was 6.96 +/- 0.03, recorded at myocardial temperatures of 35 to 37 degrees C. Ischemia was then produced by snare occlusion of the proximal left main coronary artery for 2 minutes. pHm decreased to 6.87 +/- 0.03 (p less than 0.01) at 1 minute and 6.80 +/- 0.04 (p less than 0.005) in 2 minutes. When flow was restored, pHm returned toward normal within 2 minutes (pH 6.86 +/- 0.03) and at 5 minutes had returned to control values (pH 6.93 +/- 0.03). In another 5 dogs under similar conditions, pHm at 4 mm. and subendocardial pH (pHe at 8 mm.) were measured. Baseline pHm (6.97 +/- 0.01) and pHe (6.84 +/- 0.02) levels were significantly different (p less than 0.0005). After 2 minutes of ischemia, pHm was 6.82 +/- 0.03, whereas pHe decreased to 6.78 +/- 0.04 (p less than 0.1). Five minutes after snare release, pHe remained at 6.73 +/- 0.07; pHm (6.93 +/- 0.03) returned to control values. Both pHm (6.93 +/- 0.02) and pHe (6.84 +/- 0.09) levels were normal 15 minutes after release of the snare. The midmyocardium and subendocardium have different pH levels which can be monitored. Ischemia produces different pH patterns in these layers. pHm returns to control values within 5 minutes after 2 minutes of ischemia, whereas pHe remains depressed for at least 5 minutes. pH monitoring provides an accurate and simple method for on-line evaluation of endocardial ischemia.

The Journal of thoracic and cardiovascular surgery

0022-5223

Print

72

1

Print

1,976

Jul

null

52-6

G L Hicks (GL); A Hill (A); J A DeWeese (JA)

Journal Article (D016428)

null

Animals (UI: D000818, Major: No); Blood Pressure (UI: D001794, Major: No); Coronary Circulation (UI: D003326, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Dogs (UI: D004285, Major: No); Endocardium (UI: D004699, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Heart Ventricles (UI: D006352, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Monitoring, Physiologic (UI: D008991, Major: Yes); Myocardial Contraction (UI: D009200, Major: No); Myocardium (UI: D009206, Major: No); Pulse (UI: D011674, Major: No); Ventricular Fibrillation (UI: D014693, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No)

|||physiopathology (1)||physiopathology (0)|physiopathology (1)|physiopathology (0)||||||physiopathology (0)

0|0|0|0|0|0|0|0|0|1|0|0|0|0

null

1976-09-01

2003-11-14

pubmed: 1976-7-1; medline: 1976-7-1 0:1; entrez: 1976-7-1 0:0

pubmed: 6826

Myocardial Ischemia

['Coronary Disease']

6,857

1

The potentialities of some antihistaminics in preanaesthetic medication.

MEDLINE

Manual

NLM

A detailed study has been carried out on the potentialities of antazoline and chlorpheneramine (C.P.M.) in preanaesthetic medication. It included a determination of their sedative action, effects on cardiovascular system and any possible anticholinergic and antiarrhythmic properties. Both drugs depressed spontaneous activity in mice. Antazoline produced hypotension in chloralosed dogs and spinal cats (a peripheral action). Both produced a negative inotropic action on isolated rabbit's heart. On rat's auricle antazoline produced a positive chronotropic action while C.P.M. produced a negative chronotropic action. Both drugs could protect the heart against adrenaline induced arrhythmias during chloroform and halothane anaesthesia. Their anticholinergic properties were demonstrated by studies on isolated rabbit's heart and intestine as well as on isolated guinea pig's ileum.

Middle East journal of anaesthesiology

0544-0440

Print

4

5

Print

1,975

Jun

null

347-62

M Kamel (M); E E Sharaf (EE); A El-Kader (A); Z Isaak (Z)

Journal Article (D016428)

Histamine H1 Antagonists (Registry: 0, UI: D006634); Hypnotics and Sedatives (Registry: 0, UI: D006993); Imidazoles (Registry: 0, UI: D007093); Parasympatholytics (Registry: 0, UI: D010276); Chlorpheniramine (Registry: 3U6IO1965U, UI: D002744); Antazoline (Registry: DHA8014SS1, UI: D000865)

Animals (UI: D000818, Major: No); Antazoline (UI: D000865, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cats (UI: D002415, Major: No); Chlorpheniramine (UI: D002744, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Dogs (UI: D004285, Major: No); Guinea Pigs (UI: D006168, Major: No); Histamine H1 Antagonists (UI: D006634, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Hypnotics and Sedatives (UI: D006993, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Imidazoles (UI: D007093, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Mice (UI: D051379, Major: No); Motor Activity (UI: D009043, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Myocardial Contraction (UI: D009200, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Parasympatholytics (UI: D010276, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Preanesthetic Medication (UI: D011229, Major: Yes); Rabbits (UI: D011817, Major: No); Ventricular Fibrillation (UI: D014693, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No)

|pharmacology (1)|drug effects (0)||pharmacology (1)|||pharmacology (0)|pharmacology (0)|pharmacology (1)||drug effects (0)|drug effects (0)|pharmacology (0)|||drug therapy (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|1|0|0

null

1976-09-01

2014-10-10

pubmed: 1975-6-1; medline: 1975-6-1 0:1; entrez: 1975-6-1 0:0

pubmed: 6857

Arrhythmias, Cardiac

['Ventricular Fibrillation']

7,100

1

Effects of metoprolol in angina pectoris. A subacute study with exercise tests and a long-term tolerability study.

MEDLINE

Manual

NLM

Eighteen patients with angina pectoris, who had previously participated in a cross-over study with 20 mg metoprolol t.i.d. and placebo, have been included in this study. During an introductory six-month open tolerability study, all patients were treated with 50 mg metoprolol t.i.d. and during a subsequent cross-over study, the efficacy of this dose was compared with that of placebo under double-blind conditions. An exercise was performed at the end of each cross-over period. Metoprolol, in a dose of 50 mg t.i.d., gave a significant improvement compared with placebo in respect of the number of anginal attacks, nitroglycerin consumption and daily subjective assessment of the patients' anginal symptoms. Metoprolol also gave a significant increase in exercise capacity, both until the appearance of 1 mm ST segment depression and until the end of exercise. Heart rate and blood pressure were reduced both at rest and during exercise. No severe unwanted effects were observed during this study ranging over eight months, and none of the patients had any signs or symptoms of cardiac failure or pulmonary dysfunction on any occasion. Unwanted effects reported were mild to moderate, and the frequency was the same as during placebo treatment. No abnormal laboratory findings were observed and the relative heart volume was not significantly changed. Administration of 50 mg metoprolol t.i.d. seems to be of greater benefit than 20 mg metoprolol t.i.d., previously investigated in these patients.

Acta medica Scandinavica

0001-6101

Print

199

6

Print

1,976

null

491-7

O Keyriläinen (O); A Uusitalo (A)

Clinical Trial (D016430); Journal Article (D016428); Randomized Controlled Trial (D016449)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Placebos (Registry: 0, UI: D010919)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: adverse effects (UI: Q000009, Major: No); therapeutic use (UI: Q000627, Major: Yes); Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cardiac Volume (UI: D002306, Major: No); Clinical Trials as Topic (UI: D002986, Major: No); Exercise Test (UI: D005080, Major: No); Female (UI: D005260, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Long-Term Care (UI: D008134, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Placebos (UI: D010919, Major: No)

adverse effects (0); therapeutic use (1)|||drug therapy (1)|drug effects (0)|||||drug effects (0)|||||

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-09-01

2007-11-15

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 7100

Myocardial Ischemia

['Angina Pectoris']

7,133

1

Mucocutaneous lymph node syndrome with coronary artery aneurysm.

MEDLINE

Manual

NLM

A white North American girl with clinical features of the mucocutaneous lymph node syndrome had a myocardial infarct and angiographic evidence of a coronary artery aneurysm and mitral regurgitation. The mucocutaneous lymph node syndrome has been extensively diagnosed in Japan in recent years. It appears to be a distinct entity, although not precisely separated from polyarteritis nodosa in childhood. The condition may be more common than previously realized.

American journal of diseases of children (1960)

0002-922X

Print

130

6

Print

1,976

Jun

null

596-8

D J Radford (DJ); H M Sondheimer (HM); G J Williams (GJ); R S Fowler (RS)

Case Reports (D002363); Journal Article (D016428)

null

Aneurysm (UI: D000783, Major: No) - Qualifiers: etiology (UI: Q000209, Major: Yes); Canada (UI: D002170, Major: No); Child, Preschool (UI: D002675, Major: No); Conjunctivitis (UI: D003231, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnosis (UI: Q000175, Major: No); epidemiology (UI: Q000453, Major: Yes); Coronary Vessels (UI: D003331, Major: Yes); Dermatitis (UI: D003872, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnosis (UI: Q000175, Major: No); epidemiology (UI: Q000453, Major: Yes); Diagnosis, Differential (UI: D003937, Major: No); Female (UI: D005260, Major: No); Fever (UI: D005334, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnosis (UI: Q000175, Major: No); epidemiology (UI: Q000453, Major: Yes); Humans (UI: D006801, Major: No); Lymphadenitis (UI: D008199, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnosis (UI: Q000175, Major: No); epidemiology (UI: Q000453, Major: Yes); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Polyarteritis Nodosa (UI: D010488, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Syndrome (UI: D013577, Major: No)

etiology (1)|||complications (0); diagnosis (0); epidemiology (1)||complications (0); diagnosis (0); epidemiology (1)|||complications (0); diagnosis (0); epidemiology (1)||complications (0); diagnosis (0); epidemiology (1)|etiology (0)|diagnosis (0)|

0|0|0|0|1|0|0|0|0|0|0|0|0|0

null

1976-09-01

2019-07-16

pubmed: 1976-6-1; medline: 1976-6-1 0:1; entrez: 1976-6-1 0:0

pubmed: 7133; doi: 10.1001/archpedi.1976.02120070022005

Myocardial Ischemia

['Myocardial Infarction']

7,134

1

Mucocutaneous lymph node syndrome in the United States.

MEDLINE

Manual

NLM

Sixteen patients with an unusual and distinct symptom complex were encountered during a four-year period. Principal features of this syndrome are (1) fever lasting more than seven days; (2) conjunctival injection; (3) changes in the mouth consisting of erythema of the oropharynx, ""strawberry tongue"", and erythema of the lips; (4) indurative edema of hands and feet with palm and sole erythema followed by desquamation of the fingertips; and (5) an erythematous rash. Associated features were lymphadenopathy, pyuria, aseptic meningitis, diarrhea, arthritis, and arthralgia. Although usually a self-limited illness, one patient died with massive coronary artery thrombosis on the 19th day of illness. This syndrome appears to be clinically and pathologically similar to mucocutaneous lymph node syndrome, an illness prevalent in Japan but previously unrecognized by American clinicians. Pathologic features suggest a relationship to infantile periarteritis nodosa.

American journal of diseases of children (1960)

0002-922X

Print

130

6

Print

1,976

Jun

null

599-607

M E Melish (ME); R M Hicks (RM); E J Larson (EJ)

Case Reports (D002363); Journal Article (D016428)

null

Arthritis, Juvenile (UI: D001171, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Child (UI: D002648, Major: No); Child, Preschool (UI: D002675, Major: No); Conjunctivitis (UI: D003231, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnosis (UI: Q000175, Major: No); epidemiology (UI: Q000453, Major: Yes); Coronary Disease (UI: D003327, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Dermatitis (UI: D003872, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnosis (UI: Q000175, Major: No); epidemiology (UI: Q000453, Major: Yes); Diagnosis, Differential (UI: D003937, Major: No); Female (UI: D005260, Major: No); Fever (UI: D005334, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnosis (UI: Q000175, Major: No); epidemiology (UI: Q000453, Major: Yes); Humans (UI: D006801, Major: No); Infant (UI: D007223, Major: No); Japan (UI: D007564, Major: No); Lymphadenitis (UI: D008199, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); diagnosis (UI: Q000175, Major: No); epidemiology (UI: Q000453, Major: Yes); Male (UI: D008297, Major: No); Polyarteritis Nodosa (UI: D010488, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Stevens-Johnson Syndrome (UI: D013262, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Syndrome (UI: D013577, Major: No); United States (UI: D014481, Major: No)

diagnosis (0)|||complications (0); diagnosis (0); epidemiology (1)|etiology (0)|complications (0); diagnosis (0); epidemiology (1)|||complications (0); diagnosis (0); epidemiology (1)||||complications (0); diagnosis (0); epidemiology (1)||diagnosis (0)|diagnosis (0)||

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-09-01

2019-07-16

pubmed: 1976-6-1; medline: 1976-6-1 0:1; entrez: 1976-6-1 0:0

pubmed: 7134; doi: 10.1001/archpedi.1976.02120070025006

Myocardial Ischemia

['Coronary Disease']

7,377

1

Tricyclic antidepressant overdosage: experimental studies on the management of circulatory complications.

MEDLINE

Manual

NLM

Tricyclic antidepressant overdosage may be complicated by cardiac arrhythmias, which were sometimes difficult to treat prior to the use of sodium bicarbonate. Experiments have been done with several antiarrhythmics in an attempt to define the optimum treatment. Sodium bicarbonate proved the most effective experimentally and this supports our clinical experience. Physostigmine is a useful second drug, having beneficial effects against arrhythmias and central nervous system manifestations of toxicity. Practolol, although reversing the arrhythmias, tends to cause hypotension. Other drugs tried were less effective.

Clinical toxicology

0009-9309

Print

9

2

Print

1,976

null

255-72

T C Brown (TC)

Journal Article (D016428)

Anti-Arrhythmia Agents (Registry: 0, UI: D000889); Antidepressive Agents, Tricyclic (Registry: 0, UI: D000929); Metals (Registry: 0, UI: D008670); Carbon Dioxide (Registry: 142M471B3J, UI: D002245); Amitriptyline (Registry: 1806D8D52K, UI: D000639)

Acid-Base Equilibrium (UI: D000136, Major: No); Amitriptyline (UI: D000639, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Animals (UI: D000818, Major: No); Anti-Arrhythmia Agents (UI: D000889, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Antidepressive Agents, Tricyclic (UI: D000929, Major: No) - Qualifiers: poisoning (UI: Q000506, Major: Yes); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: chemically induced (UI: Q000139, Major: Yes); drug therapy (UI: Q000188, Major: No); Carbon Dioxide (UI: D002245, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Dogs (UI: D004285, Major: No); Hemodynamics (UI: D006439, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Metals (UI: D008670, Major: No) - Qualifiers: blood (UI: Q000097, Major: No)

|blood (0)||therapeutic use (0)|poisoning (1)|chemically induced (1); drug therapy (0)|blood (0)||||blood (0)

0|0|0|0|0|0|0|0|0|0|0

null

1976-09-25

2013-11-21

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 7377; doi: 10.3109/15563657608988129

Arrhythmias, Cardiac

[]

7,699

1

[Dynamic observations of tolerance to physical exercise in patients with ischemic heart disease during drug therapy].

MEDLINE

Manual

NLM

Proceeding from a dynamic observation of the tolerance of physical exercises in the process of drug therapy of 90 patients with ischaemic heart disease the author concludes that a certain dissociation exists between the subjective effect of the antianginal drugs and the results of bicycle tests in the evaluation of the efficacy of the treatment. While a subjective improvement was declared in 2/3 of the patients, the exercise test indices improved only in 1/3. The bicylce test before and after the therapeutic course seems to facilitate a more precise evaluation of the efficacy of the antianginal drugs.

Kardiologiia

0022-9040

Print

15

9

Print

1,975

Sep

null

68-73

V P Lupanov (VP)

Comparative Study (D003160); English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Anabolic Agents (Registry: 0, UI: D045930); Anti-Arrhythmia Agents (Registry: 0, UI: D000889); Placebos (Registry: 0, UI: D010919); Vasodilator Agents (Registry: 0, UI: D014665)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Anabolic Agents (UI: D045930, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Anti-Arrhythmia Agents (UI: D000889, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); physiopathology (UI: Q000503, Major: Yes); Drug Evaluation (UI: D004341, Major: No); Exercise Test (UI: D005080, Major: No); Female (UI: D005260, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Myocardial Contraction (UI: D009200, Major: No); Physical Exertion (UI: D005082, Major: Yes); Placebos (UI: D010919, Major: No); Vasodilator Agents (UI: D014665, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No)

therapeutic use (0)|||therapeutic use (0)|therapeutic use (0)|drug therapy (0); physiopathology (1)||||physiopathology (1)|||||||therapeutic use (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|1|0|0

null

1976-09-25

2017-03-10

pubmed: 1975-9-1; medline: 1975-9-1 0:1; entrez: 1975-9-1 0:0

pubmed: 7699

Myocardial Ischemia

['Coronary Disease']

7,952

1

Efficacy of cardioselective beta adrenergic blockade with intravenously administered tolamolol in the treatment of cardiac arrhythmias.

MEDLINE

Manual

NLM

The efficacy of tolamolol, a cardioselective beta adrenergic blocking agent, was evaluated in the treatment of cardiac arrhythmias in 27 patients. Nineteen patients had supraventricular arrhythmias and eight had ventricular arrhythmias. Evaluation was by doulbe-blind randomized trial in 23 patients. Tolamolol was effective in reducing ventricular rate in 17 (85 percent) of 19 patients with supraventricular arrhythmias and resulted in conversion to sinus rhythm in 2 of the 17. The mean ventricular rate in 17 patients decreased from 135 to 102/min 10 minutes after initiation of administration of tolamolol and gradually decreased further to 93/min after 60 minutes. Reduction in ventricular rate was sustained for 2 hours of monitoring undergone by all patients and for 4 and 6 hours monitoring in two subgroups. Among the eight patients with ventricular ectopic beats, tolamolol reduced their frequency in four patients and had no effect in four. Six patients had chronic obstructive pulmonary disease and experienced no adverse clinical effects on respiratory function in association with administration to tolamolol. Untoward effects occurred in 10 patients, including hypotension in 3, 1 of whom required vasopressor therapy. Other side effects were sedation, nausea, dyspnea and warmth in the chest, all of which were mild and transient, requiring no treatment. Cardioselective beta adrenergic blockade with tolamolol was highly effective in controlling ventricular rate in supraventricular arrhythmias and reduced the frequency of ventricular ectopic beats in half of the small group of patients with this arrhythmia. It is particularly applicable in patients with obstructive pulmonary disease in whom cardiac beta adrenergic blockade is indicated. Hypotension is an important potential side effect.

The American journal of cardiology

0002-9149

Print

38

2

Print

1,976

Aug

null

195-9

E A Amsterdam (EA); G Lee (G); S Morrison (S); M J Tonkin (MJ); A N DeMaria (AN); D T Mason (DT)

Clinical Trial (D016430); Journal Article (D016428); Randomized Controlled Trial (D016449); Research Support, U.S. Gov't, P.H.S. (D013487)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Propanolamines (Registry: 0, UI: D011412)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Aged (UI: D000368, Major: No); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); Atrial Fibrillation (UI: D001281, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Clinical Trials as Topic (UI: D002986, Major: No); Dose-Response Relationship, Drug (UI: D004305, Major: No); Drug Therapy, Combination (UI: D004359, Major: No); Female (UI: D005260, Major: No); Heart Atria (UI: D006325, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Heart Ventricles (UI: D006352, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Infusions, Parenteral (UI: D007263, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Organ Specificity (UI: D009928, Major: No); Propanolamines (UI: D011412, Major: No) - Qualifiers: administration & dosage (UI: Q000008, Major: No); adverse effects (UI: Q000009, Major: No); therapeutic use (UI: Q000627, Major: Yes); Tachycardia (UI: D013610, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No)

therapeutic use (1)||drug therapy (1)|drug therapy (0)|drug effects (0)|||||drug effects (0)|drug effects (0)|drug effects (0)||||||administration & dosage (0); adverse effects (0); therapeutic use (1)|drug therapy (0)

0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-10-02

2019-06-22

pubmed: 1976-8-1; medline: 1976-8-1 0:1; entrez: 1976-8-1 0:0

pubmed: 7952; pii: 0002-9149(76)90149-1; doi: 10.1016/0002-9149(76)90149-1

Arrhythmias, Cardiac

['Atrial Fibrillation', 'Tachycardia']

7,957

1

Takayasu's arteritis and congenital coarctation of the descending thoracic and abdominal aorta: a critical review.

MEDLINE

Manual

NLM

A critical reappraisal of the clinical, arteriographic, and pathologic features of Takayasu's arteritis and so-called congenital aortic coarctations at atypical sites is presented. It is concluded that as an isolated cardiovascular abnormality, cases of atypical congenital coarctations of the descending thoracic and abdominal aorta are probably rare. The majority of atypical aortic coarctations previously reported in the United States and Europe as congenital lesions apparently represent unrecognized cases of Takayasu's arteritis.

AJR. American journal of roentgenology

0361-803X

Print

127

2

Print

1,976

Aug

null

227-33

A Lande (A)

Journal Article (D016428); Review (D016454)

null

Aorta, Abdominal (UI: D001012, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Aorta, Thoracic (UI: D001013, Major: No) - Qualifiers: pathology (UI: Q000473, Major: No); Aortic Coarctation (UI: D001017, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: Yes); epidemiology (UI: Q000453, Major: No); etiology (UI: Q000209, Major: No); Autoimmune Diseases (UI: D001327, Major: No) - Qualifiers: diagnosis (UI: Q000175, Major: No); Europe (UI: D005060, Major: No); Humans (UI: D006801, Major: No); Japan (UI: D007564, Major: No); Radiography (UI: D011859, Major: No); Takayasu Arteritis (UI: D013625, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); epidemiology (UI: Q000453, Major: No); United States (UI: D014481, Major: No)

pathology (0)|pathology (0)|diagnosis (1); epidemiology (0); etiology (0)|diagnosis (0)|||||diagnostic imaging (0); epidemiology (0)|

0|0|0|0|0|0|0|0|0|0

null

1976-10-01

2016-11-23

pubmed: 1976-8-1; medline: 1976-8-1 0:1; entrez: 1976-8-1 0:0

pubmed: 7957; doi: 10.2214/ajr.127.2.227

Heart Defects, Congenital

['Aortic Coarctation']

7,978

1

[Hyperbaric oxygen therapy in cerebral circulatory insufficiency].

MEDLINE

Manual

NLM

From a study bearing upon 26 patients suffering from a cerebral circulatory insufficiency induced by a stenosis or a thrombosis, the writers analyse the part played by Hyperbare Oxygen in the neurologic evolution. The defining of the efficacy criteria enabled them to determine whenever this part was prevalent and obvious (that's to say in 20 p. 100 of the cases). However, in the other cases it was hard to decide whether Hyperbare Oxygen played any part. Only functional lesions are liable to benefit from this therapy which seems mainly useful to cover the period of circulatory adaptation at a time when supply circulations may come into play. The difficulty to appreciate the importance of supply circulations urges on to treat this type of patients early enough in a systematic way and all the more so as they are young.

Annales de l'anesthesiologie francaise

0003-4061

Print

16

7

Print

1,975

Nov

null

485-500

R Chacornac (R); Y N Martin (YN); M T Fournier-Jenoudet (MT); R Deleuze (R)

English Abstract (D004740); Journal Article (D016428)

null

Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Cerebral Angiography (UI: D002533, Major: No); Cerebrovascular Disorders (UI: D002561, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); surgery (UI: Q000601, Major: No); therapy (UI: Q000628, Major: Yes); Humans (UI: D006801, Major: No); Hyperbaric Oxygenation (UI: D006931, Major: Yes) - Qualifiers: adverse effects (UI: Q000009, Major: No); Intracranial Embolism and Thrombosis (UI: D002542, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Middle Aged (UI: D008875, Major: No); Neurologic Manifestations (UI: D009461, Major: No)

|||etiology (0); surgery (0); therapy (1)||adverse effects (0)|complications (0)||

0|0|0|0|0|1|0|0|0

null

1976-09-25

2006-11-15

pubmed: 1975-11-1; medline: 1975-11-1 0:1; entrez: 1975-11-1 0:0

pubmed: 7978

Cerebrovascular Disorders

['Intracranial Embolism and Thrombosis', 'Cerebrovascular Disorders']

8,298

1

[Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)].

MEDLINE

Manual

NLM

Cardiac catheterisation with pressure measurements, left-ventricular cine-angiography and selective coronary angiography confirmed the diagnosis of hypertrophic obstructive cardiomyopathy in 20 patients. After a mean observation period of 20 months during which most of them were treated with beta-blockers, verapamil, 480 mg by mouth, was given for an average of 12 months. There was an impressive improvement in symptoms, compared with the state under beta-blocker treatment. There was a significant reduction in the ECG signs of left-ventricular hypertrophy and of the radiologically measured heart volume. Treatment of this condition with verapamil appeared to be superior to that with beta-blockers.

Deutsche medizinische Wochenschrift (1946)

0012-0472

Print

101

35

Print

1,976

Aug

27

1284-7

M Kaltenbach (M); R Hopf (R); M Keller (M)

Comparative Study (D003160); English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Verapamil (Registry: CJ0O37KU29, UI: D014700); Calcium (Registry: SY7Q814VUP, UI: D002118)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Adult (UI: D000328, Major: No); Calcium (UI: D002118, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: Yes); Cardiac Volume (UI: D002306, Major: No); Cardiomyopathy, Hypertrophic (UI: D002312, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); physiopathology (UI: Q000503, Major: No); Drug Evaluation (UI: D004341, Major: No); Electrocardiography (UI: D004562, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Long-Term Care (UI: D008134, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Verapamil (UI: D014700, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes)

therapeutic use (0)||antagonists & inhibitors (1)||drug therapy (1); physiopathology (0)||||||||therapeutic use (1)

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-10-29

2013-11-21

pubmed: 1976-8-27; medline: 1976-8-27 0:1; entrez: 1976-8-27 0:0

pubmed: 8298; doi: 10.1055/s-0028-1104257

Cardiomyopathies

['Cardiomyopathy, Hypertrophic']

8,662

1

Simplified operative technique for the long-segment atypical coarctation of the aorta.

MEDLINE

Manual

NLM

Simplified operative technique for the long-segment atypical coarctation of the aorta was described. The main objective of this technique is to gain quick access to both thoracic and abdominal aorta with minimal blood loss, and preservation of diaphragmatic function. This procedure consists of standard thoracotomy and pararectal incision with an entry into the retroperitoneal space. Long prosthetic graft was anastomosed in an end-to-side fashion to bypass the coarctated aorta. The graft is placed through peripheral circumference of the left hemidiaphragm, where phrenic nerve injury is not likely to occur. This technique was successfully applied to two cases of long-segment atypical coarctation of the aorta due to Takayasu's aortitis. Retroperitoneal placement of the graft prevents fatal hemorrhage due to direct contact with the graft. Contamination with transintestinal exudate can also be avoided. Results of the ten-year follow-up of the similar procedure in the literature is encouraging.

The Japanese journal of surgery

0047-1909

Print

5

4

Print

1,975

Dec

null

246-54

R Hatano (R); T Yamada (T); M Sunamori (M); T Tsukuura (T); T Sakamoto (T)

Case Reports (D002363); Journal Article (D016428)

null

Adult (UI: D000328, Major: No); Aorta, Abdominal (UI: D001012, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); surgery (UI: Q000601, Major: No); Aorta, Thoracic (UI: D001013, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); surgery (UI: Q000601, Major: No); Aortic Coarctation (UI: D001017, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); etiology (UI: Q000209, Major: No); surgery (UI: Q000601, Major: Yes); Blood Vessel Prosthesis (UI: D001807, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Hypertension (UI: D006973, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Radiography (UI: D011859, Major: No); Takayasu Arteritis (UI: D013625, Major: No) - Qualifiers: complications (UI: Q000150, Major: No)

|diagnostic imaging (0); surgery (0)|diagnostic imaging (0); surgery (0)|complications (0); etiology (0); surgery (1)||||etiology (0)||complications (0)

0|0|0|0|0|0|0|0|0|0

null

1976-10-20

2019-09-18

pubmed: 1975-12-1; medline: 1975-12-1 0:1; entrez: 1975-12-1 0:0

pubmed: 4777854; doi: 10.1007/BF02469767

Heart Defects, Congenital

['Aortic Coarctation']

8,885

1

[Effect of arterial hypoxia and acidosis on fibrillation threshold in the cat heart in vivo].

MEDLINE

Manual

NLM

The influence of severe arterial hypoxia and acidosis on the fibrillation threshold was checked in 22 cats. Two groups were formed: in 10 cats (group I) acidosis was produced by 2-N lactic acid infusion; in the second group of 12 animals the respirator was turned off for 60 seconds, thus producing a low arterial PO2. If hypoxia and acidosis were severe enough, the fibrillation threshold was significantly lowered in either group. The pathophysiological mechanisms of these findings are discussed.

Zeitschrift fur Kardiologie

0300-5860

Print

65

7

Print

1,976

Jul

null

585-9

R Marquardt (R); J Fischer (J); W Küstner (W)

Journal Article (D016428)

Lactates (Registry: 0, UI: D007773)

Acidosis (UI: D000138, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Animals (UI: D000818, Major: No); Arteries (UI: D001158, Major: No); Cats (UI: D002415, Major: No); Female (UI: D005260, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Hypoxia (UI: D000860, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Lactates (UI: D007773, Major: No); Male (UI: D008297, Major: No); Mathematics (UI: D008433, Major: No); Ventricular Fibrillation (UI: D014693, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes)

physiopathology (1)||||||physiopathology (1)||||physiopathology (1)

0|0|0|0|0|0|0|0|0|0|0

null

1976-10-20

2016-11-23

pubmed: 1976-7-1; medline: 1976-7-1 0:1; entrez: 1976-7-1 0:0

pubmed: 8885

Arrhythmias, Cardiac

['Ventricular Fibrillation']

8,943

1

The haemodynamic effects of unsupplemented nitrous oxide-oxygen-relaxant anaesthesia in cardiac patients.

MEDLINE

Manual

NLM

The effect on the systemic and pulmonary circulation of unsupplemented nitrous oxide in about 30% oxygen, with and without IPPV, was investigated in five cardiac patients and compared with control periods at rest with air breathing. The results of this investigation show that nitrous oxide in conventional oxygen concentration does not cause any great haemodynamic changes. During tracheal intubation, however, significant increases in both systemic and pulmonary blood pressures were registered. However, these pressures reverted to the control values immediately after the tracheal intubation. The results of this study support many earlier clinicaly good experiences obtained when using this conventional nitrous oxide-oxygen mixture in cardiac patients.

Acta anaesthesiologica Scandinavica

0001-5172

Print

20

3

Print

1,976

null

195-200

O Dottori (O); M Korsgren (M); B Ax (B); S Löf (S); L Wilhelmsen (L)

Journal Article (D016428)

Carbon Dioxide (Registry: 142M471B3J, UI: D002245); Nitrous Oxide (Registry: K50XQU1029, UI: D009609); Oxygen (Registry: S88TT14065, UI: D010100)

Adult (UI: D000328, Major: No); Anesthesia, Inhalation (UI: D000769, Major: Yes); Blood Pressure (UI: D001794, Major: No); Carbon Dioxide (UI: D002245, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Cardiac Catheterization (UI: D006328, Major: No); Cardiac Output (UI: D002302, Major: No); Cardiac Surgical Procedures (UI: D006348, Major: Yes); Female (UI: D005260, Major: No); Heart Rate (UI: D006339, Major: No); Hemodynamics (UI: D006439, Major: Yes) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Intermittent Positive-Pressure Breathing (UI: D007384, Major: No); Intubation, Intratracheal (UI: D007442, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Mitral Valve Stenosis (UI: D008946, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No); Nitrous Oxide (UI: D009609, Major: Yes); Oxygen (UI: D010100, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Oxygen Consumption (UI: D010101, Major: No); Partial Pressure (UI: D010313, Major: No); Pulmonary Circulation (UI: D011652, Major: No); Vascular Resistance (UI: D014655, Major: No); Ventilation-Perfusion Ratio (UI: D014692, Major: No)

|||blood (0)||||||drug effects (0)|||||||surgery (0)||blood (0)|||||

0|1|0|0|0|0|1|0|0|1|0|0|0|0|0|0|0|1|0|0|0|0|0|0

null

1976-10-29

2019-08-14

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 8943; doi: 10.1111/j.1399-6576.1976.tb05028.x

Heart Valve Diseases

['Mitral Valve Stenosis']

9,020

1

Interaction of anesthesia, beta-receptor blockade, and blood loss in dogs with induced myocardial infarction.

MEDLINE

Manual

NLM

The cardiovascular effects of halothane-nitrous oxide anesthesia, and beta-receptor blockade with either propranolol or practolol, were studied in 15 dogs in which severe myocardial infarction had been induced ten days earlier. The hemodynamic responses to blood loss amounting to 25 per cent of estimated blood volume, and its subsequent replacement, were studied before and after induction of beta-receptor blockade. In terms of cardiac output and aortic blood flow acceleration, cardiac performance in the absence of beta-blockade was markedly impaired during steady-state anesthesia, compared with corresponding values in normal dogs. Practolol (2.0 mg/kg) administered during anesthesia induced no significant circulatory change other than a 14 per cent decrease in heart rate and a 25 per cent increase in strode volum. Propranolol (0.3 mg/kg) caused a comparable reduction of heart rate, but significantly reduced cardiac output (-27 per cent), aortic blood flow acceleration (-26 per cent), and peak LV power (-19 per cent), and increased systemic vascular resistance (+49 per cent). The two drugs caused comparable shifts of the isoproterenol dose-response curve during anesthesia. Graduated blood loss during anesthesia, to a total of 25 per cent of blood volume, caused consistent circulatory changes (decreased mean arterial pressure cardiac output, peak LV power, LV minute work) that were essentially similar before and after beta-receptor blockade with either propranolol or practolol. The positive inotropic effect of calcium gluconate during halothane anesthesia was significantly reduced following either propranolol or practolol, but the hemodynamic responses to changes of systemic vascular resistance induced with acetylcholine or phenylephrine were not modified by beta-receptor blockade.

Anesthesiology

0003-3022

Print

45

3

Print

1,976

Sep

null

326-9

C Prys-Roberts (C); J G Roberts (JG); P Foëx (P); T N Clarke (TN); M J Bennett (MJ); W A Ryder (WA)

Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Gluconates (Registry: 0, UI: D005942); Phenylephrine (Registry: 1WS297W6MV, UI: D010656); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433); Nitrous Oxide (Registry: K50XQU1029, UI: D009609); Isoproterenol (Registry: L628TT009W, UI: D007545); Acetylcholine (Registry: N9YNS0M02X, UI: D000109); Practolol (Registry: SUG9176GRW, UI: D011217); Halothane (Registry: UQT9G45D1P, UI: D006221)

Acetylcholine (UI: D000109, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Anesthesia, General (UI: D000768, Major: Yes); Animals (UI: D000818, Major: No); Coronary Circulation (UI: D003326, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Dogs (UI: D004285, Major: No); Dose-Response Relationship, Drug (UI: D004305, Major: No); Drug Interactions (UI: D004347, Major: No); Gluconates (UI: D005942, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Halothane (UI: D006221, Major: No); Hemodynamics (UI: D006439, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Hemorrhage (UI: D006470, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Isoproterenol (UI: D007545, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Myocardial Contraction (UI: D009200, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: Yes); Nitrous Oxide (UI: D009609, Major: No); Phenylephrine (UI: D010656, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Practolol (UI: D011217, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Propranolol (UI: D011433, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No)

pharmacology (0)|pharmacology (1)|||drug effects (0)||||pharmacology (0)||drug effects (0)|physiopathology (1)|pharmacology (0)||physiopathology (1)||pharmacology (0)|pharmacology (0)|pharmacology (0)

0|0|1|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-11-01

2019-06-28

pubmed: 1976-9-1; medline: 1976-9-1 0:1; entrez: 1976-9-1 0:0

pubmed: 9020; doi: 10.1097/00000542-197609000-00015

Myocardial Ischemia

['Myocardial Infarction']

9,208

1

Oxidation of lactate by human serum.

MEDLINE

Manual

NLM

The oxidation of lactate by lactate dehydrogenase of human serum is described, and the kinetics of the reaction are examined. It seems that at higher pH values which are optimal for the faster moving isoenzymes of lactate dehydrogenase, slower moving entities show only a part of their activity. In contrast, M type isoenzymes are active at lower pH values, where H type entities are partly inactivated.

Clinica chimica acta; international journal of clinical chemistry

0009-8981

Print

71

2

Print

1,976

Sep

6

109-15

F N Nowniaz (FN); J King (J)

Comparative Study (D003160); Journal Article (D016428)

Isoenzymes (Registry: 0, UI: D007527); Lactates (Registry: 0, UI: D007773); Pyruvates (Registry: 0, UI: D011773); NAD (Registry: 0U46U6E8UK, UI: D009243); L-Lactate Dehydrogenase (Registry: EC 1.1.1.27, UI: D007770)

Hepatitis (UI: D006505, Major: No) - Qualifiers: enzymology (UI: Q000201, Major: No); Humans (UI: D006801, Major: No); Hydrogen-Ion Concentration (UI: D006863, Major: No); Isoenzymes (UI: D007527, Major: No); Kinetics (UI: D007700, Major: No); L-Lactate Dehydrogenase (UI: D007770, Major: No) - Qualifiers: blood (UI: Q000097, Major: Yes); Lactates (UI: D007773, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: Yes); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: enzymology (UI: Q000201, Major: No); NAD (UI: D009243, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Pyruvates (UI: D011773, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Temperature (UI: D013696, Major: No)

enzymology (0)|||||blood (1)|metabolism (1)|enzymology (0)|pharmacology (0)|pharmacology (0)|

0|0|0|0|0|0|0|0|0|0|0

null

1976-12-01

2019-07-06

pubmed: 1976-9-6; medline: 1976-9-6 0:1; entrez: 1976-9-6 0:0

pubmed: 9208; pii: 0009-8981(76)90520-9; doi: 10.1016/0009-8981(76)90520-9

Myocardial Ischemia

['Myocardial Infarction']

9,333

1

Association of inflammatory bowel disease and large vascular lesions.

MEDLINE

Manual

NLM

A case of inflammatory bowel disease with associated multiple large vessel vascular lesions similar to that seen in Takayasu's arteritis is described in a 15-year-old female. It is suggested that this type of vascular lesion may represent another rare systemic manifestation of inflammatory bowel disease.

Gastroenterology

0016-5085

Print

71

5

Print

1,976

Nov

null

844-6

S Yassinger (S); R Adelman (R); D Cantor (D); C H Halsted (CH); R J Bolt (RJ)

Case Reports (D002363); Journal Article (D016428)

null

Adolescent (UI: D000293, Major: No); Arterial Occlusive Diseases (UI: D001157, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Carotid Artery Diseases (UI: D002340, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Cerebral Arterial Diseases (UI: D002539, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Crohn Disease (UI: D003424, Major: No) - Qualifiers: complications (UI: Q000150, Major: Yes); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Hypertension (UI: D006973, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Radiography (UI: D011859, Major: No); Renal Artery Obstruction (UI: D012078, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Takayasu Arteritis (UI: D013625, Major: No) - Qualifiers: diagnostic imaging (UI: Q000000981, Major: No); Vascular Diseases (UI: D014652, Major: No) - Qualifiers: complications (UI: Q000150, Major: Yes)

|diagnostic imaging (0)|diagnostic imaging (0)|diagnostic imaging (0)|complications (1)|||etiology (0)||diagnostic imaging (0)|diagnostic imaging (0)|complications (1)

0|0|0|0|0|0|0|0|0|0|0|0

null

1976-12-01

2016-11-23

pubmed: 1976-11-1; medline: 1976-11-1 0:1; entrez: 1976-11-1 0:0

pubmed: 9333; pii: S0016508576002849

Cerebrovascular Disorders

['Carotid Artery Diseases']

9,345

1

[Newer aspects in the therapy of angina pectoris].

MEDLINE

Manual

NLM

Progress in coronary surgery has led to new aspects in the treatment of angina pectoris. According to the coronar-angiographic findings, which make an exact identification of the coronary heart disease possible, and according to the ventricular function a therapeutic strategy can be determined today with adequate safety for each individual case. The most important criterium for a decision for surgical or conservative treatment is not only the improvement of the subjective symptoms, in special forms of coronary heart disease the bypass-operation not only results in improved quality of life but also in a considerably increased survival time.

Fortschritte der Medizin

0015-8178

Print

94

24

Print

1,976

Aug

26

1261-6

K A Zölch (KA); H Kleinfelder (H)

English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Vasodilator Agents (Registry: 0, UI: D014665); Nitroglycerin (Registry: G59M7S0WS3, UI: D005996); Calcium (Registry: SY7Q814VUP, UI: D002118)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); surgery (UI: Q000601, Major: No); Calcium (UI: D002118, Major: No) - Qualifiers: antagonists & inhibitors (UI: Q000037, Major: No); Coronary Artery Bypass (UI: D001026, Major: No); Humans (UI: D006801, Major: No); Nitroglycerin (UI: D005996, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Vasodilator Agents (UI: D014665, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No)

therapeutic use (0)|drug therapy (1); surgery (0)|antagonists & inhibitors (0)|||therapeutic use (0)|therapeutic use (0)

0|0|0|0|0|0|0

null

1976-12-01

2013-11-21

pubmed: 1976-8-26; medline: 1976-8-26 0:1; entrez: 1976-8-26 0:0

pubmed: 9345

Myocardial Ischemia

['Angina Pectoris']

9,414

1

Surgical treatment of dissecting aortic aneurysm. Twenty years' experience.

MEDLINE

Manual

NLM

Early and late results of 40 cases of dissecting aortic aneurysm were reported. 1. Result of 6 cases with acute dissection was as follows: two of three surgical patients survived, whereas all three with drug therapy died. Surgical treatment is preferred for the dissection of the ascending aorta or the arch. Some problems of the postoperative morbidity were discussed: 2. Whether medically treated or surgically, chronic dissection of the descending aorta or the abdominal aorta had better prognosis than that of the other site. Chronic dissection with no saccular enlargement had good prognosis. More than 10 years survival is to be expected. The operative result for the chronic aortic dissection was poor, especially in case of the involved ascending aorta and arch. For the saccular enlargement of the pseudolumen wrapping method with or without the resection might be the preferable procedure to avoid early rupture.

The Journal of cardiovascular surgery

0021-9509

Print

17

5

Print

null

408-12

A Ueno (A); Y Maruyama (Y); Y Tada (Y); K Fukushima (K)

Journal Article (D016428)

null

Acute Disease (UI: D000208, Major: No); Aortic Aneurysm (UI: D001014, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); surgery (UI: Q000601, Major: Yes); Arteriosclerosis (UI: D001161, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Chronic Disease (UI: D002908, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Marfan Syndrome (UI: D008382, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); Methods (UI: D008722, Major: No); Takayasu Arteritis (UI: D013625, Major: No) - Qualifiers: complications (UI: Q000150, Major: No)

|complications (0); surgery (1)|complications (0)|||||complications (0)||complications (0)

0|0|0|0|0|0|0|0|0|0

null

1976-12-03

2016-10-26

pubmed: 1976-9-1; medline: 1976-9-1 0:1; entrez: 1976-9-1 0:0

pubmed: 9414

Heart Defects, Congenital

['Marfan Syndrome']

9,415

1

Aortitis syndrome due to Takayasu's disease. A guideline for the surgical indication.

MEDLINE

Manual

NLM

Seven cases of aortitis syndrome were surgically treated with good results: Abdominal aortic aneurysm 1, atypical coarctation of aorta 2, aortic valve insufficiency 2, renovascular hypertension 2. Several attentions were paid as following: 1. Operation should be avoided during acute phase of aortitis. 2. Synthetic graft material should be avoided if possible. Autogenous vein is advisable for reconstruction of small-sized artery. 3. Surgical intervention should be performed before the loss of organ function. 4. Hematological consideration is worthwhile to prevent hypercoagulopathy due to aortitis.

The Journal of cardiovascular surgery

0021-9509

Print

17

5

Print

null

443-56

M Sunamori (M); R Hatano (R); T Yamada (T); T Tsukuura (T); T Sakamoto (T)

Case Reports (D002363); Journal Article (D016428)

null

Adult (UI: D000328, Major: No); Angiography (UI: D000792, Major: No); Aorta, Abdominal (UI: D001012, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No); Aortic Aneurysm (UI: D001014, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No); Aortic Arch Syndromes (UI: D001015, Major: No) - Qualifiers: surgery (UI: Q000601, Major: Yes); Aortic Valve Insufficiency (UI: D001022, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Hypertension, Portal (UI: D006975, Major: No) - Qualifiers: surgery (UI: Q000601, Major: No); Male (UI: D008297, Major: No); Methods (UI: D008722, Major: No); Middle Aged (UI: D008875, Major: No); Takayasu Arteritis (UI: D013625, Major: No) - Qualifiers: surgery (UI: Q000601, Major: Yes)

||surgery (0)|surgery (0)|surgery (1)|surgery (0)|||surgery (0)||||surgery (1)

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-12-03

2016-10-26

pubmed: 1976-9-1; medline: 1976-9-1 0:1; entrez: 1976-9-1 0:0

pubmed: 9415

Heart Valve Diseases

['Aortic Valve Insufficiency']

9,522

1

Alpha-adrenoceptor-mediated coronary artery spasm.

MEDLINE

Manual

NLM

Selective coronary arteriography performed on a 41-year-old woman with angina pectoris demonstrated proximal stenosis of the right and left main coronary arteries that was unaffected by nitrate therapy. To exclude coronary artery spasm, the study was repeated, and a striking increase in the narrowing of the right coronary artery was observed. This 90% stenosis was virtually abolished by pretreatment with intravenously given phentolamine hydrochloride. Prolonged alpha-adrenoceptor blockade with phenoxybenzamine hydrochloride improved the patient's exercise tolerance and postexercise electrocardiographic abnormalities when compared to therapy in matched controls given placebo. These observations suggest that alpha-adrenoceptor-mediated coronary artery spasm may mimic organic lesions at coronary arteriography and may be a factor in the pathogenesis of angina pectoris in some patients.

JAMA

0098-7484

Print

236

9

Print

1,976

Aug

30

1018-22

D L Levene (DL); M R Freeman (MR)

Case Reports (D002363); Clinical Trial (D016430); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Phenoxybenzamine (Registry: 0TTZ664R7Z, UI: D010643)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); therapeutic use (UI: Q000627, Major: Yes); Adult (UI: D000328, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: etiology (UI: Q000209, Major: Yes); Clinical Trials as Topic (UI: D002986, Major: No); Coronary Disease (UI: D003327, Major: No) - Qualifiers: complications (UI: Q000150, Major: No); drug therapy (UI: Q000188, Major: Yes); Exercise Test (UI: D005080, Major: No); Female (UI: D005260, Major: No); Hemodynamics (UI: D006439, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Phenoxybenzamine (UI: D010643, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Spasm (UI: D013035, Major: No) - Qualifiers: complications (UI: Q000150, Major: No)

pharmacology (0); therapeutic use (1)||etiology (1)||complications (0); drug therapy (1)|||drug effects (0)||therapeutic use (1)|complications (0)

0|0|0|0|0|0|0|0|0|0|0

null

1976-12-03

2016-10-17

pubmed: 1976-8-30; medline: 1976-8-30 0:1; entrez: 1976-8-30 0:0

pubmed: 9522

Myocardial Ischemia

['Angina Pectoris', 'Coronary Disease']

9,583

1

[Longterm therapy of angina pectoris patients with a new beta-receptor blocker (author's transl)].

MEDLINE

Manual

NLM

The beta-receptor blocker Timolol was investigated for 28 weeks in a double blind trial and then for up to 100 weeks in an open trial in patients with angina pectoris. In both phases of the investigation. Timolol caused a quite marked regression in the frequency of attacks and in the pulse rate at rest. The evaluation of therapeutic success by doctor and patient was positive for Timolol.

MMW, Munchener medizinische Wochenschrift

0341-3098

Print

118

36

Print

1,976

Sep

3

1123-5

H J Schaumann (HJ); H J Diekmann (HJ); H Neuss (H); B Stegaru (B)

Clinical Trial (D016430); Controlled Clinical Trial (D018848); English Abstract (D004740); Journal Article (D016428)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Placebos (Registry: 0, UI: D010919); Propanolamines (Registry: 0, UI: D011412)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Adult (UI: D000328, Major: No); Aged (UI: D000368, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Clinical Trials as Topic (UI: D002986, Major: No); Female (UI: D005260, Major: No); Humans (UI: D006801, Major: No); Male (UI: D008297, Major: No); Middle Aged (UI: D008875, Major: No); Placebos (UI: D010919, Major: No); Propanolamines (UI: D011412, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: Yes); Pulse (UI: D011674, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No)

therapeutic use (1)|||drug therapy (1)|drug effects (0)|||||||therapeutic use (1)|drug effects (0)

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-11-21

2007-11-15

pubmed: 1976-9-3; medline: 1976-9-3 0:1; entrez: 1976-9-3 0:0

pubmed: 9583

Myocardial Ischemia

['Angina Pectoris']

9,584

1

[Angina pectoris. Results of investigations to date (author's transl)].

MEDLINE

Manual

NLM

Among the most important coronary risk factors are a diet rich in saturated fatty acids, cholesterol and calories, hypercholesterolemia, high blood pressure and excessive smoking. The typical pain can be elicited by putting a strain on the patient, e.g. climbing stairs. The disappearance of the pain after treatment with nitroglycerine is one of the most important pointers. Treatment is with nitroglycerine which, moreover, remains the drug of choice, also with nitrates such as pentaerythritol tetranitrate and with betablockers like propranolol. Favorable results have also been reported with a combination of isosorbide dinitrate and propranolol.

MMW, Munchener medizinische Wochenschrift

0341-3098

Print

118

38

Print

1,976

Sep

17

1189-94

M C Vagueiro (MC)

English Abstract (D004740); Journal Article (D016428); Review (D016454)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Nitrates (Registry: 0, UI: D009566)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Angina Pectoris (UI: D000787, Major: Yes) - Qualifiers: diagnosis (UI: Q000175, Major: No); drug therapy (UI: Q000188, Major: No); etiology (UI: Q000209, Major: No); Humans (UI: D006801, Major: No); Nitrates (UI: D009566, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No)

Adrenergic beta-Antagonists|Angina Pectoris|Humans|Nitrates

therapeutic use (0)|diagnosis (0); drug therapy (0); etiology (0)||therapeutic use (0)

0|1|0|0

null

1976-12-01

2006-11-15

pubmed: 1976-9-17; medline: 1976-9-17 0:1; entrez: 1976-9-17 0:0

pubmed: 9584

Myocardial Ischemia

['Angina Pectoris']

9,628

1

The properties of beta-adrenoceptor antagonists.

MEDLINE

Manual

NLM

After the clinical studies with pronethalol and propranolol confirmed Black's hypothesis that drugs which block beta-adrenoceptors were of value in the treatment of patients with angina pectoris and cardiac arrhythmias, other compounds have been described which block beta-adrenoceptors. Detailed pharmacological studies with propranolol and comparison of its properties with those of other beta-adrenoceptor blocking drugs have indicated that these drugs may possess properties in addition to their effect in blocking beta-adrenoceptors. These properties have been termed intrinsic sympathomimetic activity, membrane stabilizing activity and cardioselectivity. These properties have all been described in detailed observations in laboratory animals but not to the same extent in normal man or in patients. It appears that the therapeutic effectiveness of these drugs results from their beta-adrenoceptor blocking activity and that intrinsic sympathomimetic activity and membrane stabilizing activity do not contribute to the effects of these drugs in patients, although cardioselectivity may be of value in some patients.

Postgraduate medical journal

0032-5473

Print

52 Suppl 4

null

Print

1,976

null

14-20

R G Shanks (RG)

Journal Article (D016428); Review (D016454)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); therapeutic use (UI: Q000627, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Animals (UI: D000818, Major: No); Cell Membrane (UI: D002462, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Humans (UI: D006801, Major: No); Hypertension (UI: D006973, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: No); Propranolol (UI: D011433, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No); Sympathetic Nervous System (UI: D013564, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No)

pharmacology (1); therapeutic use (0)|drug therapy (0)||drug effects (0)|drug effects (0)||drug therapy (0)|pharmacology (0)|drug effects (0)

0|0|0|0|0|0|0|0|0

null

1976-11-21

2013-11-21

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 9628

Myocardial Ischemia

['Angina Pectoris']

9,629

1

Beta-blockade and mechanisms of disease.

MEDLINE

Manual

NLM

In this review an attempt has been made to define the contribution of beta-antagonists to out understanding of the mechanisms of disease. It is concluded that beta-antagonists, and propranolol in particular, have clarified mechanisms in angina pectoris, cardiac arrhythmias and some aspects of essential hypertension as well as hypertrophic obstructive cardiomyopathy. The study of beta-antagonists in anxiety states shows that they can help to define the somatic component but give no clue as to central mechanisms involved. There is no substantial evidence that beta-antogonists are of value in the psychoses and these negative findings suggest that disturbances of brain catecholamines contribute little to the pathogenesis of these conditions.

Postgraduate medical journal

0032-5473

Print

52 Suppl 4

null

Print

1,976

null

184-90

J D Fitzgerald (JD)

Journal Article (D016428); Review (D016454)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Catecholamines (Registry: 0, UI: D002395); Renin (Registry: EC 3.4.23.15, UI: D012083)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Arrhythmias, Cardiac (UI: D001145, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Cardiomyopathy, Hypertrophic (UI: D002312, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Cardiovascular Diseases (UI: D002318, Major: No) - Qualifiers: etiology (UI: Q000209, Major: Yes); Catecholamines (UI: D002395, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Humans (UI: D006801, Major: No); Hypertension (UI: D006973, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Myocardial Infarction (UI: D009203, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No); Myocardium (UI: D009206, Major: No) - Qualifiers: metabolism (UI: Q000378, Major: No); Renin (UI: D012083, Major: No) - Qualifiers: blood (UI: Q000097, Major: No); Tachycardia (UI: D013610, Major: No) - Qualifiers: etiology (UI: Q000209, Major: No)

pharmacology (1)|etiology (0)|etiology (0)|drug effects (0)|etiology (0)|etiology (1)|metabolism (0)||etiology (0)|etiology (0)|metabolism (0)|blood (0)|etiology (0)

0|0|0|0|0|0|0|0|0|0|0|0|0

null

1976-11-21

2009-10-27

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 9629

Myocardial Ischemia

['Angina Pectoris', 'Myocardial Infarction']

9,630

1

Mechanism of action of beta-blocking drugs in angina pectoris: a review.

MEDLINE

Manual

NLM

The effect of beta-blockers in improving exercise tolerance in angina pectoris can be accounted for by the reduction in heart rate and arterial pressure than they produce. The failure of a few patients to respond despite reduction in heart rate and the failure of those who do respond to obtain the full expected benefit suggests that beta-blockade has some action that offsets in while or in part the advantage gained from reduction in heart rate and pressure. This action might include an increase in left ventricular size with consequent increase in work, or an increase in left ventricular diastolic pressure with resultant impairment of blood flow to the inner layers of the myocardium.

Postgraduate medical journal

0032-5473

Print

52 Suppl 4

null

Print

1,976

null

43-5

B F Robinson (BF)

Journal Article (D016428); Review (D016454)

Adrenergic beta-Antagonists (Registry: 0, UI: D000319); Propranolol (Registry: 9Y8NXQ24VQ, UI: D011433); Nitroglycerin (Registry: G59M7S0WS3, UI: D005996)

Adrenergic beta-Antagonists (UI: D000319, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: Yes); therapeutic use (UI: Q000627, Major: No); Angina Pectoris (UI: D000787, Major: No) - Qualifiers: drug therapy (UI: Q000188, Major: Yes); physiopathology (UI: Q000503, Major: No); Blood Pressure (UI: D001794, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Coronary Circulation (UI: D003326, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Drug Therapy, Combination (UI: D004359, Major: No); Heart (UI: D006321, Major: No) - Qualifiers: physiopathology (UI: Q000503, Major: No); Heart Rate (UI: D006339, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Heart Ventricles (UI: D006352, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Nitroglycerin (UI: D005996, Major: No) - Qualifiers: therapeutic use (UI: Q000627, Major: No); Oxygen Consumption (UI: D010101, Major: No) - Qualifiers: drug effects (UI: Q000187, Major: No); Propranolol (UI: D011433, Major: No) - Qualifiers: pharmacology (UI: Q000494, Major: No)

pharmacology (1); therapeutic use (0)|drug therapy (1); physiopathology (0)|drug effects (0)|drug effects (0)||physiopathology (0)|drug effects (0)|drug effects (0)|therapeutic use (0)|drug effects (0)|pharmacology (0)

0|0|0|0|0|0|0|0|0|0|0

null

1976-11-21

2013-11-21

pubmed: 1976-1-1; medline: 1976-1-1 0:1; entrez: 1976-1-1 0:0

pubmed: 9630

Myocardial Ischemia

['Angina Pectoris']